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ABSTRACT 
Highly active antiretroviral therapy (HAART), a multidrug combination regimen, 
commonly consisting of Nucleoside Reverse Transcriptase Inhibitors, non- Nucleoside 
Reverse Transcriptase Inhibitors and Protease Inhibitors, has radically decreased mortality 
and morbidity rates among people living with HIV/AIDS and is currently the treatment of 
choice in South Africa and around the world. The emphasis of the original development of 
the antiretroviral drugs was on clinical effectiveness (reducing mortality), before all other 
considerations. Presently, emphasis has shifted from the initial short-term considerations to 
the long-term undesirable or harmful effects induced by this treatment regimen. Studies on 
the effects of HAART on the incidence and progression of HIV/AIDS associated cancers, 
non-Hodgkin’s lymphoma, cervical cancer and Kaposi’s sarcoma have provided 
contrasting data. While there has been a decrease in the incidence of Kaposi’s sarcoma, 
HAART has reportedly not had a significant impact on the incidence of the other two 
AIDS defining malignancies, while some evidence even suggests an increase in these 
cancers. It has also been extensively reported that the widespread use of HAART has 
increased the risk of non-AIDS defining malignancies, including breast cancer.  
Whether individual antiretroviral compounds or their combinations are oncogenic is 
therefore widely speculated. These speculations led to the investigation of the effects of 
some of the antiretroviral drugs used in the South African treatment guidelines on the 
expression of key apoptotic regulatory genes, BAX and BCL-2 in two human breast, MCF-
7 and MCF-10A and two human cervical cell lines, HCS-2 and NCE16IIA by Real Time 
qPCR gene expression and immunofluorescence. This is because cancer is initiated when 
there is an up-regulation of anti-apoptotic genes (e.g. BCL-2,) and down regulation of pro-
apoptotic genes (e.g. BAX).  
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Because the formation of new blood vessels from pre-existing vasculature (angiogenesis) 
is required for cancer growth and development, this study also investigated the effects of 
the antiretroviral drugs on the expression levels of key angiogenic regulatory genes; 
hypothesising that the antiretroviral compounds might up-regulate pro-angiogenic 
VEGF165a and/or down-regulate anti-angiogenic VEGF165b gene expression. This study also 
evaluated the cytotoxicity of the antiretroviral drugs in normal and cancer cell lines of the 
breast and cervix at clinically relevant concentrations of the drugs and at different time 
points – 24, 48, 72 and 96 hours, employing the Neutral Red Toxicology/Viability Assay. 
In addition, the potential anti-apoptotic effects of the protease inhibitors - LPV/r were 
investigated by cell death detection ELISA and acridine orange staining.     
         
This study shows that the antiretroviral drugs; tenofovir disoproxil fumarate, emtricitabine, 
efavirenz, lopinavir, ritonavir and the two triple combinations (all at clinically relevant 
concentrations which reflect their steady-state peak plasma concentrations in patients 
receiving these drugs) demonstrated varying degrees of cytotoxicity in the normal breast 
and cervical cells. The resulting DNA damage associated with cytotoxicity is strongly 
implicated in the processes of tumor initiation. The results of the qPCR data demonstrated 
differences in the response of the two tissue types used in this study, which, though is not 
statistically significant, showed trends and often opposite trends between the breast and 
cervical and between the normal and cancer cell lines. All the antiretroviral drugs and 
combinations tested did not significantly alter BAX and BCL-2, VEGF165a and VEGF165b 
gene expression in both cell lines. The protein localisation of BAX, BCL-2 and VEGF165b 
were also not altered.  
 
vi 
 
The protease inhibitors - LPV/r exhibited significant (p<0.05) inhibition of Camptothecin 
induced apoptosis in the cervical cancer HCS-2 cell line but not in the normal immortalised 
NCE16IIA or the two breast cell lines. This anti-apoptotic property of HIV protease 
inhibitors, although shown here not to involve BAX or BCL-2 protein and RNA synthesis 
might promote the development of cervical cancer. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW  
  
1.1 General Introduction 
The Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome HIV/AIDS 
pandemic have had a catastrophic effect on the world population. By 2012, HIV had 
infected a cumulative total of about 75 million, out of which about 36 million had died 
(UNAIDS Global AIDS Fact sheet, 2013). 
UNAIDS GLOBAL FACT SHEET: 
People living with HIV 
 In 2012, there were 35.3 million [32.2 million–38.8 million] people living with 
HIV. 
New HIV infections 
 New HIV infections have fallen by 33% since 2001. 
 Worldwide, 2.3 million [1.9 million–2.7 million] people became newly 
infected with HIV in 2012, down from 3.4 million [3.1 million–3.7 million] 
in 2001. 
 New HIV infections among adults and adolescents decreased by 50% or 
more in 26 countries between 2001 and 2012. 
 New HIV infections among children have declined by 52% since 2001. 
 Worldwide, 260 000 [230 000–320 000] children became newly infected 
with HIV in 2012, down from 550 000 [500 000–620 000] in 2001. 
AIDS-related deaths 
 AIDS-related deaths have fallen by 30% since the peak in 2005. 
 In 2012, 1.6 million [1.4 million–1.9 million] people died from AIDS-
related causes worldwide compared to 2.3 million [2.1 million–2.6 million] 
in 2005. 
Since the start of the epidemic, an estimated 36 million [30 million – 42 million] people 
have died of AIDS-related illnesses (UNAIDS Global AIDS Fact sheet, 2013). 
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Sub-Saharan Africa, which is home to just 10% of world’s population, contains an 
overwhelming 70 percent of people living with HIV/AIDS (UNAIDS Global AIDS Fact 
sheet, 2013). South Africa (SA) has the highest number of people living with HIV in sub-
Saharan Africa and in the world. It is for this reason that in November 2003, SA started the 
world’s largest public sector rollout of Highly Active Antiretroviral Treatment (HAART) 
(Abdool Karim et al., 2009; Kranzer et al., 2010). 
Prior to the advent of antiretroviral drugs, the management of the Human 
Immunodeficiency Virus-1 was essentially the management of AIDS-related illnesses and 
prevention against common opportunistic infections (Arts and Hazuda, 2012). Towards the 
close of the twentieth century, the development of inhibitors of two of the three most 
important enzymes (protease and reverse transcriptase) of the HIV-1 machinery 
dramatically changed the management of HIV patients (Arts and Hazuda, 2012). The 
introduction of regimens that combined the different drug classes further enhanced the 
overall effectiveness of the therapy (Arts and Hazuda, 2012).  
Highly active antiretroviral therapy (HAART), a multidrug combination regimen, has 
dramatically reduced mortality and morbidity among Human Immunodeficiency Virus-1 
(HIV-1) infected individuals (Nachega et al., 2004; Sikora et al., 2010) and is currently the 
treatment of choice in South Africa (Maqutu et al., 2011). The multidrug combination 
therapy markedly stems HIV-1 replication and decreases the plasma viral load to levels 
almost undetectable by very sensitive clinical assays, which then leads to increased levels 
of circulating CD4+ T-lymphocytes and a significantly reconstituted immune system 
(Autran et al., 1997; Komanduri et al., 1998; Lederman et al., 1998). The development of 
combination therapy also became the foundation for preventing the evolution of drug 
resistance because the components of the combination act against two or more molecular 
2 
 
machinery of the virus (Arts and Hazuda, 2012).                      
If patients adhere appropriately to the HAART regimen, viral replication can be suppressed 
for many years, considerably increasing the life expectancy of HIV-infected individuals 
(Arts and Hazuda, 2012). Since HIV-1 is currently an incurable chronic infection, HAART 
on its own cannot resolve the HIV problem (Arts and Hazuda, 2012), so the option of 
continuing therapy for a lifetime, poses major problems, while the chances remain for 
continuous viral replication in reservoirs and compartments which may continually drive 
pathogenic disease processes (Finzi et al., 1997; Finzi et al., 1999). 
Table 1.1 shows currently available antiretroviral (ARV) drugs used for the treatment of 
HIV infection (FDA: US Food and Drug Administration www.fda.gov ). 
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Table 1.1: Currently available ARVs drugs for the treatment of HIV infection (FDA: 
United States Food and Drug Administration www.fda.gov ). Highlighted drugs were used 
in this study. 
ARV DRUG CLASS ARV DRUG 
Multi-class Combination Products 
Atripla® efavirenz, emtricitabine & tenofovir disoproxil 
fumarate 
  
Complera® emtricitabine, rilpivirine, and tenofovir 
disoproxil fumarate 
  
Stribild® elvitegravir, cobicistat, emtricitabine, tenofovir 
disoproxil fumarate 
    
Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
Combivir®    lamivudine and zidovudine; Emtriva®   
emtricitabine, FTC 
 
Epivir® lamivudine, 3TC, Epzicom® abacavir and 
lamivudine 
  
Hivid® zalcitabine, dideoxycytidine, ddC (no longer 
marketed) 
  Retrovir®   zidovudine, azidothymidine, AZT, ZDV 
  Trizivir®  abacavir, zidovudine, and lamivudine 
  
Truvada®   tenofovir disoproxil fumarate and 
emtricitabine 
  
Videx EC® enteric coated didanosine, ddI EC; Videx® 
didanosine, dideoxyinosine, ddI 
  
Viread® tenofovir disoproxil fumarate, TDF; Zerit® 
stavudine, d4T; Ziagen® abacavir sulfate, ABC 
    
non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTIs) 
Intelence® etravirine; Rescriptor® delavirdine, DLV; 
 Edurant® rilpivirine 
 
Sustiva®  efavirenz, EFV; Viramune®   nevirapine, NVP 
    
Protease Inhibitors (PIs) 
Agenerase®   amprenavir, APV; Aptivus®   tipranavir, 
TPV; Crixivan®   indinavir, IDV 
  
Fortovase®   saquinavir (no longer marketed); Invirase®   
saquinavir mesylate, SQV 
  Kaletra® lopinavir and ritonavir, LPV/RTV 
  
Lexiva®   Fosamprenavir Calcium, FOS-APV; Norvir®   
ritonavir, RTV 
  
Prezista®    darunavir; Reyataz®   atazanavir sulfate, 
ATV; Viracept®   nelfinavir mesylate, NFV 
    
Fusion Inhibitors Fuzeon® enfuvirtide, T-20 
Entry Inhibitors - CCR5 co-
receptor antagonist Selzentry® maraviroc 
HIV integrase strand transfer 
inhibitors Isentress® raltegravir; Tivicay® dolutegravir 
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1.1.1 Antiretroviral Drug Classes 
Based on their mechanisms of action (De Clercq, 2005), antiretroviral constituent drugs 
can be divided into the following major classes:                   
Reverse transcriptase inhibitors (RTIs):                               
This class targets the construction of viral DNA and inhibits the activity of viral reverse 
transcriptase (De Clercq, 2005). There are two subcategories of RTIs based on different 
mechanisms of action: nucleoside analogue RTIs (NRTIs) and non-nucleoside-analogue 
RTIs (NNRTIs). NRTIs incorporate themselves into the viral DNA thus leading to chain 
termination, while NNRTIs alter the binding potential of the reverse transcriptase enzyme 
(De Clercq, 2005). RTIs can also be divided into three categories: Nucleoside analogue 
reverse transcriptase inhibitors (NARTIs or NRTIs), Nucleotide analogue reverse 
transcriptase inhibitors (NtARTIs or NtRTIs) and non-nucleoside reverse transcriptase 
inhibitors (NNRTIs).     
The mechanism of action of NRTIs and NtRTIs are similar; these are equivalent to the 
naturally occurring deoxynucleotides used to synthesise the viral DNA. They compete with 
the naturally occurring deoxynucleotides to be incorporated into the elongating DNA chain 
of the Human Immunodeficiency Virus (Jochmans, 2008). Unlike the naturally occurring 
deoxynucleotides, however, NRTIs and NtRTIs lack a 3'-hydroxyl group on their 
deoxyribose moiety. Therefore, when an NRTI or an NtRTI is incorporated into the DNA, 
sequential formation of the next 5'-3' phosphodiester bond required to elongate the DNA 
chain is not present and therefore the DNA strand is terminated. This process is described 
as chain termination of viral DNA synthesis (Jochmans, 2008). While NRTIs and NtRTIs 
are described as competitive substrate inhibitors, NNRTIs, on the other hand, have a totally 
different mechanism of action. The NNRTIs are classified as non-competitive inhibitors of 
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the reverse transcriptase. They inhibit reverse transcriptase activity by binding at an 
alternate site on the enzyme different from the binding site of NRTIs and NtRTIs (De 
Clercq, 2005). Unlike NRTIs and NtRTIs, NNRTIs do not compete for incorporation into 
the viral DNA; rather they block the activity of protein domains of the reverse transcriptase 
required for the process of synthesising viral DNA (De Clercq, 2005).  
Protease Inhibitors (PIs):                          
Protease inhibitors affect viral organisation by blocking the activity of HIV-1 protease, an 
enzyme utilised by HIV to split newly developing proteins required for assembling new 
virons (Richman, 2001). The HIV-1 protease is a complex enzyme comprising two similar 
halves with an active site positioned at the base of the cleft. In the final stages of the HIV 
life cycle, it is required for splitting of the larger viral precursor polypeptide chains into 
smaller, functional proteins, needed for maturing the HIV virion (Richman, 2001). HIV 
protease inhibitors particularly target the peptide bonds in the gag and gag-pol polyproteins 
which should be split by HIV-1 protease (Monini et al., 2003). By inhibiting the HIV-1 
protease, PIs structurally disorganise the virus, leading to the production of non-infectious 
viral particles (Monini et al., 2003).               
Fusion Inhibitors:                       
This class of drugs prevents the entrance of HIV into cells by blocking HIV from fusing 
with host cell membranes. HIV-1 needs the envelope glycoprotein complex (Env) to enter 
cells. The Env glycoprotein complex facilitates attachment to and eventually aids the 
fusion of HIV-1 to the membrane of host target cells (Eggink et al., 2010). Env consist of 
three gp41 subunits necessary for membrane fusion. One of the currently approved fusion 
inhibitors, Enfuvirtide, is a peptide based on the gp41 sequence which competitively binds 
to gp41 and blocks the formation of the post-fusion structure (Eggink et al., 2010).    
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Integrase Inhibitors:                      
This class of drugs inhibits the enzyme integrase, which is responsible for integrating viral 
DNA into the DNA of the infected cell. Integrating the reverse transcribed viral genome 
into host cell DNA represents an irreversible step during HIV infection (Messiaen et al., 
2013). This class of antiretroviral drugs targets the process of strand transfer while 
integration is taking place by binding in the catalytic core domain of the enzyme (Messiaen 
et al., 2013).   
 
 
 
 
Figure 1.1: Schematic diagram of the HIV-1 life cycle in a susceptible CD4+ cell identifying 
distinct steps in HIV-1 life cycle as current target for antiretroviral drugs (Adapted from 
Splettstoesser, 2013) 
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1.1.2 HAART and its Adverse Effects 
The focus of the initial development of the antiretroviral drugs was on clinical 
effectiveness (lowering mortality) –all other considerations were secondary (Blas-Garcia et 
al., 2010). However, as HIV infection and AIDS has been better managed, emphasis has 
shifted from the initial short-term considerations to the long-term undesirable or harmful 
effects induced by this treatment regimen (Blas-Garcia et al., 2010). Continuous 
administration of the drugs in the cocktail has been associated with multiple adverse 
effects (Sikora et al., 2010; Franzetti et al., 2013). For example, while NRTI drug 
combinations have provided improved anti-HIV therapy/prophylaxis, specific NRTIs are 
thought to be possible chemical carcinogens and mutagens (Olivero et al., 1997; Blanche 
et al., 1999; IARC 2000, Torres et al., 2007) with their triphosphate derivatives inducing 
chain termination and cytotoxicity in healthy cells (Lewis et al., 2001; Lewis et al., 2003; 
Huber-Ruano and Pastor-Anglada, 2009). 
Studies carried out on the effects of HAART with regards to the incidence and progression 
of HIV/AIDS associated cancers; non-Hodgkin’s lymphoma, cervical cancer and Kaposi 
sarcoma, have provided contrasting data (Barbaro and Barbarini, 2007). While there has 
been a decrease in the incidence of Kaposi sarcoma, HAART has reportedly not had a 
significant impact on the incidence of the other two AIDS defining malignancies (Barbaro 
and Barbarini, 2007) - some evidence even suggests an increase in the incidence of these 
cancers (Engels et al., 2008; Palefsky, 2009; Van der Burg and Palefsky, 2009). 
On the other hand, it has been widely reported (Hessol et al., 2007; Barbaro and Barbarini, 
2007; Nguyen et al., 2010) that the widespread use of HAART has increased the risk of 
non-AIDS defining malignancies (NADMs) including breast, kidney (Nguyen et al., 2010), 
anal (Palefsky, 2009) and Hodgkin’s lymphoma (Powles et al., 2009). 
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In a review of the potential causes of the increased incidence of NADMs in the HAART 
era and also as a result of HAART use, Nguyen et al. (2010) lists as key factors, oncogenic 
viruses, (Epstein–Barr virus, Human papillomavirus, Hepatitis-B, Hepatitis-C), impaired 
immune surveillance, direct HIV-1 oncogenic effect, longer life expectancy associated 
with HAART (providing the longer latency period required for the development of certain 
malignancies) and other customary risk factors such as smoking, sun exposure, alcohol 
consumption, illicit drug use and genetic inheritance. Whether the antiretroviral 
compounds themselves are oncogenic is not clear (Powles et al., 2009). Powles et al. 
(2009) reported that there may be an association between the use of NNRTIs and the 
development of non-AIDS defining malignancies, especially in Hodgkin’s lymphoma. 
Reports from in vitro studies confusingly suggest that the use of antiretroviral drugs could 
either lead to or potentially protect against the development of cancer (Olivero et al., 2005; 
Gills et al., 2007). This information, along with the evidence that the incidence of NADMs 
may be increasing (Powles et al., 2009), has led to the opinion that HAART itself may 
have a negative effect on the risk of cancers (Franzetti et al., 2013). Assessing the 
correlation between the individual classes of ARV drugs and cancer risk becomes 
important because the oncogenic potential of different drug classes may be different 
(Olivero et al., 2005; Gills et al., 2007). Additionally, drugs within the cocktail may have 
effects on the DNA of host cells leading to genomic instability and carcinogenesis (Powles 
et al., 2009). Studies by Torres et al. (2007) suggest that the improved chemoprotective 
effects of NRTI drug pairs used clinically may be associated with additive or synergistic 
phenomena that compound the long-term risk for cancer gene mutations and potential 
carcinogenesis. 
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A body of data (reviewed by Badley, 2005; Rizza and Badley, 2008) show that HIV PIs are 
anti-apoptotic, (which favours carcinogenesis) but the precise molecular mechanisms 
underlying these anti-apoptotic effects are still under active investigation in vitro and in 
vivo. Paradoxically, high-dose PIs have been shown to have pro-apoptotic effects, as 
demonstrated in implanted mouse models and transformed cell lines (Badley, 2005; Gills 
et al., 2007). 
The current work was designed to investigate the carcinogenic effects of some of the drugs 
in the South African HAART treatment guidelines individually and in combination on four 
human cell lines at clinically relevant concentrations. Recommended ARVs and 
combinations in South Africa include; 
Emtriva®   emtricitabine, FTC     (NRTIs) 
Viread®    tenofovir disoproxil fumarate, TDF    
 
Sustiva®    efavirenz, EFV      (NNRTI)           
Kaletra®   lopinavir and ritonavir, LPV/rtv                   (PIs) 
 
1st Line: TDF + FTC/3TC + EFV ------- All new patients including pregnant women. 
2nd Line: TDF + FTC/3TC + LPV/r –Protease Inhibitor based regimen. (2010 South 
African Antiretroviral Treatment Guidelines, Department of Health, RSA) 
The normal and cancer cell lines of the breast and cervix used in this study were chosen as 
representations of AIDS-defining malignancies (Cervix) and non-AIDS-defining 
malignancies (Breast). 
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1.2  DRUGS 
1.2.1 Tenofovir Disoproxil Fumarate (TDF) 
VIREAD®, or generically, tenofovir disoproxil fumarate is a pro-drug of tenofovir which is 
a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. 
Tenofovir disoproxil fumarate (TDF) in vivo is converted to tenofovir, an acyclic 
nucleoside phosphonate (nucleotide) analog of adenosine 5’-monophosphate. Tenofovir 
acts against HIV-1 reverse transcriptase (Drug information, VIREAD® Gilead Sciences, 
2010). The chemical name of tenofovir disoproxil fumarate is 9-[(R)-
2[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate 
(1:1).  
TDF has a molecular formula of C19H30N5O10P • C4H4O4 and a molecular weight of 
635.52 (Drug information, VIREAD® Gilead Sciences, 2010). It is a nucleoside reverse 
transcriptase inhibitor widely used in the initial therapy for HIV-1 infection. It is orally 
administered to adults in a single daily dose of 300mg, which produces therapeutic plasma 
concentrations of up to 0.3 + 0.09μg/ml (Drug information, VIREAD® Gilead Sciences, 
2010). Tenofovir is polar and ionized with poor oral bioavailability, so the disoproxil di-
ester prodrug tenofovir disoproxil fumarate was produced to conceal the two ionic regions 
of the phosphonic acid, thereby enhancing transportation across gut membranes (Cihlar 
and Ray, 2010; Anderson et al., 2011).  
After the initial intestinal absorption, TDF is considered to be rapidly changed to a 
monoester by a carboxylesterase and then to tenofovir by a phosphodiesterase after passing 
through the liver and as such tenofovir becomes the predominant circulating compound 
(Naesens et al., 1998; Kearney et al., 2004). 
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 Figure 1.2: Two Dimensional structure of tenofovir disoproxil fumarate, a prodrug 
of tenofovir which is a nucleotide analog reverse transcriptase inhibitor (Drug information, 
VIREAD® Gilead Sciences, 2010) 
 
The current South African practice guidelines recommend the use of TDF with one other 
NRTI and one NNRTI or one PI, thus potentially different combinations exist. Although 
regarded as a harmless drug, TDF-containing regimens have been linked to mutagenesis in 
the in-vitro mouse lymphoma assay (Drug information, VIREAD® Gilead Sciences, 2010), 
renal toxicity (Gitman et al., 2007; Gilead sciences, 2010) glycosuria, proteinuria and 
calciuria (Drug information, VIREAD® Gilead Sciences, 2010). 
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1.2.2  Emtricitabine (FTC) 
EMTRIVA® is the brand name for emtricitabine, a synthetic nucleoside analog with 
activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. The 
chemical name of emtricitabine is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-
5-yl]cytosine.  
 
Figure 1.3: Two Dimensional structure of emtricitabine which is a nucleoside reverse transcriptase 
inhibitor (Drug information, EMTRIVA® Gilead Sciences, 2010). 
 
Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other 
cytidine analogues in that it has a fluorine in the 5-position of the benzene ring. It has a 
molecular formula of C8H10F.N3OS and a molecular weight of 247.24. Administering 
FTC to adults in a single daily dose of 200 mg produces therapeutic plasma concentrations 
of 1.8 ± 0.7μg/ml (Drug information, EMTRIVA® Gilead Sciences, 2010). FTC is 
associated with mitochondrial toxicity (Venhoff et al., 2007), lactic acidosis and severe 
hepatomegaly with steatosis, even though the molecular pathways and cellular mechanisms 
remain largely unknown (Drug information, EMTRIVA® Gilead Sciences, 2010). 
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1.2.3  Efavirenz (EFV) 
SUSTIVA® (efavirenz) is an HIV-1 specific, non-nucleoside reverse transcriptase inhibitor 
(NNRTI). The chemical name of Efavirenz is (S)-6-chloro-4 (cyclopropylethynyl)-1,4-
dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.  
 
Figure 1.4: Two Dimensional structure of efavirenz; a non-nucleoside reverse transcriptase 
inhibitor (Fvasconcellos, 2008). 
 
EFV has a molecular formula of C14H9Cl.F3NO2 and its molecular weight is 315.68 (Drug 
Information SUSTIVA® GILEAD SCIENCES 2010).  It is utilised in the initial therapy for 
HIV-1. Administering EFV to adults in a single daily dose of 600 mg produces therapeutic 
plasma concentrations of up to 4.07+1.17μg/ml (Drug Information SUSTIVA® Gilead 
Sciences 2010). EFV containing regimens have been linked to lipid disturbances (Perez-
Molina et al., 2008) and hepatotoxicity (Blas-Garcia et al, 2010). Sikora et al. (2010) 
reported that EFV induces breast cancer cell growth by directly modulating oestrogen 
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receptors. Jover et al. (2004) suggest that an EFV based regimen is associated with breast 
enlargement. 
1.2.4  LOPINAVIR/ritonavir (LPV/r) 
LPV/r is a co-formulated boosted protease inhibitor marketed as KALETRA®. Lopinavir is 
an inhibitor of the HIV-1 protease while ritonavir inhibits the CYP3A-mediated 
metabolism of LPV, thereby providing increased plasma levels of LPV (Drug information, 
KALETRA® Abbott laboratories, 2010). LPV/r is considered to be a single antiretroviral 
agent because the levels of ritonavir achieved in plasma are subinhibitory and therefore the 
antiretroviral effect of the combination is based on the activity of lopinavir alone (Pierone 
et al., 2006). Administering LPV/r to adults in a twice-daily dose of 400/100mg (or 
800/200mg once daily) produces steady state plasma concentrations of 9.8+ 3.3 μg/ml 
(Drug information, KALETRA® Abbott laboratories, 2010). 
The chemical name for Lopinavir is [1S-[1R*,(R*), 3R*, 4R*]]-N-[4-[[(2,6-
dimethylphenoxy)acetyl]amino]3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-
alpha-(1-methylethyl)-2-oxo-1(2H)pyrimidineacetamide (Drug information, KALETRA® 
Abbott laboratories, 2010). Its molecular formula is C37H48N4O5, and its molecular weight 
is 628.80. Lopinavir is a white to light tan powder. It is freely soluble in methanol and 
ethanol, soluble in isopropanol and practically insoluble in water (Drug information, 
KALETRA® Abbott laboratories, 2010). 
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 Figure 1.5: Two Dimensional structure of lopinavir; a protease inhibitor (Drug information, 
KALETRA® Abbott laboratories, 2010). 
 
 
Figure 1.6: Two Dimensional structure of ritonavir; a protease inhibitor (Yikrazuul, 2008; Drug 
information, KALETRA® Abbott laboratories, 2010). 
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The chemical name for Ritonavir is 10-hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1-
methylethyl)-4thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-
oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is 
C37H48N6O5S2, and its molecular weight is 720.95. Ritonavir is a white to light tan 
powder and is insoluble in water. 
Even though the absolute bioavailability of ritonavir had not been determined in humans at 
the beginning of this study and until now (Drug information, NORVIR® Abbott 
laboratories, 2013), across studies, administration of Kaletra® 400/100mg daily yields 
mean steady-state lopinavir plasma concentrations 15 to 20 times higher than those of 
ritonavir in HIV-1 patients (Drug information, KALETRA® Abbott laboratories, 2010). 
LPV/r at doses 0.5 times the human exposure in male rats results in the occurrence of 
hepatocellular adenoma and carcinoma (Drug information, KALETRA® Abbott 
laboratories, 2010). It has also been associated with the onset of diabetes or the aggravation 
of pre-existing diabetes (Drug information, KALETRA® Abbott laboratories, 2010). 
1.2.5 Camptothecin 
Camptothecin (CPT), a cytotoxic plant alkaloid compound (Fig. 1.7) obtained from the 
bark of the Chinese tree Camptotheca acuminate, was originally observed to impede 
leukaemia cell growth (Wall et al., 1966). The chemical name of CPT is                                                                                        
(S)-4-ethyl-4-hydroxy-1H pyrano[3',4':6,7]indolizino[1,2-b] quinoline-3,14-(4H,12H)-
dione. CPT molecular Formula is C20H16N2O4 and its molecular weight is 348.4 
(Product Information Camptothecin, Sigma, 2012).  
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 Figure 1.7: Two Dimensional structure of Camptothecin, a cytotoxic plant alkaloid compound 
(Product Information (S)-(+)-Camptothecin, Sigma, 2012). 
CPT is a class I DNA topoisomerase inhibitor that reversibly induces single-strand DNA 
breaks, and as a result altering the replication capacity of the cell. Camptothecin binds to 
and stabilises the topoisomerase 1/DNA complex (Legarza and Yang, 2006). These 
topoisomerase-linked DNA strand breaks are rescindable pre-lethal lesions that inhibit 
DNA metabolism (Bertrand et al., 1991; Pommier, 1997). But, when a DNA replication 
fork comes into contact with the cleavable complex, single-strand breaks are transformed 
to irreversible double-strand breaks (Hsiang et al., 1985; 1989). Then, apoptosis is 
facilitated by the activation of caspases (Sanchez-Alcazar et al., 2000). 
In this study, CPT was used to induce apoptosis as has been widely reported (Nieves-Neira 
and Pommier, 1999; Rastogi et al., 2006; Rudolf et al., 2011). This was done so as to 
determine whether the protease inhibitors inhibit drug induced apoptosis in the cervical and 
breast cell lines since it had been reported (Phenix et al, 2001, Badley, 2005, Vlahakis et 
al., 2007, Rizza and Badley, 2008) that protease inhibitors have potent anti-apoptotic 
effects in different cellular systems, the majority of which are immune cells. The anti-
apoptotic effect of LPV/r was assessed to test whether these generalised effects are seen in 
the currently investigated cell lines. 
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1.3.1  Carcinogenesis 
Carcinogenesis has been established as a multistep process with a large number of 
molecular events responsible for the initiation and progression of many human tumours 
(Grizzi and Chiriva-Internati, 2006). The detection of genomic modifications or changes 
that produce oncogenes with an assertive gain of function and tumour-suppressor genes 
with a suppressed loss of function has been important in this regard (Grizzi and Chiriva-
Internati 2006). Results from numerous studies reveal that cancerous cells have a mutual 
collection of characteristics or “acquired capabilities” that function and are regulated at 
diverse multi-dimensional and progressive scales (Grizzi and Chiriva-Internati 2006; 
Wickstrom et al., 2010). 
 These include the ability to create their own mitogenic signals, resist exogenous growth-
restraining signals, elude programmed cell death and senescence, multiply endlessly, 
develop vasculature, and invade and metastasise in distant sites (Grizzi and Chiriva-
Internati 2006). Carcinogenesis requires more than one mutation in a number of genes that 
control cell division, DNA repair and apoptosis (Wickstrom et al., 2010). Non-mutagenic 
carcinogens are believed to encourage cancer initialisation by stimulating high rates of cell 
division, which often result in high error rates with regard to the inherent DNA repair 
mechanisms (Wickstrom et al., 2010). 
1.3.1.1  Carcinogenicity and Genotoxicity Reports on NRTIs                    
It has been shown that 7 out of 8 nucleoside reverse transcriptase inhibitors tested positive 
in one or more genotoxicity assays (except FTC). Abacavir, stavudine, tenofovir, 
zalcitabine, and zidovudine were shown to be rodent carcinogens (NTP, 1999) and tested 
positive in genotoxicity assays, including the in vitro human lymphocyte or mouse 
lymphoma assays. Zidovudine was positive in the Ames (bacterial reverse mutagenicity), 
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in vivo micronucleus, and in vitro hamster ovary cells assays (Wu et al., 2012). All these 
corroborate the opinion that NRTIs, which are nucleoside analogues, are possibly 
genotoxic, while operating as chain terminators or through modification of the nucleotide 
pool (Wu et al., 2012). Didanosine and lamivudine tested negative for carcinogenicity but 
tested positive for genotoxicity (NTP, 1999). This implies that genotoxicity data cannot be 
relied upon exclusively to predict tumorigenicity for this subclass of drugs (Wu et al., 
2012). Emtricitabine is the only NRTI that tested negative for both genotoxicity and 
carcinogenicity (NTP, 1999; Wu et al., 2012). Zidovudine reportedly produced distinctive 
malignant vaginal tumors in both adult rats and mice (NTP, 1999) and also demonstrated 
transplacental carcinogenicity in pregnant mice; showing an increased tumor rate in the 
female reproductive tracts of the mice offspring (NTP, 1999). 
1.3.1.2  Carcinogenicity and Genotoxicity Reports on NNRTIs.           
NNRTIs have not been shown to be positive in genotoxicity assays, irrespective of their 
DNA synthesis chain termination properties. This has been attributed to the characteristics 
of NNRTIs non-competitive (versus NRTIs’ competitive) inhibition of nucleoside 
phosphorylation (Wu et al., 2012). In spite of the negative genotoxicity data, all NNRTIs 
are reportedly rodent carcinogens (delavirdine, etravirine, rilpivirine, efavirenz and 
nevirapine); all producing hepatocellular adenoma/carcinoma. Tumors of the lung and 
urinary bladder were also observed for efavirenz and delavirdine respectively (Wu et al., 
2012). 
1.3.1.3  Carcinogenicity and Genotoxicity Reports on Protease Inhibitors.                
With regards to PIs, nine out of ten have been shown to be carcinogenic in animals, 
including atazanavir, amprenavir, fosamprenavir, daurunavir, lopinavir, indinavir, 
tipranavir, nelfinavir and ritonavir (NTP, 1999; Wu et al., 2012). Saquinavir was the only 
20 
 
PI that was not linked with carcinogenesis in rodents and among all PIs, atazanavir was the 
only agent that was genotoxic (tested positive by chromosomal aberration assay) (NTP, 
1999; Wu et al., 2012).           
1.3.2    Breast Cancer 
Breast cancer is the most common cancer seen in women worldwide (Oluwole et al., 
2005). Although HIV/AIDS is involved in carcinogenesis of some cancers, it has not been 
shown to cause breast cancer (Oluwole et al., 2005). Some studies have reported the 
occurrence of breast cancer in young infected patients. Interestingly, the detected breast 
cancers demonstrate unusual characteristics when compared to breast cancer in uninfected 
patients. These unusual characteristics include poor differentiation, occurrence of 
metastasis at an earlier stage, poor prognosis and more ‘‘aggressiveness’’ (Voutsadakis and 
Silverman, 2002; Pantanowitz and Connolly, 2002; Oluwole, 2005). The acquired 
immunodeficiency syndrome that results from HIV infection weakens the immune system 
and therefore increases the chances of opportunistic infections and development of various 
cancers, including breast neoplasm (Pantanowitz and Connolly, 2002). It was suggested 
that malignancies, like breast cancer, will concurrently increase in HIV infected patients 
(Hajjar et al., 1992; Spina et al., 1994; Patil et al., 1995); however, this opinion is opposed 
by some authors who do not consider HIV to have a significant effect on the occurrence of 
breast cancer (Klassen et al., 1997; Cooksley et al., 1999; Silverberg and Abrams, 2007; 
Andrade et al., 2011).                                                
The occurrence of breast cancer in HIV infected patients was found to be increased in 
African and developing countries (Pantanowitz and Connolly, 2002). The vulnerability to 
malignant neoplasm is high in HIV infected people as a result of suppression of 
immunologic reaction to tumour cells and higher chances of oncogenic viral infections 
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(Pantanowitz and Connolly, 2002). HIV has been shown to have adverse effects on normal 
human mammary epithelial cells by inhibiting their growth (Pantanowitz and Connolly, 
2002). However, HIV infected patients on antiretroviral treatment have a longer survival 
due to the treatment and therefore are at danger of developing breast cancer because its risk 
increases with age (Clay et al., 2008; Phillips and Justman, 2009). Other studies suggest 
that the use of ARV drugs that prevent the wasting condition caused by AIDS might 
increase breast cancer risk by fat re-distribution from peripheral and gluteal tissues to the 
breast and abdomen as a result of increased production of oestrogen (Oluwole et al., 2005; 
Sikora et al., 2010). The total influence of HAART on the risk for NADM is far from 
concluded. In a recent meta-analysis (Shiels et al., 2009), the standardized incidence ratio 
(SIR) of some NADMs including breast cancer, was substantially discrete prior to and in 
the HAART era. A Swiss HIV Cohort Study, a mega prospective cohort of people tracked 
for an average of 5 years after HAART, revealed no definite influence of HAART on SIRs 
of NADMs (Clifford et al., 2005). However, another HIV/AIDS meta-analysis on a cohort 
conducted in England (Powles et al., 2009), showed that a substantial total rise in the risk 
for NADMs accompanied HAART treatment. Non AIDS-defining cancers now generally 
account for more deaths in HIV infected individuals than AIDS defining cancers. Although 
traditional risk factors may account for part of this discrepancy, they certainly do not 
provide all the explanation for the explosion of these cancers in HIV affected people on 
HAART (Silverberg and Abrams, 2007). Engels et al. (2008) found that non-AIDS 
defining cancers comprise 58% of all cancer deaths post-HAART (1996-2002) in 
comparison to 31.4% in the pre-HAART era (1991-1995). This data strongly suggests that 
antiretroviral drugs influence cancer development and progression. 
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1.3.3  Cervical Cancer  
Cervical cancer is aetiologically linked to the human papilloma virus and considered to be 
the second most malignant tumour globally (Stamataki et al., 2010). South Africa is 
reported to have the highest incidence of cervical cancer in the world and is the most 
common cancer in coloured and black South African women (Denny, 2006; Gaym et al., 
2007). Cervical cancer, Kaposi sarcoma and non-Hodgkin’s lymphoma are AIDS defining 
cancers (Barbaro and Barbarini, 2007, Engels et al., 2008). The incidence of Kaposi 
sarcoma and non-Hodgkin’s lymphoma have been reportedly reduced by HAART, the 
incidence of cervical cancer; however, is not declining and some evidence suggests that the 
incidence may even be increasing (Engels et al., 2008; Palefsky, 2009; Van der Burg and 
Palefsky, 2009).  
The institution of the combined antiretroviral therapy in 1996 (Dal Maso et al., 2009) 
resulted in significant enhancement of clinical aftermaths and life prospect for individuals 
living with HIV/AIDS. It also provided the optimism that the enhanced immunological 
condition seen in the patients would lead to the elimination of human papilloma virus 
(HPV) infection in HIV-infected women, just as is the case for other opportunistic and 
AIDS-related infections, and lead to a significant decline in the occurrence and 
advancement of cervical neoplasia (Heard, 2009). However, a review (Bratcher and 
Sahasrabuddhe, 2010) of data from numerous studies has not shown a definite reduction in 
the problem and gravity of cervical disease since the beginning of HAART, as opposed to 
the other AIDS-associated cancers. Bratcher and Sahasrabuddhe (2010) reported that while 
the majority of published literature suggested that being on HAART has not caused a 
decline in the occurrence of cervical precancerous lesions and cervical intraepithelial 
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neoplasia in HIV-infected women, other studies found an increased chance in the post-
HAART era. 
1.4  Apoptosis and Regulatory genes 
Apoptosis (programmed cell death) is a critical process that is dysregulated during 
tumourigenesis (Fiebig et al., 2006). In many cancers, there is a consistent pattern of 
apoptosis inhibition and deregulation of cell and tissue homeostasis. There is a growing 
body of literature implicating apoptosis-related genes and their products in the 
development of cancer (Fiebig et al., 2006; Eum and Lee, 2011).            
The induction of apoptosis occurs via two major pathways: The extrinsic (death receptor) 
pathway and the intrinsic (mitochondria) pathway (Eum and Lee, 2011).  
The extrinsic pathway is activated by the attachment of the FAS plasma-membrane death 
receptor (and related receptors like tumour necrosis receptor 1 and its family) to its 
extracellular ligand, FAS-L. When death stimuli take place, FAS-L binds to FAS and 
forms the death complex (Eum and Lee, 2011). The FAS/FAS-L complex enlists death 
domain-containing protein (FADD) and pro-caspase-8, which together forms the death-
inducing signalling complex (DISC). Consequently, the protein complex activates its pro-
caspase-8, which proceeds to trigger pro-caspase-3, the second to last enzyme for 
execution of the apoptotic process (Ouyang et al., 2012).  
The intrinsic pathway also leads to apoptosis but under the control of mitochondrial pro-
enzymes. Most cell death in vertebrates occurs via the mitochondrial pathway of apoptosis 
(Llambi and Green, 2011). This pathway is controlled by the B-cell CLL/lymphoma 2 
(BCL-2) family of proteins and they regulate the integrity of the mitochondrial outer 
membrane. When apoptosis arises as a result of cooperation among these proteins, the two 
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pro-death BCL-2 effector proteins: BCL-2-associated X protein (BAX) and BCL-2 
antagonistic killer (BAK), disrupt the mitochondrial outer membrane in a process known 
as ‘mitochondrial outer membrane permeabilisation’ (MOMP) (Llambi and Green, 2011). 
If MOMP takes place, proteins located in the mitochondrial inter-membrane compartment 
enter the cytosol and activate caspases and cysteine proteases that coordinate the 
disassembling of the cell (Llambi and Green, 2011). If these caspase proteases are 
inhibited or their activation is hindered, apoptosis can still take place by disruption of 
mitochondrial performance (mitochondrial catastrophe). However, if a small number of 
mitochondria remain and divide to repopulate the cytoplasm, the cell can continue 
glycolysis and the cells may still survive (Llambi and Green, 2011). These phenomena 
may provide explanation as to why cancer cells usually exhibit malfunctions in the 
mitochondrial pathway downstream of MOMP (Llambi and Green, 2011). The process of 
MOMP is opposed by the pro-survival BCL-2 proteins, such as BCL-2, BCL-W, BCL-xL, 
A1/Bfl1 and MCL-1, which impede the capacity of BAX and BAK to permeabilise the 
outer mitochondrial membrane. The relevance of this process in cancer is highlighted by 
the remark that oncogenes, like MYC, which promotes proliferation, also promote cell 
death that is inhibited by the anti-apoptotic BCL-2 proteins (Llambi and Green, 2011).  
The widely studied genes associated with apoptosis include BCL-2; the anti-apoptotic gene 
and BAX; a pro-apoptotic gene (Sjostrom and Bergh, 2001). Hypothetically, BCL-2 over-
expression renders a survival advantage for cancer cells; in contrast, an in vivo study has 
shown that expression of BCL-2 was linked to a better prognosis in malignant diseases 
(Sjostrom and Bergh, 2001). For example in breast cancer, tumours expressing BCL-2 
were found to have oestrogen receptors and resulted in a better prognosis, therefore 
oestrogen has been suggested to be an up-regulator of BCL-2 (Sjostrom and Bergh, 2001). 
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The BCL-2 protein is encoded by a gene which is triggered by the translocation of 
chromosomes in human follicular lymphomas (Gee et al., 1994). This translocation is a 
cytogenetic defect of chromosomes and it overlaps the BCL-2 gene with the 
immunoglobulin heavy chain locus, resulting in the over-expression of the BCL-2 protein 
(Gee et al., 1994). BCL-2 occupies various locations within the cell including the inner 
mitochondrial membrane, the endoplasmic reticulum and the nuclear envelope (Gee et al., 
1994). The BCL-2 protein has two forms; an alpha 26KDa form or a beta 22KDa form. 
The process of programmed cell death is blocked by the BCL-2 alpha protein (Gee et al., 
1994). The alpha protein has also been reported to alter the cytotoxicity of some anticancer 
agents by preventing apoptosis from occurring (Gee et al., 1994). The expression of BCL-2 
can increase the life span of a cell, therefore increasing the likelihood of various genetic 
abnormalities (Gee et al., 1994). 
BAX is the most well studied member of the BCL-2 family with regards to its role in 
cancer and it serves as a key pro-apoptotic protein (Sjostrom and Bergh, 2001; Roucou et 
al., 2005). BAX is located in the cytosol or found lightly affixed to the mitochondrial outer 
membrane (Roucou et al., 2005). When the cell is exposed to a pro-apoptotic stimulus, 
BAX is translocated into the mitochondria from the cytosol. Once in place, it exposes its 
N-terminal domain by changing conformation and thereby forms an oligomer at the 
mitochondria (Roucou et al., 2005). The translocation of BAX to the mitochondria results 
in the discharge of apoptogenic proteins exclusively found in the mitochondria; such as 
cytochrome c, endonuclease G, SMAC/DIABLO, Htr2/ Omi and AIF, initiating the 
caspase-dependent and independent pathways for apoptosis (Roucou et al., 2005). BAX 
stimulation restores sensitivity to apoptosis induced by drugs or radiation. In contrast, its 
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over expression has the opposite effect in that it suppresses apoptosis (Sjostrom and Bergh, 
2001). 
1.5  Angiogenesis and Regulatory Genes 
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is 
required for cancer growth and development. It is the growth and multiplication of a 
system of blood vessels that invades tumors, supplying nutrients and oxygen serving to 
remove wastes (Bates et al., 2002). Tumor angiogenesis begins when cancer cells release 
factors that convey signals to neighbouring normal host cells and tissue. This process 
triggers specific genes in the host cells that consecutively synthesise proteins that promote 
the development of new blood vessels (Bates et al., 2002).  
The creation of new blood vessels is a complicated process that involves more than 50 co-
dependent growth factors, cytokines, enzymes and receptors (Carmeliet, 2000), and several 
of them are from the vascular endothelial growth factor A (VEGFA), angiopoietin and 
ephrin families. The VEGF family performs important functions in vasculogenesis, 
angiogenesis and lymphangiogenesis. There are five members of the human VEGF family: 
VEGF (or VEGF-A), VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF) 
(Olofsson et al., 1996; Joukov et al., 1996; Achen et al., 1998; Ferrara, 2004; Hoeben et 
al., 2004). Alternative gene splicing of the respective human VEGF pre-mRNAs produces 
several isoforms of each gene. The VEGFA family of ligands have three receptor protein-
tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3) and two non-enzymatic receptors 
(neuropilin-1 and -2) (Roskoski, 2007). Many ligands of the VEGF family also attach to 
heparan sulphate proteoglycans that are located on the plasma membrane and the 
extracellular matrix (Roskoski, 2007). Binding sites for the VEGF gene were identified on 
vascular endothelial cells (Plouet and Moukadiri 1990; Vaisman et al., 1990), 
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corresponding to VEGFR1 (Flt-1) (Shibuya et al., 1990) and VEGFR2 (Flk-1/KDR) 
(Matthews et al., 1991; Terman et al., 1991; Terman et al., 1992). Their presence on 
endothelial cells is responsible for VEGF specificity. VEGF-C and VEGF-D are bound by 
VEGFR3 (Flt-4) (Pajusola et al., 1992), from the same receptor family.  
VEGFA signalling denotes a complex but crucial rate-limiting phase in angiogenesis and as 
a result is the subject of concentrated research (Nowak et al., 2008). The VEGFA gene 
consists of 8 exons set apart by 7 introns and spans 14 kilo bases (Houck et al., 
1991). VEGF pre-mRNA is differently spliced to generate mRNAs that encode about 12 
isoforms that have been researched widely, some possessing pro-angiogenic and others 
possessing anti-angiogenic properties (Perrin et al., 2005). One of the isoforms is 
VEGF165, with 165 amino acids in its complete structure. However, recent evidence 
indicates that 2 families of VEGF proteins are formed by alternative splice-acceptor-site 
assortment in the 3′ untranslated region (UTR) within the terminal exon 8 to give 2 
different C-terminal sequences that differ in only 6 amino acids (Bates et al., 2002, Qiu et 
al., 2009).  
Proximal splice-acceptor-site selection in exon 8 results in classic proangiogenic 
VEGFxxx isoforms that contain the exon 8a sequence, whereas distal splice-acceptor-site 
selection produces anti-angiogenic VEGFxxxb isoforms that contain the exon 8b sequence 
(with xxx denoting the number of amino acids) (Qiu et al., 2009). The proangiogenic 
isoforms encode a terminal 6–amino acid sequence of Cys-Asp-Lys-Pro-Arg-Arg, while 
the anti-angiogenic isoforms encode Ser-Leu-Thr-Arg-Lys-Asp. The most widely studied 
VEGFxxxb isoform is VEGF165b, but other isoforms have also been identified at both the 
mRNA and protein levels (Qiu et al., 2009). There is extensive expression of the VEGF165b 
transcript and protein in the majority of normal human tissues and in nonangiogenic 
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tissues. In contrast to the other VEGF isoforms, VEGF165b expression is reduced in 
angiogenic conditions, such as renal, prostate, colon, and skin cancers and proliferative 
diabetic retinopathy (Bates et al., 2002; Perrin et al., 2005). On the other hand, in 
nonangiogenic pathological conditions, like glaucoma, the anti-angiogenic VEGFxxxb 
isoforms are upregulated (Ergorul et al., 2008). VEGF165b protein was reported to 
substantially and dose proportionally block VEGF165-induced multiplication and 
movement of endothelial cells, vasodilation of mesenteric arteries, and angiogenesis in 2 
separate prototypes of VEGF165-induced vascular growth (Woolard et al., 2004). 
VEGF165b has dimerisation and receptor-binding regions; therefore, it functions as a 
competitive inhibitor of VEGF165; such that it binds to the receptor but fails to trigger the 
complete tyrosine phosphorylation of VEGF Receptor-2 and the subsequent signaling 
provoked by VEGF165 (Woolard et al., 2004). VEGF165b therefore seems to be an intrinsic 
anti-angiogenic agent produced by alternate splicing. Reports indicate that the control of 
alternative splicing by growth and splicing factors represents an important step in 
influencing the comparative expression of proangiogenic versus anti-angiogenic VEGF 
isoforms (Nowak et al., 2008; Qiu et al., 2009; Rennel et al., 2009).  
Since the amino acid configuration of anti-angiogenic VEGF165b is 95% to 96% similar to 
that of VEGF165a (Woolard et al., 2004; Qiu et al., 2009), the majority of past studies that 
have investigated VEGF expression could not differentiate between these proangiogenic 
and anti-angiogenic VEGF isoforms. It is noted that the majority of these studies were 
conducted before the discovery of anti-angiogenic VEGF isoforms or used in situ 
hybridisation riboprobes, antibodies, and ELISAs that detect both VEGF165a and 
VEGF165b isoforms (Manetti et al., 2011). One of the aims of the present study, therefore, 
was to investigate whether the expression of VEGF splice variants (VEGF165a and 
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VEGF165b) could be altered in breast and cervical cell lines exposed to different classes of 
antiretroviral drugs, individually and in combination. 
1.6  STUDY OBJECTIVES 
1.6.1  Broad Objectives 
To determine the effects of some of the antiretroviral drugs (included in the 2010 South 
African Antiretroviral Treatment Guidelines), individually and in combination, on 
apoptosis and on the expression of apoptotic and angiogenic genes such as BCL-2-
associated X protein (BAX), B-cell CLL/lymphoma 2 (BCL-2), vascular endothelial 
growth factor A (VEGFA), transcript variant 4 (VEGF165a) and vascular endothelial growth 
factor A (VEGFA), transcript variant 7 (VEGF165b) in normal and cancer human breast and 
cervical cell lines. This study looks at two cancers which are relevant in women living with 
HIV/AIDS. Cervical cancer; an AIDS associated cancer and breast cancer; a cancer 
commonly found in AIDS patients in the HAART era. 
1.6.2  Specific Objectives 
1. To assess the cytotoxicity of TDF, FTC, EFV and LPV/r (individually and at clinically 
relevant combinations) in normal and cancer cell lines of the breast and cervix at 
clinically relevant concentrations of the drugs and at different time points – 24, 48, 72 
and 96 hours employing the Neutral Red Toxicology/Viability Assay.  
2. To assess the effects of each of the drugs at clinically relevant concentrations on 
mRNA expression of BAX, BCL-2, VEGF165a and VEGF165b in each of the cell lines 
utilising Real Time Polymerase Chain Reaction (qPCR). 
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3. To assess the extent to which combinations of TDF/FTC/EFV; LPV/r and 
TDF/FTC/LPV/r alter the mRNA expression of BAX, BCL-2, VEGF165a and VEGF165b 
in each of the cell lines employing qPCR. 
4. To investigate the extent to which each of the drugs (at clinically relevant 
concentrations) alter protein localisation of BAX, BCL-2 and VEGF165b in each of the 
cell lines, employing confocal microscopy on immunofluorescence. Fluorescence 
intensities reflecting protein quantities will be measured. 
5. To investigate the extent to which combinations of TDF/FTC/EFV; LPV/r and 
TDF/FTC/LPV/r affect protein localisation of BAX, BCL-2 and VEGF165b in each of 
the cell lines employing confocal microscopy on immunofluorescence. 
6. To determine whether the Protease Inhibitors LPV/r inhibit drug induced apoptosis in 
all four cell lines employing the Acridine Orange staining for the morphological 
evaluation of apoptotic cells and the Cell Death Detection Enzyme Linked 
Immunosorbent assay (ELISA) for the quantification of internucleosomal DNA 
fragmentation - an important hallmark of apoptosis.    
1.7 Anticipated Outcome 
It was projected that completion of the aforementioned specific aims would provide a 
comparative and comprehensive evaluation of the effects of tenofovir disoproxil fumarate, 
efavirenz, emtricitabine and lopinavir/ritonavir (individually and in combination) on 
apoptosis, apoptotic and angiogenic gene expression, which could indicate the potential for 
carcinogenesis. Insights gained from the experiments might lead to intervention strategies 
to attenuate oncogenicity without altering drug efficacy, thus improving the quality of life 
of HIV/AIDS patients that are mainly women in this instance. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Kits, Antibodies and reagents 
The Neutral Red TOX-4 kit, Methanol, Acridine orange (AO), ethylenediamine-tetraacetic 
acid (EDTA) and Camptothecin (CPT) were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). Rabbit polyclonal anti-BAX antibody and mouse monoclonal anti-
BCL-2 were purchased from DAKO (DK-2600 Glostrup, Denmark). Primary antibodies-
polyclonal rabbit anti-human VEGF165b and secondary antibodies-goat anti rabbit 
Rhodamine conjugated and goat anti mouse FITC conjugated were purchased from 
ABCAM (Cambridge, UK). The GeneJET RNA Purification kit, DNase I, RNase-free kit 
and O'GeneRuler Low Range DNA Ladder were purchased from Thermo Scientific 
(Pittsburgh PA. USA). High Capacity cDNA Reverse Transcription Kit and Power SYBR® 
Green PCR Master Mix were purchased from Life Technologies (CA, USA). Oligos for 
qPCR were purchased from Integrated DNA Technologies, Inc. (Coralville, Iowa, 
USA). Agarose D-1 Low EEO-GQT was purchased from Conda Laboratories (Madrid, 
Spain). 
2.2.1 Cells 
Human squamous cell carcinoma cells (HCS-2) from the uterine cervix (Japanese 
Collection of Research Bio-resources, JCRB, Cell Bank) were cultured in Eagle's Minimal 
Essential Medium (EMEM) (Lonza, Verviers, Belgium) supplemented with 15% fetal calf 
serum (FCS) (Gibco, Germany) together with L-Glutamine (Gibco, Germany). 
Transformed normal human cervical cells (NCE16IIA) (Japanese Collection of Research 
Bio-resources, JCRB, Cell Bank) were cultured in Keratinocyte Basal Medium KBM-
GOLD (Lonza, Walkersville, MD USA) supplemented with human recombinant epidermal 
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growth factor, transferrin, hydrocortisone, epinephrine, insulin and bovine pituitary extract 
(Lonza, Walkersville, MD USA). 
Human breast carcinoma MCF-7 cells (American Type Culture Collection Rockville, MD, 
USA) were cultured in DMEM medium (Gibco, MD, USA) containing 10% fetal bovine 
serum (Gibco, MD, USA).  
Immortalized human breast epithelial cells, MCF-10A (American Type Culture Collection 
Rockville, MD, USA) were cultured in Mammary Epithelium Growth Medium (MEGM) 
(Lonza, Walkersville, MD USA) containing human recombinant epidermal growth factor, 
hydrocortisone, insulin and bovine pituitary extract (Lonza, MD, USA).  
2.2.2 Cell Culture 
Cells were propagated and sub-cultured according to supplier’s instructions, available at; 
http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?ID=5979 (for HCS-2 cells) 
http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?ID=3303 (for NCE16IIA cells) 
www.atcc.org/products/all/HTB-22.aspx (for MCF-7 cells)        
www.atcc.org/en/Global/Products/1/6/3/A/CRL-10317.aspx (for MCF-10A cells). All cell data 
sheets are included in Appendix A3. 
Briefly, cells were cultivated as a stationary monolayer in plastic tissue-culture dishes 
(Nunclon, Denmark) and were incubated at 37°C in a 5% CO2 humidified environment.  
Cells were grown to 70-80% confluence and washed with 1X 0.1 M phosphate buffered 
saline (PBS) (Sigma, St. Louis, MO, USA) pH 7.4 and trypsinized with 2 ml of Trypsin-
EDTA (Sigma, St. Louis, MO, USA). Following detachment, serum containing medium 
was added to deactivate the trypsin followed by centrifugation at the recommended rpm for 
each cell line in a Hermle Z400 centrifuge (HERMLE Labortechnik GmbH, Wehingen, 
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Germany), for 5 minutes. The supernatant was discarded and the cells were re-suspended 
in the appropriate culture media or freezing media for subculturing or storage respectively. 
Cells were stored at -80oC. 
2.2.2.1 Pre-treatment culture conditions 
The normal MCF-10A and NCE16IIA cells were cultured in serum-free media. MCF-7 
and HCS-2 cells were synchronised by serum starvation for 24 hours (Razandi et al., 2003; 
Pan et al., 2006) prior to all experiments. After being cultured in complete medium for 
overnight attachment, MCF-7 and HCS-2 cells were incubated with serum-free media for 
24 hours. The cells were then treated with the antiretroviral drugs (as described below; 
Table 2.2) in medium supplemented with serum for the indicated periods. 
2.3.1 Drugs  
Emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), efavirenz (EFV), lopinavir 
(LPV) and ritonavir (RTV) were purchased from Toronto Research Chemicals (Toronto, 
Ontario. Canada). FTC and TDF were dissolved in distilled water, while EFV, LPV and 
RTV were dissolved in methanol (appropriate diluents obtained from the certificate of 
analysis for each drug; Toronto Research Chemicals, Toronto, Canada).  
2.3.2 Stock Solutions of Antiretroviral Drugs 
Stock solutions of the antiretroviral drugs used in this study were prepared as follows; 
0.6mg TDF and 3.6mg FTC were weighed and dissolved in 1ml autoclaved distilled water. 
40.7mg EFV, 98mg LPV and 6mg RTV were weighed and dissolved in 1ml methanol 
(appropriate diluents obtained from the certificate of analysis for each drug; Toronto 
Research Chemicals, Toronto, Canada). Table 2.1 shows the volume of stock 
concentrations added to the growth media to obtain the final concentrations and the final 
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diluent concentration. All drugs were kept frozen in stock solutions and were diluted to the 
required concentrations in the appropriate growth media (Section 2.2.1) before use. 
Table 2.1: Preparation of stock and final concentrations of ARVs added to the cells 
Drug 
Original Stock 
Solution 
Volume of 
stock  
Volume of 
Growth   
2x 
concentration  
Final 
concentration  
% of 
diluent  
    added (µl) 
Medium added 
(µl) µg/ml 
added to cells 
µg/ml 
added to 
cells 
TDF 
0.6mg/ml 
dH2O 10 9990 0.6 µg/ml 0.3 µg/ml - 
FTC 
3.6mg/ml 
dH2O 10 9990 3.6 µg/ml 1.8 µg/ml - 
EFV 
40.7mg/ml 
meth 10 49990 8.14 µg/ml 4.07 µg/ml 
0.01% 
meth 
LPV 
98mg/ml 
meth 10 49990 19.6 µg/ml 9.8 µg/ml 
0.01% 
meth 
RTV 6mg/ml meth 10 49990 1.2 µg/ml 0.6 µg/ml 
0.01% 
meth 
dH2O= distilled water; meth=methanol 
2.3.3 Treatment  
The drugs were administered at clinically relevant concentrations which reflect their 
steady-state plasma peak concentration (Cmax) (Apostolova et al., 2010; Bumpus, 2011). 
The drug concentrations used in this study are the mean clinical Cmax plasma 
concentrations achieved after daily oral administration of the drugs in HIV patients 
receiving HAART (Drug information, VIREAD®, EMTRIVA®, SUSTIVA®, Gilead 
Sciences, 2010; Drug information, NORVIR®, KALETRA®, Abbott laboratories, 2010; 
Apostolova et al. 2010; Bumpus, 2011). The cells were incubated with the drugs 
individually and in combination at the indicated concentrations (Table 2.2) for 24, 48, 72 
and 96 hours. Untreated and vehicle control groups were exposed to growth medium and 
vehicle respectively (Groups 1 and 2). 
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 Table 2.2: Treatment groups and drug concentrations administered for each cell line. 
GROUP TREATMENT 
1 Growth Medium  
2 0.01% Methanol 
3 0.3µg/ml TDF 
4 1.8µg/ml FTC 
5 4.07µg/ml EFV 
6 TDF+FTC+EFV (ATRIPLA) 
7 9.8µg/ml LPV 
8 0.6µg/ml RTV 
9 LPV/r (KALETRA) 
10 TDF+FTC+LPV/r 
 
The cells were exposed to 0.3 μg/ml TDF; 1.8 μg/ml FTC; 4.07 μg/ml EFV, individually 
(Groups 3-5) and in combination (Group 6), as recommended by the 2010 South African 
antiretroviral treatment guideline and as in ATRIPLA®. Cells were also exposed to 9.8 
μg/ml LPV (Group 7) and LPV/r (KALETRA®). Even though the absolute bioavailability 
of Ritonavir had not been determined in humans at the time of this study and until now 
(Drug information, NORVIR® Abbott laboratories, 2013), across studies, administration of 
Kaletra® 400/100 mg daily yields mean steady-state lopinavir plasma concentrations 15 to 
20 times higher than those of ritonavir in HIV-1 patients (Drug information, KALETRA® 
Abbott laboratories, 2010). Therefore, a 9.8 μg/ml LPV:  0.6 μg/ml RTV ratio of lopinavir 
to ritonavir was used. In group 8, cells received 0.6 μg/ml RTV only. Another group of 
cells (Group 10) received a combination of TDF, FTC and LPV/r; recommended as a 2nd 
line regimen in the 2010 South African antiretroviral treatment guideline. 
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2.4 Neutral Red Uptake Assay 
The Neutral Red Uptake cytotoxicity assay is a precise, easy and reproducible assay that 
allows for distinguishing between viable and non-viable cells (Borenfreund and Puerner, 
1985). Neutral red is a weak cationic supravital dye that readily penetrates cell membranes 
by non-ionic diffusion and predominately accumulates intracellularly in lysosomes. 
Alterations to the lysosomal membrane integrity arising from the toxicity of substances 
reduces NR uptake thereby allowing the distinction between viable and damaged cells 
(Borenfreund and Puerner, 1985). After the viable cells have incorporated the dye, the dye 
is subsequently liberated from the cells and the degree of cytotoxicity, quantified by a 
spectrophotometer, is a measure of how many cells excluded the dye (Borenfreund and 
Puerner, 1985). 
This assay was used to evaluate the cytotoxic effects of the NRTI/nNRTI and PIs used in 
this study. HCS-2, NCE16IIA, MCF-7 and MCF-10A cells were cultured as described 
(Section 2.2.2.1). For each cell line, 96-well Falcon tissue culture plates containing 
approximately 5000cells/well, in 125 µl of growth medium were treated with different 
media containing the test compounds and drug combinations (Table 2.1 and 2.2) for 24, 48, 
72 and 96 hours. The negative control consisted of untreated cells, left in growth medium 
and diluent controls cells were exposed to 0.01% methanol. Each group consisted of four 
replicates. After treatment, the medium was removed and the protocol of Borenfreund and 
Puerner, (1985) was followed for the assay. Briefly, cells were rinsed in phosphate 
buffered saline (PBS). Neutral red medium was added to each well and plates were 
incubated for 2 hours at 37oC for the neutral red dye to be taken up by viable cells. 
Thereafter the NR solution was removed and cells were rinsed with PBS. The solubilising 
solution (1% acetic acid in 50% ethanol) was added to each well for 10 minutes in order to 
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extract the dye. The absorbance of the extracted dye was measured in a microplate reader 
(Anthos 2010 Model 17-550, Austria) at a wavelength of 540 nm. Background absorbance 
was read at 690 nm and subtracted from the 540 nm measurement. All experiments were 
repeated three times on three different days. The absorbance values were converted into 
percentage viability values as described in NICEATM, 2003. Statistical analysis was 
performed using JMP® (Version 10.0 SAS Institute Inc., Cary, NC). Data are reported as 
mean + standard deviation. After verifying the normal distribution and the homogeneity of 
the variance using an F test (p < 0.05), a one way analysis of variance (where a 
significance level of p < 0.05 was set) was used to compare the results. All means were 
then compared using the Tukey-Kramer HSD. The effects of each treatment on percentage 
viability were compared between the breast cell lines and between the cervical cell lines 
using the Tukey-Kramer HSD. Comparisons were made at 24, 48, 72 and 96 hours.  
2.5 Reverse Transcription and Real time qPCR 
This section describes the use of reverse transcriptase and quantitative real-time 
polymerase chain reaction to study the expression of the apoptotic genes; BAX and BCL-2 
and the angiogenic pathway-related genes; VEGF165a and VEGF165b mRNA in the cervical 
(cancer-HCS-2 and normal immortalized-NCE16IIA) and breast (cancer MCF-7 and 
normal immortalized-MCF10A) cells exposed to the antiretroviral drugs as described in 
Table 2.2. Total RNA was extracted (described below; Section 2.5.1) from the cells 
following treatment with the antiretroviral drugs or vehicle. The RNA extracts were 
reverse transcribed to cDNA using MultiScribe Reverse Transcriptase (described below; 
Section 2.5.3) and cDNA representing portions of each of the genes of interest were 
amplified with real-time qPCR. The relative expression of the specific genes of interest 
were normalised as a ratio to the amount of the two most stably expressed reference genes 
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according to the 2–ΔΔCT method of Livak and Schmittgen (2001). Three reference genes 
were used for these experiments as follows; Homo sapiens TATA box binding protein 
(TBP), Transferrin receptor (TFRC) and Homo sapiens ribosomal protein, Large P0 
(RPLP0). 
2.5.1 Total RNA Extraction 
Cells were cultured in 25 cm3 plastic tissue-culture dishes (Nunclon, Denmark) as 
described (Section 2.2.2.1). For each cell line, total RNA was extracted from each group 
(Table 2.2), three different times on three different days from different experiments to 
generate the biological replicates required to validate the qPCR experiments (Bustin, 2002, 
Fleige and Pfaffl, 2006, Bustin et al., 2009). After cells were exposed to the drugs for 96 
hours, total RNA extraction was performed using the GeneJET RNA Purification kit (Van 
Phuc et al., 2011) according to the manufacturer’s instructions (Thermo Scientific, 
Pittsburgh PA. USA). The protocol was adapted from Chomczynski and Sacchi, (1987) 
and Boom et al., (1990). The procedure for total RNA extraction is detailed in Appendix 
B1. RNA concentration and purity were determined using the Nanodrop®-1000 
(NanoDrop® Technologies, USA) spectrophotometer (Derks et al., 2008). RNA integrity 
was determined by gel electrophoresis (Derks et al., 2008). The RNA was stored at -80oC 
in 10 μl aliquots for future use. 
2.5.1.1 RNA Gel Electrophoresis 
The formaldehyde agarose (FA) gel electrophoresis procedure described by the RNeasy 
Mini Handbook (QIAGEN®, USA) was followed. The procedure for RNA gel 
electrophoresis is detailed in Appendix B2. Illumination of the stained gels under UV light 
(254-366 nm) allowed bands of RNA to be visualised against a background of unbound 
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dye. Gel images were acquired with the BioRad Gel Doc® XR (Model 170-8170 Segrate, 
Milan. Italy). The integrity and size distribution of total RNA was checked by observing 
the stained RNA. The respective ribosomal bands appeared as sharp bands on the stained 
gel. The 28S ribosomal RNA band was present at approximately twice the intensity of the 
18S ribosomal RNA band (RNeasy Mini Handbook, QIAGEN®, USA). 
2.5.1.2 RNA Quantification 
Quantification of RNA was done using a Nanodrop®-1000 spectrophotometer (NanoDrop® 
Technologies, USA). Readings were taken at 260 nm and 280 nm as described by the 
manufacturer. A 260/280 ratio of approximately 2 was regarded as pure quality (Derks et 
al., 2008). 
2.5.2 Genomic DNA (gDNA) Removal 
Genomic DNA contamination was removed from total RNA using the DNase I, RNase-
free kit (Thermo Scientific, Pittsburgh PA. USA) according to the protocol adapted from 
Kienzle et al., (1996) and Sambrook and Russel, (2001). The procedure for gDNA removal 
is detailed in Appendix B3. 
2.5.3 Reverse Transcription for Complementary DNA (cDNA) Synthesis 
Using the High Capacity cDNA Reverse transcription kit (Life Technologies, California, 
USA) and as previously reported in Szwagierczak et al. (2010), cDNA was synthesised 
using MultiScribe™ Reverse Transcriptase from 700ng RNA. The reverse transcriptase 
reaction was carried out in a GeneAmp® PCR system 9600 Thermal Cycler for 10 mins at 
25°C, 120 mins at 37°C and then the enzyme was deactivated for 5 mins at 85°C. 
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cDNA samples were either used immediately for real time PCR or stored at -20oC for later 
use. RNase-free and standard sterile protocols, according to the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) (Bustin, 2002; Fleige 
and Pfaffl, 2006; Bustin et al., 2009) were exercised at all times and for all RNA, cDNA 
and qPCR procedures. Reagents were thawed on ice before use, and kept on ice while in 
use. 
Table 2.3: Components of the Reverse Transcription reaction 
Component  Volume/Reaction (μL) 
10✕ RT Buffer 2 
25✕ dNTP Mix (100 mM)  0.8 
10✕ RT Random Primers  2 
MultiScribe™ Reverse Transcriptase 1 
RNase Inhibitor  1 
RNA  Variable 
Nuclease-free H2O  added to increase total vol to 20 
Total per Reaction  20 
     
For all samples, the reverse transcription (RT) reaction was carried out without the reverse 
transcriptase enzyme to generate the minus RT controls. The minus RT samples were later 
amplified to confirm the absence of genomic DNA. 
2.5.4 Primer Design 
According to the MIQE guidelines (Bustin et al., 2009), primers should be obtained from 
RTPrimerDB. RTPrimerDB is a public database for primer and probe sequences used in 
real-time PCR assays employing popular chemistries (SYBR Green I, Taqman, 
Hybridisation Probes, Molecular Beacon) to prevent time-consuming primer design and 
experimental optimisation, and to introduce a certain level of uniformity and 
standardisation among different laboratories.  
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The database is available online at http://medgen.ugent.be/rtprimerdb/. Primers for the 
human BAX gene was obtained from this database; Assay ID 1539. The RTPrimerDB 
website did not contain deposited primers for the other genes of interest required for this 
study, therefore, the appropriate forward and reverse primers were designed using the 
primer design tool of the National Centre for Biotechnology Information (NCBI) website 
at; http://www.ncbi.nlm.nih.gov/tools/primer-blast/  
Designed primer pairs were then analysed with the Integrated DNA Technologies (IDT) 
SciTools Oligo Analyzer® 3.1 online tools. All primers were synthesised by IDT 
(Coralville, Iowa, USA) and all primer pairs were used at an annealing temperature of 
60oC. Primer sequences are listed in Table 2.4. (See also Appendix C1). 
Table 2.4: Oligonucleotide sequences used for qPCR 
Gene Sequences (5'-3' direction) 
Product size 
(bp) 
BAX Forward CCT TTT CTA CTT TGC CAG CAA AC 148 
BAX Reverse GAG GCC GTC CCA ACC AC   
BCL-2 Forward ATG TGT GTG GAG AGC GTC AAC C 122 
BCL-2 Reverse GCA TCC CAG CCT CCG TTA TC   
TBP Forward TGA TGC CTT ATG GCA CTG GAC TGA 86 
TBP Reverse CTG CTG CCT TTG TTG CTC TTC CAA   
RPLP0 Forward TGC AGC TGA TCA AGA CTG GAG ACA 178 
RPLP0 Reverse TCC AGG AAG CGA GAA TGC AGA GTT   
TFRC Forward GGC ACC ATC AAG CTG CTG AAT GAA 133 
TFRC Reverse GTT GAT CAC GCC AGA CTT TGC TGA   
VEGF 165A Forward CAA GAT CCG CAG ACG TGT AA 100 
VEGF 165A Reverse GCT TGT CAC ATC TGC AAG TA   
VEGF 165B Forward CGC AGA CGT GTA AAT GTT CCT G 97 
VEGF 165B Reverse TTC CTG GTG AGA GAT CTG CAA G   
 
 
 
42 
 
2.5.5 Determination of qPCR Amplification Efficiencies 
For each primer pair, amplification efficiencies were determined by amplifying serial 
dilutions of cDNA. Data from these are used by the Applied Biosystem’s ABI 7500 
software to plot the slope and efficiency of the reaction for each primer pair. According to 
the MIQE guidelines (Bustin et al., 2009), the ranges of accepted efficiencies are 90-110%. 
The amplification efficiencies for all primer pairs used were within this range. (Appendix 
C2). 
2.5.6 qPCR Protocol 
The Power SYBR® Green PCR Master mix was used for the qPCR procedure. This 
protocol contains adaptations from Mullis and Faloona (1987), Saiki et al. (1988) and 
Kwok and Higuchi (1989). The Power SYBR® Green PCR Master Mix is a premix of the 
components (except primers, template, and water) necessary to perform real-time PCR 
using SYBR® Green I dye with enhanced sensitivity and specificity (Life Technologies, 
California, USA, 2011). The SYBR Green dye binds to double-stranded (ds) DNA, thus 
providing a fluorescent signal that reflects the amount of ds-DNA product generated during 
PCR (Life Technologies, California, USA, 2011). The qPCR reaction was set up in 
MicroAmp® Optical 8-tube Strips (Life Technologies, CA, USA) as follows (Table 2.5) 
Table 2.5: qPCR Reaction setup 
Component 
Volume per 20μl 
reaction 
Final 
Concentration 
Power SYBR® Green PCR Master Mix 
(2X) 10 1X 
Forward Primer 0.4 200-400nM 
Reverse Primer 0.4 200-400nM 
Template 5 10ng 
Water 4.2   
Total 20   
43 
 
 PCR reactions were amplified for 40 cycles prior to which the AmpliTaq Gold® DNA 
polymerase was activated for 10 mins at 95°C. Each cycle consisted of a denaturing step 
for 15 secs at 95°C, and annealing/extension step for 1 min at 60°C. PCR amplification 
was performed in a final volume of 20 μl using the Power SYBR® Green PCR Master Mix 
with the ABI 7500 and Step-One real-time PCR machines. To confirm the absence of 
nonspecific amplification, PCR products were separated on 3% agarose gels. Melt curves 
were generated for each PCR product using the Applied Biosystems ABI 7500 software 
(Appendix C3).  
2.5.7 Agarose Gel Electrophoresis of DNA 
A 3% (w/v) agarose gel was prepared per 50 ml gel as follows; 
1.5 g agarose, 50 ml 1X TBE buffer (10X Tris Borate EDTA; 0.89 M Tris, 0.02 M EDTA, 
0.89 M Boric Acid made up to 1000 ml with DEPC treated water pH + 8.3). Agarose was 
boiled in a microwave until no crystals were visible and allowed to cool to hand warmth. 
Two (2) μl of ethidium bromide was added. Gel was poured into the casting unit and 
allowed to set for 30 minutes. Samples were prepared by mixing 1 volume of 6X DNA 
loading dye (Thermo Scientific, Pittsburgh PA, USA) and 5 volumes of DNA samples. 
After the gel was set, the aluminium gates and the combs were removed. The gel was 
placed into the tank containing 1X TBE. PCR products were loaded into the well and 
loading order recorded. An equal volume of O'GeneRuler Low Range DNA Ladder 
(Thermo Scientific, Pittsburgh PA, USA) was loaded into the first and last wells of each 
comb. Electrodes were then connected so that samples ran from negative to positive (from 
black to red leads). Gels were run at 100 V, 180 mA for 3 hours. Gel images were acquired 
with the BioRad Gel Doc® XR (Model 170-8170 Segrate, Milan. Italy) (Appendix C4). 
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2.5.8 qPCR Data Analysis 
The relative mRNA expression levels of target genes in each sample were calculated using 
the qbasePLUS software (Biogazelle, Zulte, Belgium). The stability of reference genes 
expression was evaluated using qbasePLUS version 2.3. This software employs a pair-wise 
comparison model to calculate the stability of each reference gene, and selects the two or 
more most stable genes from a panel of reference genes for normalisation (Hellemans et 
al., 2007). Genes were ranked based on a gene stability parameter M, where a low M value 
indicates high expression stability. In addition, the qbasePLUS software also calculates the 
coefficient of variation (CV) to determine how stable a gene is expressed. PCR base line 
Cq values were exported from the ABI 7500 software as an Excel file (Microsoft, 
Redmond, WA, USA) and imported into the qbasePLUS software. The data were then 
analysed using the default settings and the arithmetic mean of replicates was used. Data 
from standard curve experiments from the ABI 7500 software, imported into the qbasePLUS 
software, was used to generate amplification efficiencies and standard errors that are used 
downstream by the qbasePLUS software to determine normalised gene expression levels. 
The relative quantity of each target/sample combination was scaled to the average Cq of 
corresponding target (scale set to untreated control in the qbasePLUS software). The relative 
expression of specific genes in the experiment were normalised as a ratio to the amount of 
the two most stably expressed reference genes according to the 2–ΔΔCT method of Livak 
and Schmittgen (2001). To determine whether the expression of the genes of interest from 
the untreated differed significantly from those from the treated groups, the 
qbasePLUS software was used to conduct the analysis of variance (ANOVA) with 
significance level set at p<0.05. 
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2.6 Immunofluorescence 
2.6.1 BAX and BCL-2 
The genes carrying the genetic information for BAX and BCL-2 proteins belong to the 
BCL-2 family, and they comprise the most biologically relevant classes of apoptosis 
regulators involved in the critical stages of apoptosis (Basu and Haldar, 1998). Generally, 
the relative ratio of pro-survival (BCL-2) and anti-survival (BAX) proteins is believed to 
determine cell sensitivity or resistance to the apoptotic stimuli (Ola et al., 2011). BAX 
promotes apoptosis while BCL-2 inhibits it, therefore they were co-localised to determine 
whether the antiretroviral drugs used in this study affects apoptotic cell function through 
this pathway.  
2.6.2 VEGF165 
VEGF165b behaves as a competitive inhibitor of VEGF165a by binding to its receptor but 
not stimulating the full tyrosine phosphorylation of the VEGFR-2 and the downstream 
signaling triggered by VEGF165a (Woolard et al., 2004). VEGF165b is therefore considered 
to be an endogenous anti-angiogenic agent produced by alternative splicing (Woolard et 
al., 2004). The effects of the antiretroviral drugs on VEGF165b localisation was determined 
by immuno-cytochemistry.  
2.6.3 Cell Staining 
The immunofluorescence staining procedure used in this study was adapted from the 
ABCAM® double labelling procedure, available at 
http://www.abcam.com/ps/pdf/protocols/Double%20immunofluorescence%20-
simultaneous%20protocol.pdf (Appendix B5). 
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2.6.3.1 Optimization 
A guide for cell staining was provided with the datasheet accompanying the primary and 
secondary antibodies used in this study, but to ensure specific antibody binding and 
optimal visualization of the target proteins, the following parameters required initial 
optimization; primary and secondary antibody dilutions, the blocking solution and duration 
and the duration of incubation with primary and secondary antibodies. The parameters 
optimized for immune-fluorescence are detailed in Appendix B4.  
2.6.3.2 Immuno-staining 
Cells (1x104) were plated on cover slips 1 day before the experiment. Cells were then 
cultured as described (Section 2.2.2.1). Cells were treated with the drugs at the indicated 
combinations and concentrations (Table 2.2) for 96 hours. Following treatment, cells were 
washed three times with 0.5% BSA in PBS, followed by fixation in 10% phosphate 
buffered formalin for 10 min. The fixed cells were rinsed in PBS and permeabilized with 
0.05% Triton-X 100 in PBS, washed and blocked with 10% normal goat serum in PBS for 
60 mins to eliminate non-specific binding of secondary antibody. Cells were then 
incubated with polyclonal rabbit anti-human BAX (1:1000 DAKO) and monoclonal mouse 
anti-human BCL-2 (1:100 DAKO) or polyclonal rabbit anti-human VEGF165b (5 μg/ml) 
(ABCAM). Following overnight incubation, the cells were washed and incubated for 2 
hours with a FITC-conjugated goat anti-mouse antibody (1:500 ABCAM) and Rhodamine-
conjugated goat anti-rabbit antibody (1:1000 ABCAM) in the dark. Slides were rinsed, 
nuclei counterstained in 4',6-diamidino-2-phenylindole (DAPI) 300 nm for 5mins, rinsed 
and mounted with Fluoromount (Sigma). Negative control groups were set up to ensure 
that the secondary antibodies were specific for their primary antibodies. The primary 
antibodies were substituted with 0.1% BSA/PBS and the normal protocol was carried out. 
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In a second negative control, the cells were treated in the same way as the experimental 
slides, but the secondary antibodies were substituted with PBS. The positive controls used 
in this study were HeLa cells, which had been shown to express BAX and VEGF165b ( 
Tsuruta et al., 2002, http://www.abcam.com/vegf-165b-antibody-mrvl561-ab14994.html, 
http://www.abcam.com/vegf-165b-antibody-ab90719.html, http://www.abcam.com/BAX-
antibody-ab10813.html?productWallTab=Abreviews&applications=3688, 
http://www.ptglab.com/Products/BAX-Antibody-50599-2-Ig.htm) and HepG2 cells, shown 
to express BCL-2 (Tan et al., 2009). These controls were set up to ensure that cross-
reactivity was not taking place.  
Cells were visualized using a Zeiss Laser Scanning Confocal Microscope 780 under a 
Zeiss 100X oil immersion objective. For digital image analysis, ZEN 2010 software was 
used. Slides were kept dark once fluorescent antibodies had been added to prevent 
bleaching. As fading of the fluorochromes will take place, images were analysed within the 
same time period. The image acquisition settings remained constant for all exposures. 
Images were taken and using the ZEN 2010 (Carl Zeiss, Germany) image analysis 
software, the intensity of the fluorescence of each micrograph was analysed. This was done 
by using the software to initially define the regions of interest (ROIs); namely, the nucleus 
and cytoplasm. The mean intensity of each ROI from the treatment groups (according to 
Table 2.2) was then analysed with the statistics software JMP® (Version 10.0 SAS Institute 
Inc., Cary, NC, USA). Data are reported as mean + standard deviation. After verifying the 
normal distribution and the homogeneity of the variance using an F test (p < 0.05), a one 
way analysis of variance (where a significance level of p < 0.05 was set) was used to 
compare the results. Representative images are shown. 
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2.7 Acridine Orange Staining 
Fluorescence light microscopy with differential uptake of fluorescent DNA binding dyes 
such as Acridine Orange (AO) provides a simple, rapid, and accurate method for 
measuring apoptosis and cell membrane integrity (Coligan et al., 1995). Acridine Orange 
permeates all cells, making the nuclei appear green (Excitation; 488 nm laser line: Emitted 
fluorescence acquired at 500–560 nm (green region of spectrum, for AO). Live cells 
therefore have normal green nuclei; early apoptotic cells have bright green nuclei with 
condensed or fragmented chromatin; late apoptotic cells display condensed and fragmented 
chromatin and membrane blebbing (Ribble et al., 2005; Yang et al., 2013). This procedure 
was carried out to determine whether the protease inhibitors inhibit drug induced apoptosis 
in the cervical and breast cell lines since it had been reported (Phenix et al, 2001, Badley, 
2005, Vlahakis et al., 2007, Rizza and Badley, 2008) that protease inhibitors have potent 
anti-apoptotic effects in different cellular systems, the majority of which are immune cells. 
The anti-apoptotic effect of LPV/r was assessed to test whether these generalised effects 
are seen in the currently investigated cell lines. 
2.7.1 Induction of Apoptosis 
It was reported previously that 1 μM CPT significantly induced apoptosis in MCF-7 cells 
(Nieves-Neira and Pommier, 1999) and that 30 μM CPT significantly induced apoptosis in 
MCF10A cells (Rastogi et al., 2006). For this study, these CPT concentrations were further 
optimised to determine the appropriate exposure time. In the breast cell lines, 1 μM CPT 
significantly increased the percentage of apoptotic MCF-7 cells from 3-4% (spontaneous 
apoptosis) to 15-18% following a 6 hour exposure, while the percentage of apoptotic MCF-
10A cells increased from 1-2% to 8-9% following a 6 hour exposure to 30 μM CPT as 
determined by the AO staining.  No literature was found describing the induction of 
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apoptosis with CPT in the cervical cell lines, so the CPT concentrations used to induce 
apoptosis in the cervical cell lines in this study were determined by optimisation 
experiments. HCS-2 and NCE16IIA cells were exposed to 1 μM CPT, 5 μM CPT, 10 μM 
CPT, 15 μM CPT, 20 μM CPT, 25 μM CPT, 30 μM CPT, 50 μM CPT for 6, 12, 18 and 24 
hours. 25 μM CPT significantly increased the percentage of apoptotic HCS-2 cells from 1-
2% (spontaneous apoptosis) to 10-12% following a 6 hour exposure, while the percentage 
of apoptotic NCE16IIA cells increased from 2% to 14-16% following a 6 hour exposure to 
5 μM CPT. 
2.7.2 Cell treatment and AO staining 
HCS-2, NCE16IIA, MCF-7 and MCF-10A cells were cultured as described (Sections 2.2.1 
and 2.2.2.1) on 22-mm square coverslips placed into 35-mm culture dishes (Costar, 
Cambridge MA, USA). Cells were treated with 0.01% methanol (vehicle) and the PI based 
combinations; LPV/r (in the appropriate medium; Section 2.2.1) for 96 hours before being 
stimulated (Phenix et al., 2001) to undergo apoptosis with 25 μM CPT in EMEM (HCS-2), 
5 μM CPT in KGM (NCE16IIA), 1 μM CPT in DMEM (MCF-7) and 30 μM CPT in 
MEGM (MCF-10A) for 6 hours. After induction of apoptosis, the CPT-containing medium 
was discarded, cells rinsed with PBS and 1ml AO dye mix (100 μg/ml AO in PBS) 
(Coligan et al., 1995; Mironova et al., 2007), was added into the culture dishes for 5 
minutes. After AO staining, cells were rinsed with PBS and culture dishes were inverted 
and fixed with formaldehyde vapour for 1 minute to prevent the photo-damaging effects of 
continuous excitation on living cells due the photosensitizing effects of most fluorescent 
dyes (Canete et al., 2001). Fluorescence images were captured using a Zeiss (Carl Zeiss 
MicroImaging GmbH, Germany) LSM 780 confocal microscope equipped with an argon 
ion laser of 25 mW (excitation wavelengths 458, 488 and 514 nm). A total of 600 cells per 
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cell line per group were counted from 3 independent experiments to determine the 
percentage of apoptotic cells. Data analysis was performed using JMP® (Version 10.0 SAS 
Institute Inc., Cary, NC). Data are reported as mean + standard deviation. After verifying 
the normal distribution and the homogeneity of the variance using an F test (p < 0.05), a 
one way analysis of variance (significance level p < 0.05) was used to compare the results. 
If there was a significant difference between the means (p<0.05) then a Tukey-Kramer post 
hoc analysis was performed to determine which treatment groups were significantly 
different from each other. 
2.8 Cell Death Detection ELISA 
The Cell Death Detection ELISA plus kit (Roche Molecular Biochemicals, Mannheim, 
Germany) is used to measure changes in apoptosis (Liu et al., 2003; Tu et al., 2009). In 
this procedure, internucleosomal DNA fragmentation is quantitatively assayed by antibody 
mediated capture and detection of cytoplasmic mononucleosome and oligonucleosome 
associated histone-DNA complexes. Cells were cultured as described (Sections 2.2.1 and 
2.2.2.1) in 96 well plates in duplicate. Cells were treated with 0.01% methanol (vehicle) 
and the PI based combination; LPV/r (in the appropriate medium; Section 2.2.1); for 96 
hours before being stimulated (Phenix et al., 2001) to undergo apoptosis with 25 μM CPT 
(HCS-2), 5 μM CPT (NCE16IIA), 1 μM CPT (MCF-7) (Nieves-Neira and Pommier, 1999) 
and 30 μM CPT (MCF10A) (Rastogi et al., 2006) for 6 hours.       
According to the protocol described by Liu et al., (2003) and Tu et al., (2009), cells were 
centrifuged (200 g), resuspended in 200 μl of the lysis buffer supplied in the kit and 
incubated for 30 min at room temperature. Nuclei were then pelleted at 200 g for 10 mins 
and 20 μl of the supernatant (cytoplasmic fraction) from treated group, untreated group, 
positive control and background control were transferred into the corresponding 
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streptavidin coated wells for the enzyme-linked immunosorbent assay (ELISA) according 
to the manufacturer’s standard protocol (Tu et al., 2009). Eighty (80) μl of the 
immunoreagent was added to each well containing the 20 μl supernatant or controls. The 
wells were covered with adhesive foil and incubated on a microplate shaker under gentle 
shaking (300 rpm) for 2 hours at room temperature. The solution was then removed by 
gentle pipetting; wells were rinsed three times with 250 μl incubation buffer and removed. 
One hundred (100) μl of the ABTS solution was pipetted into the wells and incubated on a 
plate shaker at 250 rpm until the colour development was sufficient for photometric 
analysis (approximately 10-20 minutes). One hundred (100) μl of the ABTS stop solution 
was added to each well. Absorbance was measured at 405 nm and 490 nm (reference 
wavelength) with a microplate reader (Anthos 2010 Model 17-550, Austria). Signals in 
wells containing the substrate only were subtracted as background. Data were analysed 
from three independent experiments. Data analysis was performed using JMP® (Version 
10.0 SAS Institute Inc., Cary, NC). Data are reported as mean + standard deviation. After 
verifying the normal distribution and the homogeneity of the variance using an F test 
(p < 0.05), a one way analysis of variance (significance level p < 0.05) was used to 
compare the results. If there was a significant difference between the means (p<0.05) then 
a Tukey-Kramer post hoc analysis was performed to determine which treatment groups 
were significantly different from each other. 
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CHAPTER 3: RESULTS 
 
3.1 Effects of Antiretroviral drugs on the viability of breast and cervical cells 
3.1.1 Effects of TDF on the viability of the cervical cells 
After 24 and 48 hours of exposure, the NRTI, TDF, significantly (p<0.05) increased the 
viability of the normal cervical (NCE16IIA) cells; when compared to their control groups 
(Fig. 3.1A). With prolonged treatment (72 to 96 hours), these effects were not significantly 
different (Fig. 3.1A). The viability of the cancer cervical (HCS-2) cells was initially (24 to 
48 hours) not altered by TDF, but at 72 hours, HCS-2 percentage viability became 
significantly (p<0.05) reduced when compared to the control group and the normal cervical 
cells (also at 72 hours) (Fig. 3.1A). After 96 hours of exposure to TDF, the cancer cervical 
cells exhibited reduced (but not significant p<0.05) viability when compared to its control 
and the normal cells at 96 hours (Fig. 3.1A).  
 
 
Fig. 3.1A: Effects of TDF on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 0.3μg/ml TDF for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.2 Effects of TDF on the viability of the breast cells 
The viability of the normal breast MCF-10A cells was significantly (p<0.05) reduced by 
TDF after 24 hours of exposure; when compared to its control (at 24 hours) and the cancer 
MCF-7 cells(also at 24 hours) (Fig. 3.1B). With prolonged treatment, the MCF-10A cells 
recovered from the initial cytotoxic effects of TDF such that after 48 hours and up to 96 
hours, there were no significantly (p<0.05) different alterations to their viability when 
compared to their controls at the respective time points (Fig. 3.1B). At 48 hours, however, 
TDF significantly (p<0.05) reduced the viability of the cancer MCF-7 cells when 
compared to the normal MCF-10A cells (Fig. 3.1B). TDF produced no significant (p<0.05) 
alterations to the viability of the cancer MCF-7 cells at all time points when compared to 
their respective controls (Fig. 3.1B).  
 
Fig. 3.1B: Effects of TDF on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 0.3μg/ml TDF for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.3 Effects of FTC on the viability of the cervical cells 
The NRTI, FTC, exhibited no significant (p<0.05) alterations to the viability of the normal 
cervical (NCE16IIA) cells from 24 to 72 hours (Fig. 3.2A); however, at 96 hours, FTC 
significantly (p<0.05) reduced their viability (Fig. 3.2A); when compared to the control. 
FTC also significantly (p<0.05) reduced the viability of the normal cervical cells when 
compared to the cancer cervical HCS-2 cells at 96 hours (Fig. 3.2A). With respect to the 
cancer cervical cells, from 24 hours through 96 hours, FTC did not significantly (p<0.05) 
alter cell viability.     
 
 
 
Fig. 3.2A: Effects of FTC on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 1.8μg/ml FTC for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
 
 
%
 V
ia
bi
lit
y 
A 
55 
 
3.1.4 Effects of FTC on the viability of the breast cells 
FTC increased the viability of normal breast MCF10-A cells at 24 hours of exposure, 
however, the difference was not statistically significant (p<0.05) (Fig. 3.2B). From 48 
through 96 hours, FTC did not significantly alter the viability of the normal breast MCF-
10A cells (Fig. 3.2B). FTC significantly (p<0.05) reduced the viability of the cancer MCF-
7 cells (when compared to the untreated control) after 48 hours of exposure (Fig. 3.2B). 
The effects of FTC on the cancer breast MCF-7 cells were not significantly different from 
the vehicle controls at 24, 72 and 96 hours (Fig. 3.2B). 
 
 
 
Fig. 3.2B: Effects of FTC on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 1.8μg/ml FTC for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.5 Effects of EFV on the viability of the cervical cells 
The NNRTI, EFV, did not significantly (p<0.05) alter the viability of the normal 
(NCE16IIA) and cancer (HCS-2) cervical cells through all the time points tested when 
compared to their respective controls (Fig. 3.3A). However, at 48 hours, EFV showed 
opposing effects on the normal and cancer cervical cells. EFV significantly (p<0.05) 
reduced the viability of the normal NCE16IIA cells when compared to the cancer HCS-2 
cells after 48 hours of exposure (Fig. 3.3A).  
 
 
 
Fig. 3.3A: Effects of EFV on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 4.07μg/ml EFV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.6 Effects of EFV on the viability of the breast cells 
EFV significantly (p<0.05) reduced the viability of the normal breast MCF-10A cells at all 
time points measured (24 to 96 hours); when compared to their control groups (Fig. 3.3B). 
EFV also significantly (p<0.05) reduced the percentage viability of the normal breast cells 
when compared to the percentage viability of the cancer breast MCF-7 cells at all time 
points (Fig. 3.3B). While EFV increased MCF-7 viability at 72 and 96 hours, this increase 
was not statistically significant (Fig. 3.3B).  
 
 
 
Fig. 3.3B: Effects of EFV on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 4.07μg/ml EFV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.7 Effects of ATP on the viability of the cervical cells 
The combination of TDF, FTC and EFV, as combined in ATRIPLA®, reduced the 
percentage viability of the normal cervical (NCE16IIA) cells from 24 to 96 hours, but the 
differences were not statistically significant (p<0.05) when compared to their vehicle 
controls (Fig. 3.4A). However, ATP significantly (p<0.05) reduced the viability of the 
NCE16IIA cells when compared to the cancer cervical HCS-2 cells at 48 and 72 hours 
(Fig. 3.4A). When compared to their controls, ATP did not significantly alter the viability 
of the cancer cervical HCS-2 cells from 24 through 96 hours (Fig. 3.4A).  
 
 
Fig. 3.4A: Effects of ATP on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 1.8μg/ml FTC; 0.3μg/ml TDF; 4.07μg/ml EFV for 
24 – 96 hrs. Graphs were plotted with mean +SEM percentage viability from a mean of three 
independent experiments. Groups not connected by the same letter are significantly different 
(p<0.05). 
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3.1.8 Effects of ATP on the viability of the breast cells 
ATP significantly (p<0.05) reduced the percentage viability of the normal breast MCF-10A 
cells after 24 hours when compared to the vehicle control (Fig. 3.4B). Also at 24 hours, 
there was a significant (p<0.05) difference between the percentage viability of the normal 
breast MCF-10A and the cancer breast MCF-7 cells (Fig. 3.4B). With continuous exposure 
(48 to 96 hours), ATP did not significantly alter the percentage viability of the normal and 
cancer breast cells (Fig. 3.4B). 
 
 
Fig. 3.4B: Effects of ATP on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 1.8μg/ml FTC; 0.3μg/ml TDF; 4.07μg/ml EFV for 
24 – 96 hrs. Graphs were plotted with mean +SEM percentage viability from a mean of three 
independent experiments. Groups not connected by the same letter are significantly different 
(p<0.05). 
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3.1.9 Effects of LPV on the viability of the cervical cells 
The PI, LPV, did not significantly (p<0.05) alter the percentage viability of the normal and 
cancer cervical cells when compared to their vehicle controls from 24 to 96 hours (Fig. 
3.5A). There were significant (p<0.05) differences, however, between the percentage 
viability of normal and cancer cells at 24 to 48 hours in response to LPV; with the viability 
of the normal cervical (NCE16IIA) cells significantly (p<0.05) reduced (Fig. 3.5A). 
 
 
Fig. 3.5A: Effects of LPV on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 9.8μg/ml LPV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.10 Effects of LPV on the viability of the breast cells 
LPV significantly (p<0.05) reduced the viability of the normal breast MCF-10A cells at 24 
hours when compared to the vehicle control (Fig. 3.5B). Also at 24 hours, LPV 
significantly (p<0.05) reduced the percentage viability of the normal breast cells when 
compared to the cancer breast MCF-7 cells (Fig. 3.5B). With continuous exposure, the 
normal breast cells recovered from the initial cytotoxic effects of LPV, such that at 48 to 
96 hours, there were no significant differences between the treated cells and their vehicle 
controls (Fig. 3.5B). LPV did not significantly (p<0.05) alter the percentage viability of the 
breast cancer MCF-7 cells from 24 to 96 hours when compared to their vehicle controls 
(Fig. 3.5B). 
 
 
Fig. 3.5B: Effects of LPV on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 9.8μg/ml LPV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.11  Effects of RTV on the viability of the cervical cells 
The PI, RTV, did not significantly (p<0.05) alter the percentage viability of the normal 
(NCE16IIA) and cancer (HCS-2) cervical cells from 24 to 96 hours when compared to 
their respective vehicle controls and to each other at the respective time points (Fig. 3.6A). 
 
 
Fig. 3.6A: Effects of RTV on the percentage viability of normal cervical (NCE16IIA) and cervical 
cancer (HCS-2) cells. Cells were incubated with 0.6μg/ml RTV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.12 Effects of RTV on the viability of the breast cells 
RTV significantly (p<0.05) reduced the viability of the normal breast MCF-10A cells 
when compared to the vehicle control and the breast cancer MCF-7 cells at 24 hours (Fig. 
3.6B). At 48 hours there was no significant (p<0.05) alteration in percentage viability 
between RTV treated and untreated in either cell line. At 72 hours, RTV treated MCF-10A 
cells demonstrated significantly (p<0.05) increased viability, while at 96 hours, there was 
no statistical significance in the difference between RTV treated and untreated MCF-10A 
cells (Fig. 3.6B). RTV did not alter the percentage viability of the breast cancer MCF-7 
cells from 24 to 96 hours (Fig. 3.6B).  
 
 
Fig. 3.6B: Effects of RTV on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 0.6μg/ml RTV for 24 – 96 hrs. Graphs were 
plotted with mean +SEM percentage viability from a mean of three independent experiments. 
Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.13  Effects of LPV/r on the viability of the cervical cells 
The combination of LPV and RTV, as combined in KALETRA®, did not significantly 
(p<0.05) alter the percentage viability of the normal (NCE16IIA) and cancer (HCS-2) 
cervical cells from 24 to 96 hours when compared to their respective vehicle controls and 
to each other at the respective time points (Fig. 3.7A). 
 
 
Fig. 3.7A: Effects of LPV/r on the percentage viability of normal cervical (NCE16IIA) and 
cervical cancer (HCS-2) cells. Cells were incubated with 9.8μg/ml LPV/0.6μg/ml RTV for 24 – 96 
hrs. Graphs were plotted with mean +SEM percentage viability from a mean of three independent 
experiments. Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.14  Effects of LPV/r on the viability of the breast cells 
The combination LPV/r did not significantly (p<0.05) alter the percentage viability of the 
normal (MCF-10A) and cancer (MCF-7) breast cells from 24 to 96 hours when compared 
to their respective vehicle controls and to each other at the respective time points (Fig. 
3.7B). 
 
 
Fig. 3.7B: Effects of LPV/r on the percentage viability of normal breast (MCF-10A) and breast 
cancer (MCF-7) cells. Cells were incubated with 9.8μg/ml LPV/0.6μg/ml RTV for 24 – 96 hrs. 
Graphs were plotted with mean +SEM percentage viability from a mean of three independent 
experiments. Groups not connected by the same letter are significantly different (p<0.05). 
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3.1.15  Effects of TDF/FTC/LPV/r on the viability of the cervical cells 
TDF/FTC/LPV/r significantly (p<0.05) reduced the viability of the normal cervical 
(NCE16IIA) cells when compared to the vehicle control and the cervical cancer HCS-2 
cells at 24 hours (Fig. 3.8A). At 48 hours, the viability of the NCE16IIA cells remained 
reduced when compared to the HCS-2 cells but the difference was not significant (p<0.05) 
when compared to the vehicle controls (Fig. 3.8A). With continuous exposure (72 to 96 
hours), the combination had no significant effects on the percentage viability of the normal 
and cancer cervical cells (Fig. 3.8A). 
 
 
Fig. 3.8A: Effects of TDF/FTC/LPV/r on the percentage viability of normal cervical (NCE16IIA) 
and cervical cancer (HCS-2) cells. Cells were incubated with 1.8μg/ml FTC; 0.3μg/ml TDF; 
9.8μg/ml; LPV/0.6μg/ml RTV for 24 – 96 hrs. Graphs were plotted with mean +SEM percentage 
viability from a mean of three independent experiments. Groups not connected by the same letter 
are significantly different (p<0.05). 
 
 
%
 V
ia
bi
lit
y 
A 
67 
 
3.1.16  Effects of TDF/FTC/LPV/r on the viability of the breast cells 
At 24 hours, the combination of TDF/FTC/LPV/r reduced the viability of the normal breast 
MCF-10A cells, but the reduction was not significantly (p<0.05) different from the vehicle 
control or from the breast cancer MCF-7 cells (at 24 hours) (Fig. 3.8B). At 48 hours, this 
combination significantly (p<0.05) reduced the viability of the cancer MCF-7 cells when 
compared to the normal MCF-10A cells. The effects of this combination on the breast cells 
at 48 hours were, however, not significantly different from their respective vehicle controls 
(Fig. 3.8B). At 72 hours, TDF/FTC/LPV/r significantly (p<0.05) increased the viability of 
the normal breast cells when compared to the vehicle control (Fig. 3.8B). At 72 and 96 
hours, there were no significant differences between the viability of the normal and breast 
cancer cells (Fig. 3.8B). 
 
Fig. 3.8B: Effects of TDF/FTC/LPV/r on the percentage viability of normal breast (MCF-10A) and 
breast cancer (MCF-7) cells. Cells were incubated with 1.8μg/ml FTC; 0.3μg/ml TDF; 9.8μg/ml; 
LPV/0.6μg/ml RTV for 24 – 96 hrs. Graphs were plotted with mean +SEM percentage viability 
from a mean of three independent experiments. Groups not connected by the same letter are 
significantly different (p<0.05). 
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Table 3.1: Summary of the effects of ARVs on normal and cancer cervical and normal and 
cancer breast cell lines with regard to cell survival using the Neutral red assay.   
Drugs Normal 
Cervical 
(NC) 
Cancer  
Cervical 
(CC) 
Normal 
Breast 
(NB) 
Breast 
Cancer 
(BC) 
Result Remark 
TDF  (+0) (0-) (-+) (0-) Promotes normal 
cell survival (NC 
initially and NB 
later) over cancer 
cells. Decreasing 
effect on both 
cancers. 
Has an initial cytotoxic 
effect on cell survival in 
the normal breast. It has 
a slow ongoing effect in 
the cervix. Generally 
seems to promote normal 
cell survival over cancer 
cells 
FTC (+-) 0 (0-) (-0) Prolonged treatment 
show decreasing 
effects on normal 
cells. Favours CC 
with prolonged 
treatment 
Has opposing effects on 
NC and CC after 96 
hours of treatment.  
EFV (-0) (+-) (--) (0+) Promotes BC, 
decreases NB and 
CC.  
Cytotoxic to normal 
breast cells, but favours 
breast cancer cells 
ATP (--) (++) (-0) (+0) Decreases NC 
promotes CC. 
Decreases NB at 24 
hrs and has 
increasing effect on 
BC up to 72 hrs 
Favours the survival of 
cancer cells compared to 
the normal  
LPV (-0) (+0) (-+) (0+) Promotes NB and 
BC. Decreasing 
effect on  CC (72 to 
96 hrs) 
Generally appear to 
promote survival in the 
breast and CC in the 
short term  
RTV 0 0 (-+) 0 Promotes NB.  Has opposing effects on 
NB and BC at 24 hours. 
Generally appears to 
promote survival in 
normal breast after an 
initial toxic effect 
LPV/r 0 0 0 0 No effect Interestingly, the 
combination of the two 
PIs has no effects on all 
cell lines  
TDF/FTC
/LPV/r 
(-0) (+0) (-+) (0+) Has promoting 
effects on NB and 
BC. Has opposing 
effects on NC and 
CC at 24 and 48 hrs 
Shows a trend towards 
breast cell survival 
(0) = No effect on cell viability, (+) = increased cell viability, (-) = decreased cell viability. 
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3.2 Effects of Antiretroviral drugs on apoptotic BAX; BCL-2, and angiogenic 
VEGF165a and VEGF165b gene expression in cervical and breast cell lines 
BAX is a pro-apoptotic gene that is involved in the release of cytochrome c from the inner 
mitochondrial membrane (Rosse et al., 1998). BCL-2 is a human proto-oncogene that 
modulates apoptotic pathways by regulating the release of pro-apoptotic molecules from 
the mitochondria. The effects of the antiretroviral drugs on BAX and BCL-2 mRNA 
expression in all cell lines were investigated after a 96 hour exposure. The mRNA 
expression levels of the pro-angiogenic and anti-angiogenic VEGFA splice variants 
(VEGF165a and VEGF165b) were also investigated. 
3.2.1 The NRTI – TDF 
TDF increased BAX and BCL-2 gene expression in the two cervical cell lines, though to a 
lesser degree in the cancer cervical cells (Fig. 3.9A). TDF slightly up-regulated the pro-
angiogenic VEGF165a in the normal cervical cells but slightly down-regulated both 
VEGF165a and the anti-angiogenic VEGF165b in the cervical cancer cells (Fig. 3.9A). With 
respect to the breast cell lines, TDF slightly down-regulated BAX in the normal and cancer 
cell lines (Fig. 3.9B). TDF increased and decreased BCL-2 slightly in the normal and 
breast cancer cells respectively (Fig. 3.9B). In response to TDF, VEGF165a and VEGF165b 
were both slightly up-regulated in the normal breast cells and both down-regulated in the 
breast cancer MCF-7 cells, with VEGF165a more so than VEGF165b in both cases (Fig. 
3.9B). In all breast and cervical cells treated with TDF, the differences in fold changes 
were not significantly (p<0.05) different from the untreated controls for BAX, BCL-2, 
VEGF165a and VEGF165b (Fig. 3.9). BAX was slightly up-regulated in the cervical cells, but 
down-regulated in the breast cell lines. In addition, the expression of BCL-2 followed 
70 
 
opposite patterns in the two cancer cell lines; increased in the cervical cancer and 
decreased in the breast cancer cells.   
 
 
Figure 3.9: Effects of TDF on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 0.3μg/ml TDF for 96 hours. Data (mean ± SEM), 
are represented as fold changes of gene expression relative to values from the vehicle-treated cells 
(defined as 1) and representative of 3 independent experiments for RNA extraction. Groups not 
connected by the same letter are significantly (p<0.05) different. 
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3.2.2 FTC 
After 96 hours of exposure, FTC slightly increased BAX expression in the normal cervical 
but not the cancer cervical cells (Fig. 3.10A). BCL-2 expression was also slightly increased 
in both cervical cell lines. The expression of the pro-angiogenic VEGF165a was up-
regulated by FTC in the normal but not the cancer cervical cells (Fig. 3.10A). FTC did not 
affect the levels of the anti-angiogenic VEGF165b (Fig. 3.10A) in the cervical cells.  
FTC up-regulated BAX and BCL-2 in the normal breast MCF-10A cells while BAX and 
BCL-2 levels were down-regulated in the cancer breast MCF-7 cells (Fig. 3.10B). The 
levels of both the pro and anti-angiogenic VEGF165 were down-regulated in the breast 
cancer MCF-7 cells (Fig. 3.10B). In all cell lines treated with FTC, the differences in fold 
changes were not significantly (p<0.05) different from the untreated controls for BAX, 
BCL-2, VEGF165a and VEGF165b (Fig. 3.10). FTC treatment produced opposite trends of 
BAX and BCL-2 mRNA expression in the two cancer cell lines; slightly up-regulated in the 
cervical cancer and down-regulated in the breast cancer cell line. 
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Figure 3.10: Effects of FTC on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 1.8μg/ml FTC for 96 hours. Data (mean ± SEM), 
are represented as fold changes of gene expression relative to values from the vehicle-treated cells 
(defined as 1) and representative of 3 independent experiments for RNA extraction. Groups not 
connected by the same letter are significantly (p<0.05) different. 
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3.2.3 EFV 
In the normal cervical (NCE16IIA) cells, EFV slightly up-regulated BAX and down-
regulated BCL-2 expression, while in the cancer cervical HCS-2 cells, EFV down-
regulated the levels of both BAX and BCL-2 (Fig. 3.11A). EFV also slightly increased the 
levels of the pro-angiogenic VEGF165a in the normal cervical cells and slightly reduced the 
levels of both angiogenic VEGF165 genes in the cervical cancer cells (Fig. 3.11A). 
In the normal breast cells, EFV only slightly increased the levels of BCL-2, while in the 
breast cancer MCF-7 cells, the levels of BAX, BCL-2 and VEGF165a were slightly reduced 
(Fig. 3.11B). EFV also slightly increased the levels of the anti-angiogenic VEGF165b in the 
breast cancer cells (Fig. 3.11B). In all cell lines treated with EFV, the differences in fold 
changes were not significantly (p<0.05) different from the untreated controls for BAX, 
BCL-2, VEGF165a and VEGF165b (Fig. 3.11). However, EFV treatment produced opposing 
trends of BCL-2 mRNA expression in the two normal cell lines; slight down-regulation in 
the normal cervical and up-regulation in the normal breast cell line. 
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Figure 3.11: Effects of EFV on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 4.07μg/ml EFV for 96 hours. Data (mean ± SEM), 
are represented as fold changes of gene expression relative to values from the vehicle-treated cells 
(defined as 1) and representative of 3 independent experiments for RNA extraction. Groups not 
connected by the same letter are significantly (p<0.05) different. 
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3.2.4 ATP 
ATP slightly increased the levels of BAX in the normal cervical cells but decreased the 
levels of BAX in the cervical cancer cells (Fig. 3.12A). The level of BCL-2 was also 
slightly increased in the normal cervical cells but not in the cervical cancer cells (Fig. 
3.12A). The level of the pro-angiogenic VEGF165a was slightly increased in the normal 
cervical cells, but only slightly reduced in the cervical cancer cells (Fig. 3.12A). 
In the normal breast MCF-10A cells, in response to ATP, BAX levels were slightly up-
regulated while it was down-regulated in the breast cancer MCF-7 cells (Fig. 3.12B). BCL-
2 levels were decreased in the normal breast cells. VEGF165a levels were decreased in the 
breast cancer cells compared to the normal cells while the levels of VEGF165b were slightly 
increased in the normal breast but decreased in the breast cancer cells (Fig. 3.12B). In all 
cell lines treated with ATP, the differences in fold changes were not significantly (p<0.05) 
different from the untreated controls for BAX, BCL-2, VEGF165a and VEGF165b (Fig. 3.12). 
But opposite trends of BCL-2 mRNA expression were observed in the two normal cell 
lines in response to ATP treatment; slight up-regulation in the normal cervical and down-
regulation in the normal breast cell line.   
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Figure 3.12: Effects of ATP on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 0.3μg/ml TDF; 1.8μg/ml FTC; 4.07μg/ml EFV for 
96 hours. Data (mean ± SEM), are represented as fold changes of gene expression relative to values 
from the vehicle-treated cells (defined as 1) and representative of 3 independent experiments for 
RNA extraction. Groups not connected by the same letter are significantly (p<0.05) different. 
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3.2.5 LPV 
After 96 hours of treatment, LPV slightly increased the BAX and BCL-2 levels in the 
normal cervical (NCE16IIA) cells but decreased BAX and BCL-2 levels in the cervical 
cancer HCS-2 cells (Fig. 3.13A). VEGF165a levels were slightly increased in the normal 
cervical cells while VEGF165b levels were slightly decreased in the cervical cancer cells 
(Fig. 3.13A). 
In response to LPV, BAX levels were decreased in both normal and breast cancer cells 
(Fig. 3.13B). BCL-2 levels were decreased in the normal breast cells while it was slightly 
increased in the breast cancer MCF-7 cells (Fig. 3.13B). The pro-angiogenic VEGF165a 
levels were decreased in both breast cell lines while VEGF165b levels were decreased in the 
normal breast cells only (Fig. 3.13B). LPV treatment produced opposing trends of BAX and 
BCL-2 mRNA expression in the two normal cell lines; slightly up-regulated in the normal 
cervical and down-regulated in the normal breast cell line. In all cell lines treated with 
LPV, the differences in fold changes were not significantly (p<0.05) different from the 
untreated controls for BAX, BCL-2, VEGF165a and VEGF165b (Fig. 3.13). 
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Figure 3.13: Effects of LPV on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 9.8μg/ml LPV for 96 hours. Data (mean ± SEM), 
are represented as fold changes of gene expression relative to values from the vehicle-treated cells 
(defined as 1) and representative of 3 independent experiments for RNA extraction. Groups not 
connected by the same letter are significantly (p<0.05) different. 
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3.2.6 RTV 
In the normal cervical cells, RTV slightly increased the levels of BAX and BCL-2 genes 
(Fig. 3.14A). In response to RTV, in the cancer cervical cells, BAX levels were slightly 
decreased, while BCL-2 levels were slightly increased (Fig. 3.14A). The levels of the 
angiogenic genes VEGF165a and VEGF165b were also slightly increased in the normal 
cervical cells, while their levels were slightly decreased in the cervical cancer HCS-2 cells 
(Fig. 3.14A). 
In response to RTV, BAX levels were slightly increased in the normal breast MCF-10A 
cells, but decreased in the breast cancer MCF-7 cells (Fig. 3.14B). BCL-2 levels in both 
breast cells were decreased; but to a greater degree in the normal breast cells (Fig. 3.14B). 
The levels of the pro-angiogenic VEGF165a were also slightly decreased in the breast 
cancer MCF-7 cells but not in the normal breast cells (Fig. 3.14B). In all cell lines treated 
with LPV, the differences in fold changes were not significantly (p<0.05) different from 
the untreated controls for BAX, BCL-2, VEGF165a and VEGF165b (Fig. 3.14).   
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Figure 3.14: Effects of RTV on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 0.6μg/ml RTV for 96 hours. Data (mean ± SEM), 
are represented as fold changes of gene expression relative to values from the vehicle-treated cells 
(defined as 1) and representative of 3 independent experiments for RNA extraction. Groups not 
connected by the same letter are significantly (p<0.05) different. 
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3.2.7 LPV/r 
LPV/r slightly increased BCL-2 levels in the normal cervical (NCE16IIA) cells but 
decreased BCL-2 levels in the cervical cancer HCS-2 cells (Fig. 3.15A). VEGF165a levels 
were slightly increased in the normal cervical cells while VEGF165a levels were slightly 
decreased in the cervical cancer cells (Fig. 3.15A). VEGF165b levels were slightly 
decreased in both cervical cell lines (Fig. 3.15A).  
In response to LPV/r, BAX levels were slightly decreased in both normal and breast cancer 
cells (Fig. 3.15B). BCL-2 and VEGF165a levels were slightly increased in the normal breast 
cells but their levels were slightly decreased in the breast cancer cells (Fig. 3.15B). 
VEGF165b levels were slightly increased in the breast cancer cell line (Fig. 3.15B). LPV/r 
produced similar trends of BAX and BCL-2 mRNA expression in the two cancer cell lines. 
In all cell lines treated with LPV/r, the differences in fold changes were not significantly 
(p<0.05) different from the untreated controls for BAX, BCL-2, VEGF165a and VEGF165b 
(Fig. 3.15). 
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Figure 3.15: Effects of LPV/r on BAX, BCL-2, VEGF165a and VEGF165b mRNA expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 9.8μg/ml LPV; 0.6μg/ml RTV for 96 hours. Data 
(mean ± SEM), are represented as fold changes of gene expression relative to values from the 
vehicle-treated cells (defined as 1) and representative of 3 independent experiments for RNA 
extraction. Groups not connected by the same letter are significantly (p<0.05) different. 
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3.2.8 TDF/FTC/LPV/r 
TDF/FTC/LPV/r slightly increased the BAX and BCL-2 levels in the normal cervical 
(NCE16IIA) cells but slightly decreased BAX levels in the cervical cancer HCS-2 cells 
(Fig. 3.16A). VEGF165a levels were slightly increased in the normal cervical cells but 
slightly decreased in the cervical cancer cells (Fig. 3.16A). VEGF165b levels were slightly 
decreased in both cervical cell lines (Fig. 3.16A) but more so in the cancer cell line. 
In the breast cell lines, this combination slightly increased BAX levels in the normal breast 
and slightly decreased BAX levels in the cancer MCF-7 cells. BCL-2 levels were slightly 
increased in both breast cell lines (Fig. 3.16B). VEGF165a levels were slightly increased in 
the normal breast cells but were slightly decreased in the breast cancer cells (Fig. 3.16B). 
VEGF165b levels were slightly decreased in the normal breast cells but were not altered in 
the breast cancer cells (Fig. 3.16B). In all cell lines treated with LPV/r, the differences in 
fold changes were not significantly (p<0.05) different from the untreated controls for BAX, 
BCL-2, VEGF165a and VEGF165b (Fig. 3.16). 
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Figure 3.16: Effects of TDF/FTC/LPV/r on BAX, BCL-2, VEGF165a and VEGF165b mRNA 
expression in (A) NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A 
(normal breast); MCF-7 (breast cancer) cells. Cells were incubated with 0.3μg/ml TDF; 1.8μg/ml 
FTC; 9.8μg/ml LPV; 0.6μg/ml RTV for 96 hours. Data (mean ± SEM), are represented as fold 
changes of gene expression relative to values from the vehicle-treated cells (defined as 1) and 
representative of 3 independent experiments for RNA extraction. Groups not connected by the 
same letter are significantly (p<0.05) different. 
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Table 3.2: Summary of the effects of ARVs on BAX, BCL-2, VEGF165A and VEGF165B 
mRNA expression in normal and cancer cervical and normal and cancer breast cell lines. 
+/++/+++ (up-regulation); 0 (no change); -/--/--- (down-regulation). 
 
Treatment Gene Expresion 
Normal 
Cervical 
(NCE16IIA) 
Cancer  
Cervical 
(HCS-2) 
Normal Breast 
(MCF-10A) 
Breast Cancer 
(MCF-7) 
0.3 μg/ml 
TDF 
BAX + + -- -- 
BCL-2 + + + -- 
VEGF165A + - + -- 
VEGF165B 0 - 0 0 
1.8μg/ml 
FTC 
BAX + 0 + -- 
BCL-2 + + + - 
VEGF165A + 0 - -- 
VEGF165B - 0 0 - 
4.07μg/ml 
EFV 
BAX + - 0 - 
BCL-2 - - + -- 
VEGF165A + - - -- 
VEGF165B - - 0 + 
ATRIPLA 
TDF/FTC/   
EFV 
BAX + - + -- 
BCL-2 ++ 0 - + 
VEGF165A + - - -- 
VEGF165B 0 - + - 
9.8μg/ml 
LPV 
BAX + - - -- 
BCL-2 + - - + 
VEGF165A + - - -- 
VEGF165B + -- - 0 
0.6 μg/ml 
RTV 
BAX + - + -- 
BCL-2 + + -- - 
VEGF165A + - 0 -- 
VEGF165B + - + - 
KALETRA     
(LPV/r) 
BAX + - - - 
BCL-2 + - + - 
VEGF165A + - + - 
VEGF165B - -- 0 + 
TDF/FTC/     
LPVr 
BAX + - + - 
BCL-2 + 0 + + 
VEGF165A + - + - 
VEGF165B - - - 0 
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3.3. Immunofluorescence of BAX, BCL-2 and VEGF165b proteins in cancer (HCS-
2) and normal cervical (NCE16IIA) and cancer (MCF-7) and normal breast (MCF-
10A) cells exposed to antiretroviral drugs 
The effects of the antiretroviral drugs on BAX, BCL-2 protein expression (localisation and 
intensity) in all cell lines were investigated after a 96 hour exposure. The protein 
expression levels of the anti-angiogenic VEGFA splice variant (VEGF165b) was also 
investigated. Negative control groups were set up to ensure that the secondary antibodies 
were specific for their primary antibodies. The primary antibodies were substituted with 
0.1% BSA/PBS and the normal protocol was carried out. In a second negative control, the 
cells were treated in the same way as the experimental slides, but the secondary antibodies 
were substituted with PBS. There was lack of non-specific staining in the negative controls 
and representative fluorescence micrographs of untreated cells serving as no primary 
antibody control are shown in the last slides labelled ‘K’ for each antibody staining. 
3.3.1 Immunofluorescence of BAX and BCL-2 proteins in cervical cancer (HCS-2) 
and normal cervical (NCE16IIA) cells exposed to antiretroviral drugs 
In the untreated group of HCS-2 cells (Fig. 3.17 A), BAX and BCL-2 proteins are 
expressed and co-localised in the nuclei and cytoplasm. Mean fluorescent intensities of 
BAX and BCL-2 in the nuclei and cytoplasm were statistically analysed (ANOVA) 
between the untreated/vehicle control and the treated groups (Graphical representation 
presented in Figs. 3.25-3.32; Data summaries shown in Appendix E). There are no 
differences in protein staining, localisation and intensity of vehicle (0.01% methanol) 
treated group as compared to growth medium alone (Fig. 3.17B). Both BAX and BCL-2 
localisation remained unaltered across treatment groups. Fig. 3.17 C-J illustrates the effect 
of the antiretroviral drugs on the localisation of BAX and BCL-2 in HCS-2 cell cultures. 
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Figs. 3.17 C-J are representative images illustrating the effects of the antiretroviral drugs 
on BAX and BCL-2 expression in the HCS-2 cell cultures. The untreated group of 
NCE16IIA cells (Fig 3.18A) shows the expression and localisation of BAX. BCL-2 
oncoprotein was found to be unexpressed in this normal cervical cell line. There are no 
differences in protein staining, localisation and intensity of vehicle (0.01% methanol) 
treated group as compared to growth medium alone (Fig. 3.18B). Fig. 3.18 C-J illustrates 
the effect of the antiretroviral drugs on expression of BAX and BCL-2 in the NCE16IIA 
cell cultures. Figs. 3.18 C-J are representative images illustrating the effects of the 
antiretroviral drugs on expression of BAX and BCL-2 in NCE16IIA cell cultures. BAX 
and BCL-2 localisation remain unchanged across treatment groups. Mean fluorescent 
intensities of BAX and BCL-2 in the nuclei and cytoplasm were statistically analysed 
(ANOVA) between the untreated/vehicle control and the treated groups (Graphical 
representation presented in Figs. 3.25-3.32; Data summaries shown in Appendix E). 
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 Figure 3.17 A: Fluorescence micrographs of HCS-2 cells exposed to Growth Medium for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus, Cy=Cytoplasm. Red arrow points to nuclear staining 
and White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of 
untreated cells serving as no primary antibody control are shown in Fig.3.17K. 
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 Figure 3.17 B: Fluorescence micrographs representing HCS-2 cells exposed to Vehicle-0.01% 
Methanol for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse 
IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal 
rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower 
quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined 
Images are represented in the Right Lower quadrant. Nu=Nucleus, Cy=Cytoplasm. Red arrow 
points to nuclear staining and White arrow points to cytoplasmic staining. There are no differences 
in protein staining, localisation and intensity as compared to growth medium alone. Representative 
Fluorescence micrographs of untreated cells serving as no primary antibody control are shown in 
Fig.3.17K. 
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 Figure 3.17C: Fluorescence micrographs representing HCS-2 cells exposed to 0.3μg/ml TDF for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus, Cy=Cytoplasm. Red arrow points to nuclear 
staining and White arrow points to cytoplasmic staining. Representative Fluorescence micrographs 
of untreated cells serving as no primary antibody control are shown in Fig.3.17K. 
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Figure 3.17D: Fluorescence micrographs representing HCS-2 cells exposed to 1.8μg/ml FTC for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus, Cy=Cytoplasm. Red arrow points to nuclear 
staining and White arrow points to cytoplasmic staining. Representative Fluorescence micrographs 
of untreated cells serving as no primary antibody control are shown in Fig.3.17K. 
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Figure 3.17E: Fluorescence micrographs representing HCS-2 cells exposed to 4.07μg/ml EFV for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.17K. 
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Figures 3.17F and G: Fluorescence micrographs representing HCS-2 cells exposed to (F) 
0.3μg/ml TDF, 1.8μg/ml FTC, 4.07μg/ml EFV and 9.8μg/ml LPV for 96 hours. BCL-2 was stained 
with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right 
Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were counterstained with DAPI 
(Blue channel-Left Upper quadrant). Combined Images are represented in the Right Lower 
quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow points to cytoplasmic 
staining. 
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Figure 3.17H: Fluorescence micrographs representing HCS-2 cells exposed to 0.6μg/ml RTV for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.17K. 
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Figure 3.17I: Fluorescence micrographs representing HCS-2 cells exposed to 9.8μg/ml LPV; 
0.6μg/ml RTV for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-
Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained with 
Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left 
Lower quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). 
Combined Images are represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to 
nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.17K. 
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Figure 3.17J: Fluorescence micrographs representing HCS-2 cells exposed to 0.3μg/ml TDF; 
1.8μg/ml FTC; 9.8μg/ml LPV; 0.6μg/ml RTV for 96 hours. BCL-2 was stained with Monoclonal 
Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). 
BAX was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine 
conjugated (Red channel-Left Lower quadrant). Nuclei were counterstained with DAPI (Blue 
channel-Left Upper quadrant). Combined Images are represented in the Right Lower quadrant. 
Nu=Nucleus. Red arrow points to nuclear staining and White arrow points to cytoplasmic staining. 
Representative Fluorescence micrographs of untreated cells serving as no primary antibody control 
are shown in Fig.3.17K. 
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 Figure3.17K: Fluorescence micrographs of untreated HCS-2 cells serving as no primary antibody 
control. Cells were incubated with goat serum in place of primary antibodies and incubated with 
Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant) and Goat Anti-
Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. 
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 Figure 3.18A: Fluorescence micrographs of cervical NCE16IIA cells exposed to Growth Medium 
for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus, Cy=Cytoplasm. Yellow arrow points to 
nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18 B: Fluorescence micrographs of cervical NCE16IIA cells exposed to Vehicle-0.01% 
Methanol for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse 
IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal 
rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower 
quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined 
Images are represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear 
staining and White arrow points to cytoplasmic staining. There are no differences in protein 
staining, localisation and intensity as compared to growth medium alone. Representative 
Fluorescence micrographs of untreated cells serving as no primary antibody control are shown in 
Fig.3.18K. 
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Figure 3.18C: Fluorescence micrographs of cervical NCE16IIA cells exposed to 0.3μg/ml TDF for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18D: Fluorescence micrographs of cervical NCE16IIA cells exposed to 1.8μg/ml FTC for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18E: Fluorescence micrographs of cervical NCE16IIA cells exposed to 4.07μg/ml EFV 
for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18F: Fluorescence micrographs of cervical NCE16IIA cells exposed to 0.3μg/ml TDF; 
1.8μg/ml FTC; 4.07μg/ml EFV for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained 
with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-
Left Lower quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). 
Combined Images are represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points 
to nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18G: Fluorescence micrographs of cervical NCE16IIA cells exposed to 9.8μg/ml LPV for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18H: Fluorescence micrographs of cervical NCE16IIA cells exposed to 0.6μg/ml RTV 
for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18I: Fluorescence micrographs of cervical NCE16IIA cells exposed to 9.8μg/ml LPV, 
0.6μg/ml RTV for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-
Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained with 
Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left 
Lower quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). 
Combined Images are represented in the Right Lower quadrant. Nu=Nucleus. Yellow arrow points 
to nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.18K. 
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Figure 3.18J: Fluorescence micrographs of cervical NCE16IIA cells exposed to 0.3μg/ml TDF; 
1.8μg/ml FTC, 9.8μg/ml LPV, 0.6μg/ml RTV for 96 hours. BCL-2 was stained with Monoclonal 
Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). 
BAX was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine 
conjugated (Red channel-Left Lower quadrant). Nuclei were counterstained with DAPI (Blue 
channel-Left Upper quadrant). Combined Images are represented in the Right Lower quadrant. 
Nu=Nucleus. Yellow arrow points to nuclear staining and White arrow points to cytoplasmic 
staining. Representative Fluorescence micrographs of untreated cells serving as no primary 
antibody control are shown in Fig.3.18K. 
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 Figure 3.18K: Fluorescence micrographs of untreated cervical NCE16IIA cells serving as no 
primary antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant) and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. 
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3.3.2 Immunofluorescence of BAX and BCL-2 proteins in breast cancer (MCF-7) 
and normal breast (MCF-10A) cells exposed to antiretroviral drugs 
In the untreated group of MCF-7 cells (Fig 3.19 A), BAX and BCL-2 proteins are 
expressed and co-localised in the nuclei and cytoplasm. Mean Fluorescence intensities of 
BAX and BCL-2 in the nuclei and cytoplasm were statistically analysed (ANOVA) 
between the untreated/vehicle control and the treated groups. (Graphical representation 
presented in Figs. 3.25-3.32; Data summaries shown in Appendix E).There are no 
differences in protein staining, localisation and intensity of vehicle (0.01% methanol) 
treated group as compared to growth medium alone (Fig. 3.19B). Fig 3.19 C-J shows the 
effects of antiretroviral drugs on the localisation of BAX and BCL-2 in MCF-7 cell 
cultures. Fig. 3.19 C-J are representative images illustrating the effects of the antiretroviral 
drugs on expression of BAX and BCL-2 in MCF-7 cell cultures. BAX and BCL-2, 
localisation remains unaltered across treatment groups.  
The untreated group of MCF-10A cells (Fig 3.20A) demonstrates the expression and 
localisation of BAX and BCL-2. Mean Fluorescence intensities of BAX and BCL-2 in the 
nuclei and cytoplasm were statistically analysed (ANOVA) between the untreated/vehicle 
control and the treated groups. (Graphical representation presented in Figs. 3.25-3.32; Data 
summaries shown in Appendix E). There are no differences in protein staining, localisation 
and intensity of vehicle (0.01% methanol) treated group as compared to growth medium 
alone (Fig. 3.20B). Fig 3.20 C-J illustrates the effect of the antiretroviral drugs on 
expression of BAX and BCL-2 in MCF-10A cell cultures. Fig. 3.20 C-J are representative 
images illustrating the effects of the antiretroviral drugs on expression of BAX and BCL-2 
in MCF-10A cell cultures. BAX and BCL-2 localisation remain unchanged across 
treatment groups.   
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 Figure 3.19A: Fluorescence micrographs of MCF-7 cells exposed to Growth Medium for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
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Figure 3.19B: Fluorescence micrographs of MCF-7 cells exposed to Vehicle-0.01% Methanol for 
96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. There are no differences in protein staining, 
localisation and intensity as compared to growth medium alone. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.19K. 
112 
 
 Figure 3.19C: Fluorescence micrographs of MCF-7 cells exposed to 0.3μg/ml TDF for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19D: Fluorescence micrographs of MCF-7 cells exposed to 1.8μg/ml FTC for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19E: Fluorescence micrographs of MCF-7 cells exposed to 4.07μg/ml EFV for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
115 
 
 Figure 3.19F: Fluorescence micrographs of MCF-7 cells exposed to 0.3μg/ml TDF; 1.8μg/ml FTC; 
4.07μg/ml EFV for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-
Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained with 
Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left 
Lower quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). 
Combined Images are represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to 
nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19G: Fluorescence micrographs of MCF-7 cells exposed to 9.8μg/ml LPV for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19H: Fluorescence micrographs of MCF-7 cells exposed to 0.6μg/ml RTV for 96 hours. 
BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated 
(Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-BAX and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and White arrow 
points to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19I: Fluorescence micrographs of MCF-7 cells exposed to 9.8μg/ml LPV, 0.6μg/ml RTV 
for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC 
conjugated (Green channel-Right Upper quadrant). BAX was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are 
represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to nuclear staining and 
White arrow points to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19J: Fluorescence micrographs of MCF-7 cells exposed to 0.3μg/ml TDF; 1.8μg/ml FTC; 
9.8μg/ml LPV, 0.6μg/ml RTV for 96 hours. BCL-2 was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant). BAX was stained 
with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-
Left Lower quadrant). Nuclei were counterstained with DAPI (Blue channel-Left Upper quadrant). 
Combined Images are represented in the Right Lower quadrant. Nu=Nucleus. Red arrow points to 
nuclear staining and White arrow points to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.19K. 
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 Figure 3.19K: Fluorescence micrographs of untreated breast MCF-7 cells serving as no primary 
antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Mouse IgG, FITC conjugated (Green channel-Right Upper quadrant) and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). Nuclei were 
counterstained with DAPI (Blue channel-Left Upper quadrant). Combined Images are represented 
in the Right Lower quadrant. 
 
 
121 
 
    
  
Figure 3.20 A: Fluorescence micrographs of breast MCF-10A cells exposed to Growth Medium 
for 96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
 
 
122 
 
 B2 
  
Figure 3.20B: Fluorescence micrographs of breast MCF-10A cells exposed to Vehicle-0.01% 
Methanol for 96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-
Rabbit IgG, Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-
BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained 
with DAPI (Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow 
point to cytoplasmic staining. There are no differences in protein staining, localisation and intensity 
as compared to growth medium alone. Representative Fluorescence micrographs of untreated cells 
serving as no primary antibody control are shown in Fig.3.20K. 
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Figure 3.20C: Fluorescence micrographs of breast MCF-10A cells exposed to 0.3μg/ml TDF for 
96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
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Figure 3.20D: Fluorescence micrographs of breast MCF-10A cells exposed to 1.8μg/ml FTC for 
96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
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Figure 3.20E: Fluorescence micrographs of breast MCF-10A cells exposed to 4.07μg/ml EFV for 
96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
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Figure 3.20F: Fluorescence micrographs of breast MCF-10A cells exposed to 0.3μg/ml TDF; 
1.8μg/ml FTC; 4.07μg/ml EFV for 96 hours. BAX (1) was stained with Polyclonal rabbit Anti-
BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). BCL-2 (2) was stained 
with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel). 
Nuclei were counterstained with DAPI (Blue channel). Nu=Nucleus. Red arrow point to nuclear 
staining and yellow arrow point to cytoplasmic staining. Representative Fluorescence micrographs 
of untreated cells serving as no primary antibody control are shown in Fig.3.20K. 
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Figure 3.20G: Fluorescence micrographs of breast MCF-10A cells exposed to 9.8μg/ml LPV for 
96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
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Figure 3.20H: Fluorescence micrographs of breast MCF-10A cells exposed to 0.6μg/ml RTV for 
96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-BCL-2 and 
Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained with DAPI 
(Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow point to 
cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving as no 
primary antibody control are shown in Fig.3.20K. 
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Figure 3.20I: Fluorescence micrographs of breast MCF-10A cells exposed to 9.8μg/ml LPV; 
0.6μg/ml RTV for 96 hours. BAX (1) was stained with Polyclonal rabbit Anti-BAX and Goat Anti-
Rabbit IgG, Rhodamine conjugated (Red channel). BCL-2 (2) was stained with Monoclonal Anti-
BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green channel). Nuclei were counterstained 
with DAPI (Blue channel). Nu=Nucleus. Red arrow point to nuclear staining and yellow arrow 
point to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells serving 
as no primary antibody control are shown in Fig.3.20K. 
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Figure 3.20J: Fluorescence micrographs of breast MCF-10A cells exposed to 0.3μg/ml TDF; 
1.8μg/ml FTC; 9.8μg/ml LPV; 0.6μg/ml RTV for 96 hours. BAX (1) was stained with Polyclonal 
rabbit Anti-BAX and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). BCL-2 (2) was 
stained with Monoclonal Anti-BCL-2 and Goat Anti-Mouse IgG, FITC conjugated (Green 
channel). Nuclei were counterstained with DAPI (Blue channel). Nu=Nucleus. Red arrow point to 
nuclear staining and yellow arrow point to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.20K. 
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 Figure 3.20K: Fluorescence micrographs of untreated breast MCF-10A cells serving as no primary 
antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Rabbit IgG, Rhodamine conjugated and Goat Anti-Mouse IgG, FITC 
conjugated (Right Upper quadrant). Nuclei were counterstained with DAPI (Blue channel-Left 
Upper quadrant). Combined Images are represented in the left Lower quadrant. 
 
 
 
132 
 
133 
 
3.3.3 Immunofluorescence of anti-angiogenic VEGF 165b protein in cervical cancer 
(HCS-2) and normal cervical (NCE16IIA) cells exposed to antiretroviral drugs 
The anti-angiogenic VEGF165b protein, an inhibitor of the VEGF165 mediated VEGF 
receptor 2 phosphorylation and signalling is expressed and localised in the nuclei and 
cytoplasm of HCS-2 (Fig 3.21 A) and NCE16IIA (Fig 3.22 A) cells. Mean fluorescence 
intensities of VEGF165b in the nuclei and cytoplasm were statistically analysed (ANOVA) 
between the untreated/vehicle control and the treated groups. (Graphical representation 
presented in Figs. 3.25-3.32; Data summaries shown in Appendix E). There are no 
differences in protein staining, localisation and intensity of vehicle (0.01% methanol) 
treated group as compared to growth medium alone (Fig. 3.21B and Fig. 3.22B). Exposing 
both cervical cells to the different antiretroviral drugs individually and in combination for 
96 hours did not alter the localisation of VEGF165b (Figs. 3.21 C-J and Figs. 3.22 C-J) in 
both cell lines. Fig. 3.21 C-J are representative images illustrating the effects of the 
antiretroviral drugs on expression of VEGF165b in HCS-2 cell cultures. Figs. 3.22 C-J are 
representative images illustrating the effects of the antiretroviral drugs on expression of 
VEGF165b in NCE16IIA cell cultures. 
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Figure 3.21 A-D: Fluorescence micrographs of HCS-2 cells exposed to Growth Medium (A), 
Vehicle-0.01% Methanol (B), 0.3µg/ml TDF (C), 1.8µg/ml FTC (D) for 96 hours. VEGF165b was 
stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-Rabbit IgG, 
Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue channel). 
Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to perinuclear 
staining and yellow arrow point to cytoplasmic staining. There are no differences in protein 
staining, localisation and intensity of vehicle treated (B) as compared to growth medium alone. 
Representative Fluorescence micrographs of untreated cells serving as no primary antibody control 
are shown in Fig.3.21K.        
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Figure 3.21 E-H: Fluorescence micrographs of HCS-2 cells exposed to 4.07µg/ml EFV (E), 
0.3µg/ml TDF, 1.8µg/ml FTC, 4.07µg/ml EFV (F), 9.8µg/ml LPV (G), 0.6µg/ml RTV (H) for 96 
hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-
Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue 
channel). Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to 
perinuclear staining and yellow arrow point to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.21K. 
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Figure 3.21 I-J: Fluorescence micrographs of HCS-2 cells exposed to 9.8µg/ml LPV; 0.6µg/ml 
RTV (I) and 0.3µg/ml TDF, 1.8µg/ml FTC, 9.8µg/ml LPV; 0.6µg/ml RTV (J) for 96 hours. 
VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-Rabbit 
IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue channel). 
Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to perinuclear 
staining and yellow arrow point to cytoplasmic staining. Representative Fluorescence micrographs 
of untreated cells serving as no primary antibody control are shown in Fig.3.21K. 
 
            
137 
 
 
Figure 3.21K: Fluorescence micrographs of untreated cervical HCS-2 cells serving as no primary 
antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Right Upper quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left upper quadrant). Combined images are 
shown-Left Lower quadrant. 
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Figure 3.22 A-D: Fluorescence micrographs of Normal cervical NCE16IIA cells exposed to 
Growth Medium (A), Vehicle-0.01% Methanol (B), 0.3µg/ml TDF (C), 1.8µg/ml FTC (D) for 96 
hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-
Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue 
channel). Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to 
perinuclear staining and yellow arrow point to cytoplasmic staining. There are no differences in 
protein staining, localisation and intensity of vehicle treated (B) as compared to growth medium 
alone. Representative Fluorescence micrographs of untreated cells serving as no primary antibody 
control are shown in Fig.3.22K.        
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Figure 3.22 E-H: Fluorescence micrographs of Normal cervical (NCE16IIA) cells exposed to 
4.07µg/ml EFV (E), 0.3µg/ml TDF, 1.8µg/ml FTC, 4.07µg/ml EFV (F), 9.8µg/ml LPV (G), 
0.6µg/ml RTV (H) for 96 hours. VEGF165b was stained with polyclonal rabbit anti-human 
VEGF165b (5µg/ml) and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were 
counterstained with DAPI (Blue channel). Combined Images are shown. Nu=Nucleus. 
Cy=Cytoplasm. White arrow point to perinuclear staining and yellow arrow point to cytoplasmic 
staining. Representative Fluorescence micrographs of untreated cells serving as no primary 
antibody control are shown in Fig.3.22K. 
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Figure 3.22 I-J: Fluorescence micrographs of Normal cervical (NCE16IIA) cells exposed to 
9.8µg/ml LPV; 0.6µg/ml RTV (I) and 0.3µg/ml TDF, 1.8µg/ml FTC, 9.8µg/ml LPV; 0.6µg/ml 
RTV (J) for 96 hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) 
and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with 
DAPI (Blue channel). Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow 
point to perinuclear staining and yellow arrow point to cytoplasmic staining. Representative 
Fluorescence micrographs of untreated cells serving as no primary antibody control are shown in 
Fig.3.22K. 
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Figure 3.22K: Fluorescence micrographs of untreated cervical NCE16IIA cells serving as no 
primary antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left upper quadrant). Combined images are 
shown-Right lower quadrant. 
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3.3.4 Immunofluorescence of anti-angiogenic VEGF 165b protein in breast cancer 
(MCF-7) and normal breast (MCF10-A) cells exposed to antiretroviral drugs 
The anti-angiogenic VEGF165b protein is expressed and localised in the nuclei and 
cytoplasm of MCF-7 (Fig. 3.23 A) and MCF-10A (Fig. 3.24 A) cells. Mean fluorescence 
intensities of VEGF165b in the nuclei and cytoplasm were statistically analysed (ANOVA) 
between the untreated/vehicle control and the treated groups. (Graphical representation 
presented in Figs. 3.25-3.32; Data summaries shown in Appendix E). There are no 
differences in protein staining, localisation and intensity of vehicle (0.01% methanol) 
treated group as compared to growth medium alone (Fig. 3.23B and Fig. 3.24B). Exposing 
both breast cell lines to the different antiretroviral drugs individually and in combination 
for 96 hours showed no differences in the localisation of VEGF165b (Fig. 3.23 C-J and Fig. 
3.24 C-J). Fig. 3.23 C-J are representative images illustrating the effects of the 
antiretroviral drugs on expression of VEGF165b in MCF-7 cell cultures. Fig. 3.24 C-J are 
representative images illustrating the effects of the antiretroviral drugs on expression of 
VEGF165b in MCF-10A cell cultures. 
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Figure 3.23 A-D: Fluorescence micrographs of Cancer breast MCF-7 cells exposed to Growth 
Medium (A), Vehicle-0.01% Methanol (B), 0.3µg/ml TDF (C), 1.8µg/ml FTC (D) for 96 hours. 
VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-Rabbit 
IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue channel). 
Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to perinuclear 
staining and yellow arrow point to cytoplasmic staining. There are no differences in protein 
staining, localisation and intensity of vehicle treated (B) as compared to growth medium alone. 
Representative Fluorescence micrographs of untreated cells serving as no primary antibody control 
are shown in Fig.3.23K.        
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Figure 3.23 E-H: Fluorescence micrographs of Cancer breast MCF-7 cells exposed to 4.07µg/ml 
EFV (E), 0.3µg/ml TDF, 1.8µg/ml FTC, 4.07µg/ml EFV (F), 9.8µg/ml LPV (G), 0.6µg/ml RTV 
(H) for 96 hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and 
Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with 
DAPI (Blue channel). Combined Images are shown. White arrow point to perinuclear staining and 
yellow arrow point to cytoplasmic staining. Representative Fluorescence micrographs of untreated 
cells serving as no primary antibody control are shown in Fig.3.23K. 
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Figure 3.23 I-J: Fluorescence micrographs of Cancer breast MCF-7 cells exposed to 9.8µg/ml 
LPV; 0.6µg/ml RTV (I) and 0.3µg/ml TDF, 1.8µg/ml FTC, 9.8µg/ml LPV; 0.6µg/ml RTV (J) for 
96 hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat 
Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI 
(Blue channel). Combined Images are shown. White arrow point to perinuclear staining and yellow 
arrow point to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells 
serving as no primary antibody control are shown in Fig.3.23K. 
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Figure 3.23K: Fluorescence micrographs of untreated breast MCF-7 cells serving as no primary 
antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel-Left Lower quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left upper quadrant). Combined images are 
shown-Right lower quadrant. 
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Figure 3.24 A-D: Fluorescence micrographs of normal breast MCF-10A cells exposed to Growth 
Medium (A), Vehicle-0.01% Methanol (B), 0.3µg/ml TDF (C), 1.8µg/ml FTC (D) for 96 hours. 
VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat Anti-Rabbit 
IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI (Blue channel). 
Combined Images are shown. Nu=Nucleus. Cy=Cytoplasm. White arrow point to perinuclear 
staining and yellow arrow point to cytoplasmic staining. There are no differences in protein 
staining, localisation and intensity of vehicle treated (B) as compared to growth medium alone. 
Representative Fluorescence micrographs of untreated cells serving as no primary antibody control 
are shown in Fig.3.24K.        
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Figure 3.24 E-H: Fluorescence micrographs of normal breast MCF-10A cells exposed to 
4.07µg/ml EFV (E), 0.3µg/ml TDF, 1.8µg/ml FTC, 4.07µg/ml EFV (F), 9.8µg/ml LPV (G), 
0.6µg/ml RTV (H) for 96 hours. VEGF165b was stained with polyclonal rabbit anti-human 
VEGF165b (5µg/ml) and Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were 
counterstained with DAPI (Blue channel). Combined Images are shown. White arrow point to 
perinuclear staining and yellow arrow point to cytoplasmic staining. Representative Fluorescence 
micrographs of untreated cells serving as no primary antibody control are shown in Fig.3.24K. 
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Figure 3.24 I-J: Fluorescence micrographs of normal breast MCF-10A cells exposed to 9.8µg/ml 
LPV; 0.6µg/ml RTV (I) and 0.3µg/ml TDF, 1.8µg/ml FTC, 9.8µg/ml LPV; 0.6µg/ml RTV (J) for 
96 hours. VEGF165b was stained with polyclonal rabbit anti-human VEGF165b (5µg/ml) and Goat 
Anti-Rabbit IgG, Rhodamine conjugated (Red channel). Nuclei were counterstained with DAPI 
(Blue channel). Combined Images are shown. White arrow point to perinuclear staining and yellow 
arrow point to cytoplasmic staining. Representative Fluorescence micrographs of untreated cells 
serving as no primary antibody control are shown in Fig.3.24K. 
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Figure 3.24K: Fluorescence micrographs of untreated breast MCF-10A cells serving as no primary 
antibody control. Cells were incubated with goat serum in place of primary antibodies and 
incubated with Goat Anti-Rabbit IgG, Rhodamine conjugated (Red channel- Right upper quadrant). 
Nuclei were counterstained with DAPI (Blue channel-Left upper quadrant). Combined images are 
shown- Left Lower quadrant. 
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Figure 3.25: Effects of TDF on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 0.3µg/ml TDF for 96 hours. Data (mean ± SEM), are 
represented as fluorescence intensities of protein expression relative to values from the vehicle-
treated cells and representative of 3 independent experiments for immunofluorescence staining. 
Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.26: Effects of FTC on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 1.8µg/ml FTC for 96 hours. Data (mean ± SEM), are 
represented as fluorescence intensities of protein expression relative to values from the vehicle-
treated cells and representative of 3 independent experiments for immunofluorescence staining. 
Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.27: Effects of EFV on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 4.07µg/ml EFV for 96 hours. Data (mean ± SEM), are 
represented as fluorescence intensities of protein expression relative to values from the vehicle-
treated cells and representative of 3 independent experiments for immunofluorescence staining. 
Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.28: Effects of ATRIPLA on BAX, BCL-2 and VEGF165b protein expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 0.3µg/ml TDF; 1.8µg/ml FTC; 4.07µg/ml EFV for 
96 hours. Data (mean ± SEM), are represented as fluorescence intensities of protein expression 
relative to values from the vehicle-treated cells and representative of 3 independent experiments for 
immunofluorescence staining. Groups not connected by the same letter are significantly (p<0.05) 
different. 
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Figure 3.29: Effects of LPV on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 9.8µg/ml LPV for 96 hours. Data (mean ± SEM), are 
represented as fluorescence intensities of protein expression relative to values from the vehicle-
treated cells and representative of 3 independent experiments for immunofluorescence staining. 
Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.30: Effects of RTV on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 0.6µg/ml RTV for 96 hours. Data (mean ± SEM), are 
represented as fluorescence intensities of protein expression relative to values from the vehicle-
treated cells and representative of 3 independent experiments for immunofluorescence staining. 
Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.31: Effects of LPV/r on BAX, BCL-2 and VEGF165b protein expression in (A) NCE16IIA 
(normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 (breast 
cancer) cells. Cells were incubated with 9.8µg/ml LPV; 0.6µg/ml RTV for 96 hours. Data (mean ± 
SEM), are represented as fluorescence intensities of protein expression relative to values from the 
vehicle-treated cells and representative of 3 independent experiments for immunofluorescence 
staining. Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.32: Effects of TDF/FTC/LPV/r on BAX, BCL-2 and VEGF165b protein expression in (A) 
NCE16IIA (normal cervical); HCS-2 (cervical cancer) and (B) MCF-10A (normal breast); MCF-7 
(breast cancer) cells. Cells were incubated with 0.3µg/ml TDF; 1.8µg/ml FTC; 9.8µg/ml LPV; 
0.6µg/ml RTV for 96 hours. Data (mean ± SEM), are represented as fluorescence intensities of 
protein expression relative to values from the vehicle-treated cells and representative of 3 
independent experiments for immunofluorescence staining. Groups not connected by the same 
letter are significantly (p<0.05) different. 
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Table 3.3: Summary of the effects of ARVs on BAX, BCL-2 and VEGF165B protein expression 
(fluorescence intensity) and localisation in normal and cancer cervical and breast cell lines. 
Treatment Normal Cervical (NC) Cancer  Cervical (CC) Normal Breast (NB) Breast Cancer (BC)
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear+, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear+, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear+++, Cyto++ Nuclear++, Cyto+ Nuclear+, Cyto+++ Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
Intensity Nuclear 0, Cyto 0 Nuclear++, Cyto+ Nuclear++, Cyto 0 Nuclear++, Cyto+
Localisation Nuclear and Cytoplasm Nuclear Nuclear and Cytoplasm
Intensity Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++ Nuclear+, Cyto+++
Localisation Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm Nuclear and Cytoplasm
9.8μg/ml 
LPV
BAX
BCL2
VEGF165b
TDF/FTC/     
LPVr
BAX
BCL2
VEGF165b
0.6 μg/ml 
RTV
BAX
BCL2
VEGF165b
KALETRA     
(LPV/r)
BAX
4.07μg/ml 
EFV
BAX
BCL2
VEGF165b
BCL2
VEGF165b
ATRIPLA 
TDF/FTC/   
EFV
BAX
BCL2
VEGF165b
1.8μg/ml 
FTC
BAX
BCL2
VEGF165b
0.3 μg/ml 
TDF
BAX
BCL2
VEGF165b
Growth 
Medium
BAX
BCL2
VEGF165b
Vehicle 
Control 
0.01% 
Methanol
BAX
BCL2
VEGF165b
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3.3.5 Effects of ARVs on the nuclear morphology of normal and cancer cervical and 
breast cell lines. 
 
The major (long) and minor (short) axes of the nuclei were measured (in µm). This 
approach was found to be more reliable than the degree of nuclei compactness because the 
different cultures (passages) of the same untreated cell line exhibited different degrees of 
compactness and DAPI bright and DAPI dim areas. For example, while cell nuclei 
appeared compacted in NCE166IIA (normal cervical) cell culture preparation (passage) for 
VEGF165 staining (Fig. 3.22), they appeared less compacted in the same cell line 
(different passage) for BAX/BCL-2 staining (Fig. 3.18). Another example is Fig. 3.20A1-
J1 (for BAX staining) compared to Fig.3.20A2-J2 (for BCL-2 staining). The 
morphological differences observed were not due to treatment with ARVs because there 
were notable differences between two groups of untreated cells (the same cell line but 
different cultures). These differences could be therefore be passage dependent.  
Nuclear dimensions were therefore used as a more reliable measure of the effects of the 
ARVs on nuclear morphology and presented in the graphs below (Fig. 3.33). Mean values 
were statistically analysed (ANOVA) between the untreated, vehicle control and the 
treated groups. Fig. 3.33A illustrates the effects of the antiretroviral drugs on the major and 
minor axes of untreated, vehicle treated and ARV treated normal cervical NCE16IIA cells. 
Fig. 3.33B illustrates the effect of the antiretroviral drugs on the major and minor axes of 
untreated, vehicle treated and ARV treated cancer cervical HCS-2 cells. Fig. 3.33C 
illustrates the effect of the antiretroviral drugs on the major and minor axes of untreated, 
vehicle treated and ARV treated normal breast MCF-10A cells. Fig. 3.33D illustrates the 
effect of the antiretroviral drugs on the major and minor axes of untreated, vehicle treated 
and ARV treated cancer breast MCF-7 cells. Statistical analysis was performed using 
JMP® (Version 10.0 SAS Institute Inc., Cary, NC). Data are reported as mean + standard 
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deviation. After verifying the normal distribution and the homogeneity of the variance 
using an F test (p < 0.05), a one way analysis of variance (where a significance level 
of p < 0.05 was set) was used to compare the results. All means were then compared using 
the Tukey-Kramer HSD. Data summaries are presented in Appendix F. There were no 
significant (p<0.05) differences observed between untreated, vehicle treated and ARV 
treated groups.  
Table 3.4: Summary of the effects of ARVs on the nuclear morphology of normal and cancer 
cervical and breast cell lines 
Treatment Normal Cervical (NCE16IIA) 
Cancer  Cervical 
(HCS-2) 
Normal Breast 
(MCF-10A) 
Breast Cancer 
(MCF-7) 
Growth Medium 
Nuclei with round 
to oval shape. 
Major to minor 
axis ratio is 
approximately 1.5 
Oval to round 
Nuclei with major 
and minor nuclei 
axis ratio 
approximately 1.6 
Round to oval 
nuclei. Major and 
minor nuclei axis 
ratio 
approximately 1.5 
Round Nuclei 
with major and 
minor nuclei axis 
ratio 
approximately 1.6 
Vehicle Control 
(0.01% 
Methanol) 
Nuclei with round 
to oval shape. 
Major to minor 
axis ratio similar 
to untreated 
control 
Oval to round 
Nuclei with major 
to minor nuclei 
axis ratio similar to 
untreated control 
Round to oval 
nuclei similar to 
untreated control. 
Major and minor 
nuclei axis ratio 
similar to 
untreated control 
Round Nuclei 
with major to 
minor nuclei axis 
ratio similar to 
untreated control 
TREATMENT:     
0.3 µg/ml TDF, 
1.8µg/ml FTC, 
4.07µg/ml EFV, 
ATRIPLA, 
9.8µg/ml LPV, 
0.6 µg/ml RTV, 
KALETRA, 
TDF/FTC/LPVr 
Nuclei with round 
to oval shape. 
Major to minor 
axis ratio not 
significantly 
p<(0.05) different 
from controls 
Oval to round 
Nuclei with major 
to minor nuclei 
axis ratio not 
significantly 
p<(0.05) different 
from controls 
Round to oval 
nuclei similar to 
untreated control. 
Major and minor 
nuclei axis ratio 
similar to and not 
significantly 
p<(0.05) different 
from controls 
Round Nuclei 
with major to 
minor nuclei axis 
ratio not 
significantly 
p<(0.05) different 
from controls 
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Figure 3.33A and B: Effects of ARVs on the long (LA) and short (SA) axes lengths (µm) of the 
nuclei of normal cervical NCE16IIA (A) and cancer cervical HCS-2 (B) cells. Data are represented 
as (mean ± SD). Groups not connected by the same letter are significantly (p<0.05) different. 
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Figure 3.33C and D: Effects of ARVs on the long (LA) and short (SA) axes lengths (µm) of the 
nuclei of normal breast MCF-10A (C) and cancer breast MCF-7 (D) cells. Data are represented as 
(mean ± SD). Groups not connected by the same letter are significantly (p<0.05) different. 
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3.4 Protease Inhibitors and Apoptosis Inhibition 
It has been previously shown (Phenix et al, 2001, Badley, 2005, Vlahakis et al., 2007, 
Rizza and Badley, 2008) that protease inhibitors have potent anti-apoptotic effects in 
different cellular systems, the majority of which are immune cells. The anti-apoptotic 
effect of LPV/r was assessed to test whether these generalised effects are seen in the 
currently investigated cell lines and to test whether they alter apoptosis via a pathway other 
than the BAX/BCL-2 pathway, since they had no significant effect on BAX and BCL-2 
mRNA expression (Figs. 3.9 – 3.16). From an evaluation of the many methods currently 
used to analyse apoptosis, chromatin condensation and nuclear fragmentation remain the 
hallmarks of apoptotic cells (Ribble et al., 2005).  Because it had been suggested that, as a 
rule, classification of cell death in a given model should always include morphological 
examination coupled with at least one other assay (Renvoize et al., 1998), the Acridine 
Orange staining for morphological evaluation and an ELISA based method for the 
quantitative analysis of DNA fragmentation were thus chosen.  
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3.4.1 Protease Inhibitors and apoptosis inhibition in cervical cancer HCS-2 and 
normal cervical NCE16IIA cells 
From previous optimisation experiments, it was determined that 25 µM and 5 µM 
Camptothecin (CPT) significantly induced apoptosis in the HCS-2 and NCE16IIA cells, 
respectively, after six hours. Figures 3.34 and 3.35 represent data (acquired and analysed 
as described in section 2.7.2) from AO staining showing that a 96 hour exposure to LPV/r 
significantly (p<0.05) inhibited apoptosis in the cervical cancer HCS-2 but not in the 
normal cervical NCE16IIA cells. A total of 600 cells per cell line per group were counted 
from 3 independent experiments to determine the percentage of apoptotic cells. Data 
analysis was performed using JMP® (Version 10.0 SAS Institute Inc., Cary, NC). Data are 
reported as mean + standard deviation. After verifying the normal distribution and the 
homogeneity of the variance using an F test (p < 0.05), a one way analysis of variance 
(significance level p < 0.05) was used to compare the results. If there was a significant 
difference between the means (p<0.05) then a Tukey-Kramer post hoc analysis was 
performed to determine which treatment groups were significantly different from each 
other. Data summaries are shown in Appendix G. 
Figure 3.36 represent data (acquired and analysed as described in section 2.8) quantifying 
DNA fragmentation between groups (Data summaries are shown in Appendix G). The 
ELISA results also confirm that LPV/r significantly inhibited drug induced apoptosis in the 
cancer HCS-2 but not in the NCE16IIA cells. 
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Figure legend and the graphical representation of percentage apoptosis on next page.  
Nu-Nucleus, Cy-Cytoplasm, CM-Cell membrane. Area within yellow box magnified to the 
right. 
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Figure 3.34A-D: Effects of LPV/r on CPT mediated apoptosis in HCS-2 cells. HCS-2 
cells (untreated-A) were stimulated with 25µM CPT for 6 hours without prior exposure to 
LPV/r (B), while C shows cells incubated with LPV/r prior to apoptosis induction. 
Apoptosis was assessed using acridine orange staining. Arrows point to apoptotic bodies 
and cells undergoing apoptosis with the characteristic feature of membrane blebbing. Areas 
within the yellow box are magnified to the right (A1, B1 C1). A total of 600 cells per 
group were counted from 3 independent experiments to determine the percentage of 
apoptotic cells. LPV/r significantly (p<0.05) inhibited CPT induced apoptosis. 
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Figure legend and the graphical representation of percentage apoptosis on next page.  
Nu-Nucleus, Cy-Cytoplasm. Area within yellow box magnified to the right. 
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Figure 3.35A-D: Effects of LPV/r on CPT mediated apoptosis in NCE16IIA cells. 
NCE16IIA cells (untreated-A) were stimulated with 5µM CPT for 6 hours without prior 
exposure to LPV/r (B). C shows cells incubated with LPV/r prior to apoptosis induction. 
Apoptosis was assessed using acridine orange staining. Arrows point to apoptotic bodies 
and cells undergoing apoptosis with the characteristic feature of membrane blebbing. Areas 
within the yellow box are magnified to the right (A1, B1 C1). A total of 600 cells per 
group were counted from 3 independent experiments to determine the percentage of 
apoptotic cells. LPV/r has no significant effects on CPT induced apoptosis in NCE16IIA 
cells (D). 
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Figure 3.36A-B: Effects of LPV/r on CPT mediated apoptosis in HCS-2 and NCE16IIA cells evaluated by 
the Cell Death Detection ELISA. (A) HCS-2 cells were treated with methanol or LPV/r for 96 hours and 
stimulated with 25µM CPT. Apoptosis was assessed by quantifying internucleosomal DNA fragmentation. 
LPV/r treatment significantly (p<0.05) inhibited CPT induced apoptosis. (B) NCE16IIA cells were treated 
with methanol or LPV/r for 96 hours and stimulated with 5µM CPT. Apoptosis was assessed by quantifying 
internucleosomal DNA fragmentation. LPV/r treatment did not inhibit CPT induced apoptosis. Levels not 
connected by same letter are significantly different. 
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3.4.2  Protease Inhibitors and apoptosis inhibition in breast cancer (MCF-7) 
and normal breast (MCF10-A) cells 
From previous optimisation experiments, it was determined that 1 µM and 30 µM CPT 
significantly induced apoptosis in the MCF-7 and MCF10-A cells respectively after six 
hours. Figures 3.37 and 3.38 represent data (acquired and analysed as described in section 
2.7.2) from AO staining showing that a 96 hour exposure to LPV/r did not significantly 
(p<0.05) inhibit apoptosis in both breast cell lines. A total of 600 cells per cell line per 
group were counted from 3 independent experiments to determine the percentage of 
apoptotic cells. Data analysis was performed using JMP® (Version 10.0 SAS Institute Inc., 
Cary, NC). Data are reported as mean + standard deviation. After verifying the normal 
distribution and the homogeneity of the variance using an F test (p < 0.05), a one way 
analysis of variance (significance level p < 0.05) was used to compare the results. If there 
was a significant difference between the means (p<0.05) then a Tukey-Kramer post hoc 
analysis was performed to determine which treatment groups were significantly different 
from each other. Data summaries are shown in Appendix G.  
Figure 3.39 represents data (acquired and analysed as described in section 2.8) quantifying 
DNA fragmentation between groups (Data summaries are shown in Appendix G). These 
ELISA results also confirm that LPV/r did not significantly inhibit drug induced apoptosis 
in the breast MCF-7 and MCF-10A cells. 
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Figure legend and the graphical representation of percentage apoptosis on next page.  
Nu-Nucleus, Cy-Cytoplasm. Area within yellow box magnified to the right. 
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Figure 3.37A-D: Effects of LPV/r on CPT mediated apoptosis in MCF-7 cells. MCF-7 
cells (untreated-A) were stimulated with 1µM CPT for 6 hours without prior exposure to 
LPV/r (B). C shows cells incubated with LPV/r prior to apoptosis induction. Apoptosis 
was assessed using acridine orange staining. Arrows point to apoptotic bodies and cells 
undergoing apoptosis with the characteristic feature of membrane blebbing. Areas within 
the yellow box are magnified to the right (A1, B1 C1). A total of 600 cells per group were 
counted from 3 independent experiments to determine the percentage of apoptotic cells. 
LPV/r has no significant inhibitory effects on CPT induced apoptosis in MCF-7 cells (D). 
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Figure legend and the graphical representation of percentage apoptosis on next page.  
Nu-Nucleus, Cy-Cytoplasm. Area within yellow box magnified to the right. 
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Figure 3.38A-D: Effects of LPV/r on CPT mediated apoptosis in MCF-10A cells. MCF-
10A cells (untreated-A) were stimulated with 30µM CPT for 6 hours without prior 
exposure to LPV/r (B). C shows cells incubated with LPV/r prior to apoptosis induction. 
Apoptosis was assessed using acridine orange staining. Arrows point to apoptotic bodies 
and cells undergoing apoptosis with the characteristic feature of membrane blebbing. Areas 
within the yellow box are magnified to the right (A1, B1 C1). A total of 600 cells per 
group were counted from 3 independent experiments to determine the percentage of 
apoptotic cells. LPV/r has no significant inhibitory effects on CPT induced apoptosis in 
MCF-10A cells (D). 
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Figure 3.39A-B: Effects of LPV/r on CPT mediated apoptosis in MCF-7 and MCF-10A cells evaluated by 
the Cell Death Detection ELISA. MCF-7 (A) and MCF-10A (B) cells were treated with methanol or LPV/r 
for 96 hours and stimulated with CPT (1µM and 30µM respectively) and apoptosis was assessed by 
quantifying internucleosomal DNA fragmentation. LPV/r treatment did not significantly (p<0.05) inhibit 
CPT induced apoptosis in both cell lines. Levels not connected by same letter are significantly different. 
 
CHAPTER 4: DISCUSSION 
 
4.1 Introduction 
To determine whether the use of antiretroviral drugs could be a risk factor for the initiation 
or development of cancer in patients receiving HAART, this study tested the effects of 
different classes of antiretroviral drugs (individually and in combination) on normal 
(NCE16IIA) and cancer (HCS-2) cervical and normal (MCF-10A) and cancer (MCF-7) 
breast cell lines. The cervix was chosen as a model of AIDS-defining malignancies while 
the breast was chosen as a model of non-AIDS-defining malignancies.  
The findings reported here show that the antiretroviral drugs; tenofovir disoproxil 
fumarate, emtricitabine, efavirenz, lopinavir, ritonavir and the two triple combinations (all 
at clinically relevant concentrations which reflect their steady-state peak plasma 
concentrations in patients receiving these drugs (Apostolova et al., 2010; Bumpus, 2011)) 
demonstrated some form of cytotoxicity in the breast and cervical cells, which may alter 
the activity of the nuclear and mitochondrial genome of cells and may cause genotoxic 
effects largely related to the tumor initiation processes (Bishop and Schiestl, 2001; Olivero, 
2007; Wu et al., 2012). 
Negative effects of antiretroviral drugs have been widely reported. Olivero et al. (2005) 
and Gills et al. (2007) emphasised the need to determine the risks associated with 
individual classes of ARV drugs because the oncogenic potential of the different 
antiretroviral drug classes may be different. Powles et al. (2009) suggest that drugs within 
the cocktail may have effects on the host cell DNA leading to genomic instability and 
carcinogenesis. Individual NRTIs are implicated as possible chemical carcinogens and 
mutagens (Olivero et al., 1997; Blanche et al., 1999; IARC 2000; Torres et al., 2007). 
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Studies by Torres et al. (2007) suggest that the continuous use of NRTI drug pairs may 
lead to additive or synergistic effects that compound the long-term risk for cancer gene 
mutations and potential carcinogenesis. HIV PIs at low (clinical, serum) concentrations 
inhibit apoptosis (Vlahakis et al., 2007; Rizza and Badley, 2008), which may lead to the 
development of cancer.  
In order to initiate and/or promote cancer, we formulated the hypothesis that the 
antiretroviral drugs at clinically relevant concentrations might alter the expression of BAX 
and BCL-2 (which are key regulatory genes involved in carcinogenesis and apoptotic 
signalling) and VEGF165a and VEGF165b (pro- and anti-angiogenic related splice variants of 
the VEGFA gene, which are important factors regulating tumor angiogenesis).    
4.2 Antiretroviral drugs and Cytotoxicity 
The NRTI, TDF, has an initial cytotoxic effect on cell survival in the normal breast and a 
slow ongoing effect in both cervical cells. Generally, TDF seems to promote normal cell 
survival over cancer cells. TDF did not show any cytotoxic effects on the normal cervical 
cell line following a 96 hour exposure, but it did significantly increase the percentage 
viability of the normal cervical cells from 24 to 48 hours. On the other hand, after 72 hours 
of treatment, TDF became significantly cytotoxic to the cervical cancer cells. However, the 
possibility that TDF can increase the viability of normal cervical cells, when compared 
with the untreated control, may be an indication towards the initiation of cancer. However, 
the significant increase in percentage viability disappeared with continuous administration 
of TDF.                       
In the breast, TDF demonstrated significant cytotoxic effects in the normal breast MCF-
10A cell lines after 24 hours of administration. This initial cytotoxic effect disappeared 
with continuous administration. The fact that TDF can produce an initial cytotoxic effect in 
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the normal breast cells supports the suggestion of Powles et al. (2009) that drugs within the 
HAART cocktail may have effects on the host cell DNA which may result in genomic 
instability and carcinogenesis. TDF-containing regimens have been linked to mutagenesis 
in the in-vitro mouse lymphoma assay (Drug information, VIREAD® Gilead Sciences, 
2010) and nephrotoxicity (Gitman et al., 2007). 
The other NRTI used in this study, FTC, decreased the percentage viability of the normal 
cervical (NCE16IIA) cells with prolonged administration (96 hours). Even though the 
reduction was not statistically significant when compared to the vehicle control group, the 
reduction in percentage viability was significantly different from the effects of FTC on the 
cervical cancer HCS-2 cells at the same time point. Again this supports the claim that 
antiretroviral drugs may have effects on the host cell DNA which may cause genomic 
instability and carcinogenesis (Powles et al., 2009).  
FTC did not significantly alter the percentage viability of the normal breast MCF-10A cells 
from 24 to 96 hours, but it did significantly reduce the viability of the breast cancer MCF-7 
cells after 48 hours of treatment. With continuous administration, the cytotoxic effects of 
FTC on the breast cancer cells disappeared. The potential genotoxicity of these drugs 
involves a network of complex events that may lead to genomic instability due to 
incorporation of the drug into the DNA, mutagenesis, and telomere deterioration (Olivero, 
2007; Benhammou et al., 2008). NRTIs have been shown to directly alter the activity of 
the nuclear and mitochondrial genome of cells and may cause genotoxic effects largely 
related to tumor initiation processes (Bishop and Schiestl, 2001; Olivero, 2007).  
Studies by Brüning et al. (2012) showed that most of the NRTIs they tested did not alter 
the viability of selected cancer cells, while Tenofovir and FTC only reduced cancer cell 
viability at concentrations far beyond plasma levels of the drugs in HIV patients receiving 
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HAART. NRTI medications are phosphorylated by enzymes in host cells to their active 
triphosphate (TP) anabolites (Robbins et al., 1998; Wang et al., 2004). Intracellular NRTI 
triphosphates have been identified in clinical toxicities and many of them have been 
associated with inhibition of mitochondrial DNA polymerase gamma, just as they inhibit 
HIV DNA replication (Kakuda, 2000). This non-specificity leads to decreased 
mitochondrial DNA and reduced RNA and protein output, leading to mitochondrial 
dysfunction with resultant anaerobic respiration, lactic acid production, oxidative damage 
and a variety of other clinical presentations (Mallon et al., 2005; Kohler and Lewis, 2007; 
Maagaard and Kvale, 2009) However, neither TDF nor FTC effectively inhibit DNA 
polymerase gamma when compared to other NRTIs as evaluated by in-vitro cellular and 
enzymatic assays (Johnson et al., 2001; Birkus et al., 2002; Feng et al., 2004). 
The NNRTI, EFV, reduced the percentage viability of the normal cervical cells after 48 
hours and the cervical cancer cells after 72 to 96 hours of treatment but did not 
significantly change the percentage viability of the two cervical cell lines at the indicated 
concentration over 96 hours. This result corresponds with the findings of Apostolova et al. 
(2010) in which they reported that EFV, at similar concentrations reported here, failed to 
show significant cytotoxic effects in human Hep3B cells following a 3 day treatment 
period. However, the present study found that EFV (12.8 μM) showed significant 
cytotoxicity on the non-tumorigenic breast MCF-10A cells that was consistent throughout 
the period of exposure (24 to 96 hours). Again, the DNA damage associated with 
cytotoxicity is related to the processes of tumor initiation (Guimarães et al., 2010). 
Bumpus (2011) reported similar EFV cytotoxic effects on primary human hepatocytes at 
similar concentrations (10μM). Bumpus (2011) further showed that the mechanism of cell 
death induced by EFV in primary human hepatocytes was apoptotic, evidenced by an 
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increase in caspase-3 activity and decreased mitochondrial membrane potential. This is 
also supported by the findings of Apostolova et al. (2010), Blas-Garcia et al. (2010) and 
Apostolova et al. (2011). This EFV cytotoxic effect was not observed in the breast cancer 
MCF-7 cell line at the tested concentration. Instead, EFV appeared to favour breast cancer 
cell growth, although the increase in cell viability did not reach statistical significance. A 
previous study (Thabethe et al., 2013) reported that TDF, FTC and EFV significantly 
increased MCF-7 cell viability after 24 hours of exposure at the respective 1X Cmax 
concentrations of the drugs. However, this effect was no longer seen after 48 hours of 
exposure. The study (Thabethe et al., 2013) used the maximum concentration (0.5% (v/v)) 
of diluent (either DMSO or methanol) in the final stock solution as recommended by the 
National Toxicology Programme (NTP) Interagency Centre for the Evaluation of 
Alternative Toxicological Methods (NICEATM, 2003). The NRTIs (TDF and FTC) were 
dissolved in DMSO to a final concentration of 0.5% and EFV dissolved in methanol to a 
final concentration of 0.5%. This present study, however, dissolved TDF and FTC in 
distilled water (thereby eliminating the effects of DMSO) and dissolved EFV in methanol 
to a final concentration of 0.01%. The differences in vehicle controls used in both studies 
could explain the differences observed in the effects of the antiretroviral drugs on MCF-7 
cell viability.                                                                                                                           
A Study by Sikora et al. (2010) showed that EFV induced the growth of ER-positive breast 
cancer MCF-7 and T47D, but not ZR-75-1 cell lines after 6 days of treatment. They found 
that the MCF-7 growth induction was about 1.2-fold higher than that induced by vehicle 
treatment. The efavirenz concentrations that induced growth in their cell model ranged 
from 1 to 10μM which falls within the therapeutic plasma concentration range achieved 
after daily oral administration of 600 mg daily (mean steady-state minimum and maximum 
concentrations of 5.6 and 12.9 μM). They also showed that higher efavirenz concentrations 
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(50 or 100 μM) inhibited the growth of the MCF-7, T47D and ZR-75-1 cells. In the present 
study, however, the concentration of EFV (12.8 μM) utilised neither showed MCF-7 
growth stimulation nor inhibition (Fig. 3.3). This might be because in MCF-7 cells, EFV 
stimulates growth at lower concentrations, inhibits growth at higher concentrations (Sikora 
et al., 2010), and reaches an equilibrium of neither stimulatory nor inhibitory effects at the 
concentrations used in this study.                                      
Evaluating the effects of the NNRTIs nevirapine and efavirenz on the viability of human 
adipocytes, Díaz-Delfín et al. (2011) found that nevirapine was not cytotoxic to human 
adipocytes at any of the concentrations tested and that efavirenz at lower concentrations 
(0.5 and 4 μM) was not significantly cytotoxic, but caused extensive cell death at 20 μM. 
Non-nucleoside reverse transcriptase inhibitor-based regimens, including those containing 
EFV, have been linked to negative effects such as oxidative stress, skin rash and toxicity 
(Kontorinis and Dieterich, 2003; Abrescia et al., 2005; Vrouenraets et al., 2007). Evidence 
exists for the likely role of efavirenz in causing gynaecomastia and an increased incidence 
of AIDS-defining and some non-AIDS-defining malignancies, including breast cancer, in 
HIV infected patients (Shiels et al., 2009; Sikora et al., 2010). The combined antiretroviral 
therapy has also been shown to be protective for AIDS-defining cancers, but whether this 
protection exists for non-AIDS-defining cancers has not been clearly elucidated (Sikora et 
al., 2010).  
From this study, the triple combination of TDF, FTC and EFV, as combined in the one pill 
a day drug ‘ATRIPLA®’, favours the survival of cancer cells compared to the normal cells. 
It decreased the viability of the NCE166IIA cells as determined by the Neutral Red Uptake 
assay. These cytotoxic effects were not statistically significant when compared to their 
vehicle controls but were significantly cytotoxic when compared to the cervical cancer 
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HCS-2 cells at 48 and 72 hours. ATRIPLA did not show cytotoxic effects on the cervical 
HCS-2 but did increase their percentage viability at all time points, even though it was not 
statistically significant.  
ATP was significantly cytotoxic to the normal breast cells after 24 hours of administration. 
The cytotoxic effect disappeared with continuous administration; 48 to 96 hours (Fig. 
3.4B). ATP did not significantly alter the percentage viability of the breast cancer cells 
from 24 to 96 hours. The initial cytotoxic effect on the normal breast cells can lead to DNA 
damage and mutations in the genes involved in genomic integrity – including the ones 
involved in chromosomal segregation and DNA repair, thereby increasing the probability 
of the occurrence of cancerous cells. The use of ATP has been linked to acute hepatic 
failure due to hepatotoxicity after 3 months of treatment in a patient without pre-existing 
liver disease or risk factors (Qayyum et al., 2012).  
The protease inhibitor LPV showed cytotoxic effects on the normal cervical NCE16IIA 
cells although these effects were not statistically significant (Fig. 3.5A) when compared 
with their vehicle controls at all the time points. However, when compared with the 
cervical cancer cells at 24 and 48 hours, LPV significantly reduced the viability of the 
normal cervical cells. LPV did not significantly alter the viability of the cervical HCS-2 
cells at all time points when compared to their vehicle controls.  
LPV showed an initial cytotoxic effect on the MCF-10A cells after 24hours of exposure. 
Even though this cytotoxic effect disappeared after 48, 72 and 96 hours of exposure, this 
initial cytotoxicity can produce genomic rearrangements that may act as the primary step 
toward carcinogenesis. LPV did not significantly alter the percentage viability of the 
cervical cancer HCS-2 cells from 24 to 96 hours. 
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The second protease inhibitor used in this study, RTV, did not significantly alter the 
viability of the normal and cervical cancer cells throughout all the time points measured. 
RTV, however, was significantly cytotoxic to the normal breast MCF-10A cells at 24 
hours, when compared with the control group and the breast cancer MCF-7 cells. The 
cytotoxic effects of RTV on the normal breast disappeared with continuous administration 
but can lead to DNA damage and may trigger the processes of cancer initiation in normal 
breast cells. 
The combination of lopinavir and ritonavir, as combined in KALETRA®, demonstrated 
cytotoxic effects on the normal cervical cells, but the effects did not reach statistical 
significance from 24 to 96 hours. LPV/r did not significantly alter the percentage viability 
of the cancer cervical HCS-2 or the two breast cell lines. 
Evaluating the cytotoxicity of TDF/FTC/LPV/r, a protease inhibitor based second line 
regimen administered in South Africa, it is shown here that this combination was 
significantly cytotoxic to the normal cervical (NCE16IIA) cells after 24 hours of 
administration when compared to the control group and at 48 hours when compared to the 
cervical cancer treated group. The TDF/FTC/LPV/r combination demonstrated no 
significant alteration of the viability of the cervical cancer cells from 24 to 48 hours but 
increased the viability (albeit not significantly p<0.05) of the cervical cancer cells at 48 
hours (Fig. 3.8). It can be inferred that this combination may support the viability of 
cervical cancer cells and at the same time be genotoxic to the normal cervical cells and 
favour the complex processes leading to cancer initiation.     
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4.3 Do antiretroviral drugs alter the expression of apoptotic regulatory genes?  
Taking it further, this study evaluated the effects of the drugs on BAX and BCL-2 mRNA 
expression and protein localisation. The landmark discovery of the genes responsible for 
cell death by Horvitz (1999) began a new direction of research into the mechanisms and 
genetics of apoptosis. The protein products of two C. elegans (the nematode, 
Caenorhabditis elegans - C. elegans) cell death genes (CED-3 and CED-4) were shown to 
be necessary for apoptosis in early development, with CED-9 being the functional 
homolog to the mammalian protein BCL-2 (Danial and Korsmeyer, 2004; Schaffitzel and 
Hertweck, 2006; Pecina-Slaus, 2009). The role of BCL-2, a foundation member of the 
BCL-2 family of apoptosis regulator proteins, has been clearly shown in tumorigenesis to 
dysregulate apoptotic pathways (Vaux et al., 1988; Hanahan and Weinberg, 2000). In 
contrast to the nematode, the mammalian mitochondria exhibits a greater influence in 
controlling apoptosis by releasing numerous apoptogenic mediators from the mitochondrial 
intermembrane space, leading to a cascade of downstream reactions involving caspases 
(proteases that split key cellular proteins) (Susin et al., 2000; Mohamad et al.,2005; Fan et 
al., 2005; Li and Yuan, 2008). In mammals, the mitochondrion houses the intrinsic 
apoptotic pathway while the extrinsic apoptotic pathway involves death receptors. BCL-2 
expression has been shown to block the morphologic characteristics of apoptosis, such as 
blebbing of the plasma membrane, condensation of the nucleus and DNA cleavage 
(Mohamad et al., 2005). BCL-2 influences cell survival and inhibit cell death induced by a 
variety of stimuli; such as chemical agents, heat shock, and irradiation, implying that BCL-
2 is an inhibitor of cell death. This anti-apoptotic role has also been demonstrated in vivo. 
BCL-2 knockout mice showed a variety of abnormal manifestations such as excessive 
apoptosis (Ola et al., 2011).  
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Members of the BCL-2 family of pro-apoptotic proteins are subdivided into two groups 
based on the number of BCL-2 homology (BH) domains (e.g., BCL-2 associated X protein 
- BAX, BCL-2 antagonistic killer - BAK, and BCL-2 related ovarian killer - BOX) or 
those with the BH3 domain alone (e.g., BCL-2 interacting domain death agonist - BID, 
BCL-2 interacting mediator of cell death - BIM, and BCL-2 antagonist of cell death - 
BAD) (Ola et al., 2011). BID, BAD, and BIM are located in the cytosol with respect to the 
mitochondria. When the death signal is triggered, the BH3 domain-only proteins, also 
called minimal death domain, neutralises or inhibits anti-apoptotic BCL-2 proteins 
allowing pro-apoptotic proteins like BAX/BAK-like proteins to induce apoptosis (Wang et 
al., 1996; Brunelle and Letai 2009). Generally, the relative ratio of pro-survival (BCL-2) 
and anti-survival (BAX and BH3-only) proteins is believed to determine cell sensitivity or 
resistance to the apoptotic stimuli (Ola et al., 2011).  
To promote cancer, the antiretroviral drugs, either individually or in combination at the 
clinically relevant concentrations tested, were expected to up-regulate the anti-apoptotic 
BCL-2 mRNA and/or protein expression and down-regulate pro-apoptotic BAX mRNA 
and/or protein expression. The findings reported here show that the NRTIs and NNRTIs 
did not significantly alter BAX and BCL-2 mRNA expression and protein localisation in the 
two cervical and breast cell lines after a 96 hour exposure. However, in response to TDF 
treatment, opposing trends of BAX mRNA expression were observed between the cervical 
and breast cell lines; while BAX was slightly up-regulated in the cervical cells, it was 
down-regulated in the breast cell lines. The expression of BCL-2 also followed opposite 
patterns in the two cancer cell lines; increased in the cervical cancer and decreased in the 
breast cancer cells. If the trends showed by TDF on BAX and BCL-2 expression in the 
normal breast MCF-10A cells were significant, that would have been an important 
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indication for the increased risk of cancer initiation because anti-apoptotic BCL-2 was up-
regulated and pro-apoptotic BAX was down-regulated. FTC treatment produced opposing 
trends of BAX and BCL-2 mRNA expression in the two cancer cell lines; slight up-
regulation in the cervical cancer and down-regulation in the breast cancer cell line. FTC 
also slightly decreased the BAX /BCL-2 ratio in the normal cervical NCE16IIA cells, which 
if it were significant, might have suggested the initiation of cancer. EFV treatment 
produced opposing trends of BCL-2 mRNA expression in the two normal cell lines; slight 
down-regulation in the normal cervical and up-regulation in the normal breast cell line. In 
response to ATP treatment, opposite trends of BCL-2 mRNA expression were observed in 
the two normal cell lines; slight up-regulation in the normal cervical and down-regulation 
in the normal breast cell line. ATP also slightly decreased the BAX /BCL-2 ratio in the 
normal cervical NCE16IIA cells, which, if significant, might have suggested the initiation 
of cancer. 
The PIs also did not significantly alter the mRNA expression of BAX and BCL-2, neither 
did they alter the localisation of these proteins immunocytochemically in the cervical and 
breast cell lines. However, LPV treatment produced opposing trends of BAX and BCL-2 
mRNA expression in the two normal cell lines; slight up-regulation in the normal cervical 
and down-regulation in the normal breast cell line. RTV also produced similar BCL-2 
trends as LPV. LPV/r produced similar trends of BAX and BCL-2 mRNA expression in the 
two cancer cell lines. The PI containing combination of TDF/FTC/LPV/r also showed 
similar trends between the cervical and breast cell lines. The following correlations 
between gene expression and protein fluorescence staining intensity were also observed; 
LPV/r showed the same trends in the cancer cervical cells by decreasing BAX gene 
expression and slightly decreased nuclear BAX staining. In the cancer breast cells, FTC 
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demonstrated the same trends by decreasing BAX gene expression and slightly decreasing 
nuclear BAX staining intensity, even though these trends are not statistically significant. 
These results are consistent with the findings of other researchers. Reports by Gomez-
Sucerquia et al. (2012) showed that EFV at similar concentrations did not alter the mRNA 
expression of BAX and BCL2 like 1 genes following a 24 hour treatment period in human 
Hep3B cells. Phenix et al. (2001), Badley (2005) and Rizza and Badley (2008) reported 
that protease inhibitors, including lopinavir, did not alter the mRNA expression and protein 
synthesis of BAX, BCL-2 and some other key apoptotic genes following a 3 day exposure 
in immune cells. Some other proteins and/or genes of this or another pathway, however, 
might be involved.  
Antiretroviral drugs have been implicated in the production of reactive oxygen species 
(ROS) (from the mitochondrial electron transport chain enzymes), leading to mitochondrial 
dysfunction without a concomitant increase in apoptosis (Hebert et al., 2004; Jiang et al., 
2007). Studies by Jiang et al. (2007) showed that azidothymidine (a representative NRTI) 
and indinavir (a representative PI), (individually and in combination at concentrations 
similar to therapeutic doses in humans) caused the generation of mitochondria derived 
ROS in in vitro cultures of  human umbilical vein endothelial cells and compromised 
mitochondria function by a 40-50% reduction in cellular oxygen consumption/availability. 
The drugs also caused a decrease in mitochondrial transmembrane potential which further 
highlights mitochondrial dysfunction. However, the same treatment did not produce 
significant morphological or biochemical apoptotic characteristics in the endothelial cells 
(Jiang et al., 2007). 
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4.4 Antiretroviral drugs and the expression of angiogenic related genes 
Majority of the studies conducted before the discovery of anti-angiogenic VEGF variants 
utilised in situ hybridisation riboprobes, antibodies, and ELISAs that detect both 
VEGF165a and VEGF165b isoforms (Manetti et al., 2011). Part of the specific aims of the 
current study therefore was to investigate whether the expression of pro- and anti-
angiogenic VEGF splice variants (VEGF165a and VEGF165b) would be altered in breast and 
cervical cell lines exposed to different classes of antiretroviral drugs.  
The findings of the current study show that the NRTIs and NNRTIs do not alter VEGF165a 
and VEGF165b mRNA expression in the two cervical and breast cell lines after a 96 hour 
exposure. However, TDF treatment produced opposing trends of pro-angiogenic VEGF165a 
mRNA expression between the normal and cancer cell lines; slight up-regulation in the 
normal cell lines and down-regulation in the cancer cell lines. In the normal cervical cells, 
though not statistically significant, TDF administration seems to favour angiogenesis by 
increasing pro-angiogenic VEGF165a mRNA expression and slightly decreasing anti-
angiogenic VEGF165b mRNA expression. On the other hand, FTC appeared to produce 
opposing trends of VEGF165a expression between the normal cell lines and between the 
cancer cell lines; slight up-regulation in the normal cervical and down-regulation in the 
normal breast and more down-regulation in the breast cancer than in the cervical cancer 
cells. FTC also appeared to produce opposing trends of VEGF165b expression between the 
cancer cell lines. In the normal cervical cells, though not statistically significant, FTC 
administration also seems to favour angiogenesis by increasing pro-angiogenic VEGF165a 
mRNA expression and slightly decreasing anti-angiogenic VEGF165b mRNA expression. In 
response to EFV, the cancer trends appear similar but the normal cells seem opposite. In 
the normal cervical cells, though not statistically significant, EFV administration also 
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seems to favour angiogenesis by increasing pro-angiogenic VEGF165a mRNA expression 
and slightly decreasing anti-angiogenic VEGF165b mRNA expression. 
The PIs also did not alter the mRNA expression of VEGF165 and VEGF165b in the cervical 
and breast cell lines. However, LPV treatment produced opposing trends of VEGF165a and 
VEGF165b mRNA expression in the two normal cell lines; slight up-regulation in the 
normal cervical and down-regulation in the normal breast cell line. And while both 
angiogenic genes were slightly up-regulated in the normal cervical cells, they were slightly 
down-regulated in the cervical cancer cells. RTV and LPV/r produced similar trends as 
LPV on the expression of both angiogenic genes between the normal cervical and cervical 
cancer cells. LPV/r produced similar trends between the normal and cancer breast cell lines 
too. In the normal cervical and breast cells, though not statistically significant, the 
combination of TDF/FTC/LPV/r seems to favour angiogenesis by increasing pro-
angiogenic VEGF165a mRNA expression and slightly decreasing anti-angiogenic VEGF165b 
mRNA expression. The NRTIs and NNRTIs did not alter VEGF165b protein localisation in 
the two cervical and breast cell lines after a 4 day exposure. The PIs also did not alter the 
localisation of the VEGF165b protein immunocytochemically in the cervical and breast cell 
lines (Fig. 3.21 - 3.24).  
Studies investigating the effects of antiretroviral drugs on the mRNA expression of VEGF 
splice variants VEGF165a and VEGF165b, in-vitro, in-vivo or even in other cell lines were 
not found in the literature. In a glioblastoma cell line, HIV protease inhibitors, – nelfinavir 
and amprenavir reduced the expression of vascular endothelial growth factor (VEGF) and 
hypoxia inducible factor-alpha (Pore et al., 2006). The same drugs, however, did not 
produce any decrease in VEGF expression in immortalized human astrocytes (Pore et al., 
2006).  
190 
 
Cancer development, invasion, and metastases require that cancer cells possess the ability 
to proliferate and invade tissues when the extracellular matrix is compromised. 
Inflammatory and stromal cells entering tumours take part in these processes by producing 
paracrine factors, matrix metalloproteinases and other proteases that increase cancer-cell 
growth and extracellular-matrix degradation (Carmeliet and Jain, 2000; Egeblad and Werb, 
2002). As a result, the invasion, spread and proliferation of cancer cells, together with 
extracellular matrix and basement membrane degradation are needed for angiogenesis and 
progression of tumours (Carmeliet and Jain, 2000; Egeblad and Werb, 2002). Protease 
inhibitors are considered to be strongly anti-angiogenic compounds (Sgadari et al., 2002; 
Sgadari et al., 2003). Sgadari et al. (2002) demonstrated that PIs inhibited Kaposi’s’s 
sarcoma growth with the histological characteristics of treated mice showing that the 
regression of lesions was because the protease inhibitors restrict the formation of new 
blood vessels. Because Kaposi’s’s sarcoma is hastened by angiogenic factors secreted by 
Kaposi’s sarcoma cells in human or mice lesions, they examined the effects of protease 
inhibitors, indinavir and saquinavir, on angiogenesis stimulated by subcutaneous injection 
of bFGF and VEGF in nude mice. Treatment with protease inhibitors was shown to block 
the formation of lesions and significantly reduce the amount of bFGF-induced angio-
proliferative macroscopic lesions. Under microscopic examination, the sites of bFGF 
injection showed significantly reduced angiogenesis and spindle-cell growth in mice 
treated with protease inhibitors compared to control animals treated with saline. The 
protease inhibitors (at concentrations similar to those present in plasma from treated 
patients) were also found to block angiogenesis induced by both bFGF and VEGF 
individually in the chorioallantoic membrane—an established in vivo method for 
determining angiogenesis and evaluating the potency of anti-angiogenic agents (Sgadari et 
al., 2002). The protease inhibitors indinavir and saquinavir, however, were not shown to 
191 
 
significantly affect bFGF-promoted multiplication, growth, and survival of endothelial 
cells derived from macrovasculature (Sgadari et al., 2002). Their data suggests that 
protease inhibitors effectively blocked tumour growth and tumour associated angiogenesis 
in xenograft tumour models, without creating extreme toxic effects. Protease inhibitors, 
however, are also considered to be anti-apoptotic (Rizza and Badley, 2008), and are 
therefore implicated in the development of cancer. This study, however, did not show any 
association between PIs, NRTIs and NNRTIs and altered mRNA expression of 
proangiogenic VEGF165a and anti-angiogenic VEGF165b in the two cervical and breast cell 
lines. 
4.5 Apoptosis Induction by Camptothecin 
In the present study and as utilised in others (Nieves-Neira and Pommier, 1999; Rastogi et 
al., 2006; Rudolf et al., 2011), Camptothecin (CPT) was used to induce apoptosis in the 
different cell lines. CPT is a class I DNA topoisomerase inhibitor that reversibly induces 
single-strand breaks, and as a result altering the replication capacity of the cell. 
Camptothecin binds to and stabilises the topoisomerase 1/DNA complex (Legarza and 
Yang, 2006). These topoisomerase-linked DNA strand breaks are rescindable pre-lethal 
lesions that inhibit DNA metabolism (Bertrand et al., 1991; Pommier, 1997). But, when a 
DNA replication fork comes into contact with the cleavable complex, single-strand breaks 
are transformed to irreversible double-strand breaks (Hsiang et al., 1985; 1989). Then, 
apoptosis is facilitated by the activation of caspases (Sanchez-Alcazar et al., 2000). The 
action of caspases result in the proteolysis of precise structural and homoeostatic proteins 
leading to an irrevocable commitment of cells to undergo the morphological changes 
typical of apoptosis, characterized by cytoplasmic shrinkage, membrane blebbing, 
chromatin condensation, and extensive DNA breakage (Alnemri, 1997); Sanchez-Alcazar 
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et al., 2000; Pizzolato and Saltz, 2003). This mechanism of CPT induced apoptosis 
requires active DNA replication and results in S-phase-specific cytotoxicity (Pizzolato and 
Saltz, 2003). 
Apart from S-phase dependent pathways, S-phase independent pathways have also been 
described. Bendixen et al. (1990) reported an interference with transcription, describing 
that one of the initial reactions to CPT is quick cessation of RNA synthesis.  
In Addition, Mosesso et al. (2000) reported the induction of chromosomal aberrations in 
the G2-phase connected to RNA polymerase while cell lines, in which RNA synthesis was 
inhibited, demonstrated a significant reduction in the chromosomal aberrations (Mosesso et 
al., 2000). Additional S-phase independent pathways not related to the synthesis of RNA 
have also been described. In one investigation, neurones were treated with CPT with the 
proposition that CPT would not be cytotoxic to non-mitotic, differentiated cell lines. 
Contrary to the supposition, CPT induced apoptotic cell death in the neuronal cell lines. 
Apoptotic cell death also occurred in the nerve cells, when treated independently with 
substances inhibiting DNA polymerase, RNA transcription, and DNA synthesis, alluding 
to an apoptotic mechanism that is not dependent on S-phase and mitosis (Morris and 
Geller, 1996; Legarza and Yang, 2006). 
4.6 Protease Inhibitors and Inhibition of Apoptosis 
It has been shown previously that protease inhibitors have potent anti-apoptotic effects in 
different cellular systems, the majority of which are immune cells (Phenix et al, 2001; 
Badley, 2005; Vlahakis et al., 2007; Rizza and Badley, 2008). These studies reported that 
the protease inhibitors investigated inhibited drug induced apoptosis. This anti-apoptotic 
property, (exhibited by protease inhibitors at concentrations similar to those levels 
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achieved in patients receiving the drugs) is a key step in the development of cancer. The 
anti-apoptotic effect of LPV/r was therefore assessed to test whether these generalised 
effects are seen in the currently investigated cell lines and to test whether they alter 
apoptosis via an alternate pathway other than the BAX/BCL-2 pathway, since they had no 
significant effects on BAX and BCL-2 mRNA expression.  
Pre-incubation with LPV/r for 96 hours significantly inhibited the development of 
apoptosis in the cervical cancer HCS-2 but not the normal immortalised cervical 
NCE16IIA cell line. These findings were consistent between the AO morphological 
apoptotic evaluation and the Cell Death ELISA assessment of DNA fragmentation. In the 
breast cell lines, pre-incubation with LPV/r did not significantly inhibit CPT induced 
apoptosis in either breast cell lines. The Cell Death ELISA assessment of DNA 
fragmentation showed similar results (Fig. 3.39).  
Phenix et al. (2001) demonstrated that the HIV protease inhibitor - nelfinavir inhibited 
Jurkat T-cell apoptosis induced by a variety of different stimuli, including CPT. They also 
reported that inhibition of apoptotic death was not associated with alterations of mRNA 
expression levels of a variety of pro- and anti-apoptotic factors, and did not depend on 
protein synthesis.  
On the other hand, high-dose PIs have been shown to demonstrate paradoxical pro-
apoptotic effects, as demonstrated in implanted mouse models and transformed cell lines 
(Badley, 2005; Gills et al., 2007). They display pleiotropic anti-tumorigenic effects, inhibit 
the production of inflammatory cytokines, and induce apoptotic cell death (Chow et al., 
2009). HIV protease inhibitors and other antiretroviral drugs holding similar promise are a 
new class of FDA approved drugs that are being investigated for anti-tumour effects 
(Chow et al., 2009). For instance, Dewan et al. (2006) reported that ritonavir, an HIV 
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protease inhibitor, induced apoptosis and inhibited transcriptional activation of NFκB in 
cultured Adult T-cell leukaemia cells. Ritonavir was shown to inhibit the expression of 
BIRC5. BIRC5 (survivin) is an important and widely studied member of the inhibitors of 
apoptosis (IAP) protein family which are involved in cell death, immunity, inflammation, 
cell cycle and migration (Almagro and Vucic, 2012). The members of this protein family 
are characterized by the presence of one to three baculoviral IAP repeats (BIR) domains 
and are overexpressed in cancer cells and malignancies making them highly resistant to 
therapy (Almagro and Vucic, 2012). In other studies, Nordgren et al. (2012) reported that 
ritonavir (HIV PI) alone or in combination with vincristine inhibited proliferation and 
induced apoptosis in Mantle Cell Lymphoma (MCL) cell lines. They also reported 
significant downregulation of some NFκB transcriptional targets including BIRC5 
(surviving, an important IAP) following ritonavir exposure. However, they found that 
utilising ritonavir in treating MCL as a single agent has insignificant efficacy and 
suggested that while ritonavir did not exhibit any in vivo activity against MCL as a single 
agent, evidence from in vitro studies displayed possible therapeutic potential for its 
utilisation in a combinatorial regimen for the treatment of Mantle Cell Lymphoma 
(Nordgren et al., 2012). 
There are several theories explaining how HIV PIs hold cellular apoptosis in check. 
Because HIV PIs restrict the activity of HIV-1 viral protease, it was assumed that they 
might exercise similar effects on other cellular proteases (Rizza and Badley, 2008). It was 
also hypothesised that HIV PIs may inhibit the family members of the caspases and 
inhibits apoptosis because of the earlier observations that HIV PIs inhibits FAS-mediated 
apoptosis (Phenix et al., 2001). While this model could be plausible, caspases are known to 
be cysteine proteases while HIV protease is an aspartyle protease (Chou et al., 1997; Chou 
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et al., 2000). Studies investigating the effects of HIV protease inhibitors on the activity of 
caspases found that the HIV protease inhibitors restricted HIV protease cleavage of 
gag/pol, but did not inhibit the activity of any of the caspases (Phenix et al., 2001). In other 
studies, the activity of caspases -3, -6, and -8 were not inhibited by indinavir in U937 cells 
at drug concentrations that effectively inhibited U937 apoptosis (Ghibelli et al., 2003), 
while nelfinavir failed to inhibit the activation of caspases -1, -3, -4, -5, -9, and -8 in Jurkat 
T cells undergoing FAS-mediated apoptosis (Chavan et al., 2001). Calpains, calcium 
dependent cysteine proteases, are other proteases that are associated with programmed cell 
death and have been considered as possible targets for HIV protease inhibitors to modulate 
apoptosis (Spinedi et al., 1998). It has been postulated that HIV PIs alter apoptosis by 
blocking calpain activation and calpain function because the PIs inhibit the HIV-1 
aspartyle protease (Rizza and Badley, 2008). It has been demonstrated that PIs - indinavir 
and ritonavir block m-calpain activation and directly inhibit apoptosis in cells where 
calpains are activated (Ghibelli et al., 2003). In addition, another study found that ritonavir 
inhibited the activity of calpain isoforms -μ and m- competitively in PC12 cells (Wan and 
DePetrillo, 2002). Cuerrier et al. (2005), however, reported that HIV Protease Inhibitors 
did not inhibit μ- and m- calpain activation, postulating that previous studies suggesting 
otherwise used ritonavir concentrations near its maximum solubility and this could have 
affected the results.  
Stabilisation of the mitochondria is the most alluded to mechanism through which HIV PIs 
might influence apoptosis (Rizza and Badley, 2008). The mitochrondrial permeability 
transition pore complex (PTPC) maintains the mitochondrial trans-membrane potential that 
is as a result of the unequal distribution of ions on the two sides of the inner mitochondrial 
membrane. It has been said that subsequent to an apoptotic trigger, the PTPC opens, alters 
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the membrane potential, and makes apoptogenic factors, such as pro-caspase-9 and 
cytochrome c, available. Hence, the mitochondria represent a regulatory checkpoint of 
apoptotic signaling, where many apoptotic regulatory proteins (including the BCL-2 family 
members) interact to influence apoptosis (Rizza and Badley, 2008). In CD4+T cells, over a 
narrow concentration range, it was shown that nelfinavir, but not other HIV PIs, inhibit 
cellular apoptosis (Garg and Blumenthal, 2006). Other studies have also shown that HIV 
PIs inhibit the loss of the mitochondrial trans-membrane potential in different models of 
apoptosis (Phenix et al., 2001; Badley et al., 2003; Matarrese et al., 2003; Matarrese et al., 
2005; Miro et al., 2005; Weaver et al., 2005). 
In vivo and in vitro studies by Hisatomi et al. (2008) showed that protease inhibitors 
demonstrated anti-apoptosis in a model in which the PIs (NFV and RTV) were 
administered after apoptosis induction. They demonstrated that HIV PIs suppresses the 
translocation of cytochrome c and prevents the release of AIF from the mitochondria, and 
provided experimental evidence indicating that HIV PIs disrupt both the caspase-
dependent (cytochrome c/ Apaf-1/caspase-9–mediated) and the caspase-independent 
(AIFmediated) mitochondria apoptotic pathways. They reported that PIs significantly 
reduced the mitochondria-nuclear AIF translocation and the stimulation of caspase-3 and -
9, leading to reduced apoptotic photoreceptor cell death (Hisatomi et al., 2008). AIF, 
released from mitochondria, speeds up MOMP in a positive feed-forward loop (Susin et 
al., 1999). AIF also stimulates refined mitochondria to release cytochrome c which binds 
Apaf-1 that in turn activates caspase-9, which also can directly affect mitochondrial 
function and/or disrupt the permeability of the mitochondrial membrane (Susinet al., 1997; 
Hisatomi et al., 2008). Both pathways appear to be activated after MOMP and 
simultaneously coordinate corresponding pathways climaxing in cellular death (Hisatomi 
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et al., 2008), but the PIs blocked cell death by stabilisation of MOMP (Hisatomi et al., 
2008).  
Whether HIV protease inhibitors alter the expression of proteins regulating apoptosis 
provides another plausible explanation for the anti-apoptotic effects of PIs. Matarrese et al. 
(2003) investigated the effects of HIV PI treatment on intracellular levels of apoptotic 
regulatory proteins; BAX, BCL-2 and BCL-XL by flow cytometry and found that the 
protein levels were unchanged. Estaquier et al. (2002) reported an alteration in FAS 
expression after PI treatment. Other studies, however, did not show a relationship between 
altered FAS levels and HIV PI therapy (Sloand et al., 1999; Lu and Andrieu, 2000; Isgro et 
al., 2005). While HIV PIs have been reported to block FAS and TNF-induced apoptosis 
(Estaquier et al., 2002; Matarrese et al., 2003; Wolf et al., 2003), this anti-apoptotic effect 
does not appear to be due to changes in intra- or extracellular apoptotic regulatory protein 
levels (Rizza and Badley, 2008). This view is corroborated by the findings of the present 
study because the combination of lopinavir and ritonavir as combined in KALETRA® 
significantly inhibited drug induced apoptosis in the cervical cancer HCS-2 cells without 
altering the expression of BAX and BCL-2.  
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4.7 HAART and Cervical Cancer 
The introduction of the highly active antiretroviral therapy in 1996 (Dal Maso et al., 2009) 
has led to significant improvement of clinical outcomes and life expectancies for people 
living with HIV/AIDS (PLWHA) (Heard, 2009). It also provided the hope that the 
resulting improved immunological status would translate into better removal of human 
papilloma virus (HPV) infection in HIV-infected women, in the same manner as other 
opportunistic and AIDS-related infections, and lead to a significant reduction in the 
incidence and progression of cervical neoplasia (Heard, 2009). However, a review 
(Bratcher and Sahasrabuddhe, 2010) of data from numerous studies did not point to a clear 
decrease in the burden and severity of cervical disease with introduction of the combined 
antiretroviral therapy, in marked difference to the other AIDS-associated malignancies, 
especially Kaposi’s sarcoma and non-Hodgkin’s lymphoma. Bratcher and Sahasrabuddhe 
(2010) reported that while the majority of published literature suggested that being on 
HAART does not reduce the incidence of cervical precancerous lesions and cervical 
intraepithelial neoplasia in HIV-infected women, some studies found a higher risk in the 
post-HAART era. Because of the unclear collaborations between HIV, HPV, HAART and 
the development of cervical neoplasia, this study investigated the probability that some of 
the commonly used ARVs might alter apoptotic gene expression which may lead to the 
initiation or development of cancer in the cervix.  
The findings of this study, however, are not totally inconsistent with the notion of a 
possible role of antiretroviral drugs in the mechanisms involved in the initiation and/or 
development of cervical cancer because the protease inhibitors LPV/r inhibited drug 
induced apoptosis in cervical cancer cells.  
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To further tease out the effects of HAART on site specific malignancies, future studies 
should examine the effects of ARVs on cervical cells in the presence of HPV infection as it 
has been determined (Moubayed et al., 2004) that HPV increases the sensitivity of 
conjunctival cells to ultraviolet induced mutagenesis. 
4.8 HAART and Non-AIDS-Defining Malignancies 
An analysis of the incidence of non-AIDS-defining cancers in HIV-infected patients 
suggests that the incidence of breast cancer in these patients has significantly increased 
since the introduction and implementation of the combined antiretroviral therapy (Shiels et 
al., 2009), creating the need to effectively establish or rule out the possibility that 
candidate antiretroviral drugs may promote cancer.  
In the HAART era, it is a paradox that people living with HIV and AIDS are now at an 
increased risk for developing several specific non-AIDS-defining malignancies (NADMs) 
(Engels et al., 2008; Silverberg et al., 2009; Spano et al., 2012; Calabresi et al., 2013; 
Franzetti et al., 2013; Cutrell and Bedimo 2013), including breast cancer (Shiels et al., 
2009; Franzetti et al., 2013). Such that, despite the immune reconstitution induced by 
HAART, excess NADMs deaths have been reported amongst HIV patients (Zucchetto et 
al., 2010). It has also been reported that patients with NADMs often have more aggressive 
cancers and display more advanced stages of the disease (Grulich et al., 2007; Deeken et 
al., 2012), with breast cancer metastasising early and usually more poorly differentiated 
(Gewurz et al., 2005). 
The effects of HAART on the risk for NADMs have not been clearly established. Research 
evidence has been conflicting as to whether or which antiretroviral drugs or classes 
decrease, increase, or have no effect on the risk of developing NADMs (Burgi et al., 2005; 
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Deeken et al., 2012), with no definite pattern emerging from such studies. These 
inconsistencies partly arise from data obtained from disparate researchers. A lack of 
agreement for instance, arises from contradictions in population definition of AIDS or 
HIV/AIDS. A specific calendar period may also not be a correct representation of actual 
use of HAART. Hessol et al. (2007) reported differing NADM risks when comparing 
HAART era (pre-HAART versus HAART era) to HAART use. Even with this more 
specific classification, HAART use but not HAART era was linked to a lower risk for liver 
cancer, whereas HAART era but not HAART use was connected to a higher risk for anal 
cancer among patients with AIDS (Hessol et al., 2007). Shiels et al. (2009), in a meta-
analysis, reported that the standardised incidence ratio (SIR) of individual NADMs 
(specifically breast and kidney) but not all NADMs were significantly different in the pre-
HAART and HAART era. They discovered a greater than three-fold reduction in AIDS-
defining malignancy cases from 1991–2005 (34,587 to 10,325 cancers) in contrast to an 
approximately three-fold increment in NADM cases over the same period (3193 to 10,059 
cancers). Clifford et al. (2005), in a large prospective cohort of people (called the Swiss 
HIV Cohort Study) surveyed for a median of 4.8 years after the introduction of HAART, 
reported no definite effects of HAART on SIRs of non–AIDS-defining malignancies. In an 
HIV/AIDS cohort in England, however, Powles et al. (2009) reported that HAART 
treatment was independently linked to a significant increase in the risk for NADMs. In 
addition, Crum-Cianflone et al. (2009) did not find any significant decrease in the 
incidence of malignancies in patients on HAART regimens containing protease inhibitors 
despite the chemo-preventive effects of this class of antiretroviral drugs on malignancy by 
inducing apoptosis of cancer cells. The exact mechanisms for the development of non-
AIDs-defining malignancies remain to be fully elucidated (Cutrell and Bedimo 2013). 
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Use of the combined antiretroviral therapy has led to increased life expectancy among 
people living with HIV/AIDs and this has been predicted to lead to the increased incidence 
of NADMs (Nguyen et al., 2010; Cutrell and Bedimo 2013). The effect of improved life 
expectancy as a risk for developing NADMs was underscored by the US military cohort by 
Burgi et al. (2005), which showed a very significant increase in any NADM among people 
40 years and above. Interestingly, in spite of this effect, PLWHA are diagnosed with many 
different types of NADMs at younger ages when compared to the HIV negative controls 
(Brau et al., 2007; Suneja et al., 2013).  
AIDS-defining malignancy rates have been shown to be strongly associated with the 
degree of immune suppression based on CD4 count (Nguyen et al., 2010), but the 
association between CD4 count and the risk for NADMs has provided conflicting reports. 
Initial reports did not show any correlation between lower CD4 counts and higher NADM 
risk (Mbulaiteye et al., 2003; Clifford et al., 2005). However, more recently, studies have 
shown significant correlations between currently reduced CD4 counts or continuous 
exposure to reduced CD4 counts and NADM risk (Bedimo et al., 2009; Powles et al., 
2009; Bruyand et al., 2009; Guiguet et al., 2009; Prosperi et al., 2010; Reekie et al., 2010; 
Kesselring et al., 2011; Krishnan et al., 2011). There was better correlation for some 
infection-related NADMs, while the association with the extent of immune-suppression for 
other non infection related cancer subtypes is described as more complicated or subtle 
(Dubrow et al., 2012).  
Whether the HIV virus itself exerts direct oncogenic threats on host cellular mechanisms 
provides one possible explanation for the pathogenesis of increased cancers in PLWHA. It 
has been reported that the HIV tat protein can inhibit the activity of tumor suppressor 
genes (Harrod et al., 2003; De Falco et al., 2003) and mobilise pro-oncogenes (Wright et 
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al., 1994). This HIV protein can also block cellular apoptosis (Campioni et al., 1995), alter 
cell cycle dynamics (Colombrino et al., 2004; Nyagol et al., 2006), subject tissues to the 
effects of chemical carcinogens (Altavilla et al., 2000) and also encourage angiogenic 
pathways necessary for cancer progression and metastasis (Corallini et al., 1996). 
The higher prevalence of oncogenic viral coinfection provides a plausible explanation for 
the higher occurrence of particular cancer subtypes, such as cervical cancer (HPV), liver 
(hepatitis B and C virus) and Hodgkin’s lymphoma (Epstein-Barr virus) (Cutrell and 
Bedimo 2013). However, data from numerous studies has not pointed to a significant 
reduction in the burden and severity of cervical disease with the introduction of the 
combined antiretroviral treatment, while some studies have reported a higher risk in the 
post-HAART period (Bratcher and Sahasrabuddhe, 2010). 
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4.9 Conclusion 
With universal adoption of highly active antiretroviral therapy and increased life 
expectancy among people living with HIV/AIDS, there have been chronic adverse effects 
leading to an increased burden of cancers contributing to an increasing percentage of 
deaths among the HIV population (Powles et al., 2009; Nguyen et al., 2010; Franzetti et 
al., 2013). Reducing the mortality associated with increased cancer in the HAART era will 
require a better understanding of risk factors and their pathogenesis, which will then lead 
to the improvement of prevention and therapeutic interventions.   
The speculation that some antiretroviral drugs or combinations may have an adverse effect 
on the risk of carcinogenesis among PLWHA under HAART led to this study. The results 
reported here show that tenofovir disoproxil fumarate, emtricitabine efavirenz, lopinavir, 
ritonavir and the two triple combinations demonstrated some form of cytotoxicity in the 
breast and cervical cells, which may alter the activity of the nuclear and mitochondrial 
genome of cells and may cause genotoxic effects largely related to tumor initiation 
processes (Bishop and Schiestl, 2001; Olivero, 2007; Wu et al., 2012). The results of the 
qPCR data demonstrated differences in the response of the two tissue types (breast and 
cervical) used in this study, which, though, not statistically significant, showed trends and 
often opposite trends between the breast and cervical cell lines. The antiretroviral drugs; 
tenofovir disoproxil fumarate, emtricitabine, efavirenz, Atripla, lopinavir, ritonavir, Kaletra 
and a combination of TDF/FTC/LPV/r; all at clinically relevant concentrations (which 
reflect their steady-state peak plasma concentrations) do not alter the mRNA expression of 
apoptosis related BAX and BCL-2 and angiogenic related VEGF165a and VEGF165b genes, 
neither do they alter the localisation of their proteins in the human cervical cancer cell line 
HCS-2, normal immortalised human cervical cell line NCE16IIA, human breast cancer cell 
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line MCF-7 and non tumorigenic immortalised breast cell line MCF-10A. If the ARVs 
initiate or promote cancer, these pathways are not likely to be involved, so the effects of 
these agents need to be investigated on other oncogenic pathways. 
LPV/r, however, was found to significantly inhibit drug induced apoptosis in the cervical 
cancer cell line but not in the transformed normal cervical cell line nor in the two breast 
cell lines investigated. This inhibition of apoptosis, although so far not associated with 
RNA or protein synthesis is a key step in the development of cancer. This suggests that the 
PIs LPV/r at the clinically relevant concentrations tested might contribute to the 
progression of cancer of the cervix but are probably not involved in the development of 
breast cancer in patients under the combined antiretroviral regimen. 
Recommendations and future directions 
As better understanding of the effects of the class, combination and duration of ARV 
exposure on cancer risk is required, in-vitro and in-vivo studies of longer duration need to 
be conducted to determine whether the trends observed in the gene expression data of this 
study might eventually become significant. The effects of these agents also need to be 
investigated on other oncogenic pathways in order to characterise, more precisely, the 
genetic and molecular mechanisms underlying the interesting observations of this study. 
With regards to patient management, a comprehensive family history of cancers should be 
obtained and optimal treatment protocols should be well-defined in HIV patients. 
Individual approach to patient management based on the measurement of the expression 
levels and activities of certain genes might provide useful predictive values when planning 
antiretroviral therapy. Hence, concerted efforts are required amongst medical oncologists, 
HIV specialists, and clinical pharmacists for optimising antiretroviral regimens. 
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APPENDIX A 
A1 
Solutions recipes 
Phosphate Buffered Saline (PBS) pH 7.4; 8g NaCl, 1.15g Na2HPO4, 0.2g KCl, 0.2g 
KH2PO4.                                                                                                                  
Dissolve the salts in 800ml distilled water (dH2O); adjust the pH of the solution to 7.4. 
Add 200ml dH2O to make up 1l. 
10% Phosphate buffered Formalin: Formaldehyde (37-40%) 100 ml, Distilled water 900 
ml, NaH2PO4 4.0 g, Na2HPO4 (anhydrous) 6.5 g, pH 7.2 ± 0.5 
4% Formaldehyde in PBS; 400μl formaldehyde, 9.6ml PBS               
Mix the above solutions to make-up 10ml of 4% formaldehyde in PBS. 
1% BSA in PBS; 10g bovine serum albumin (BSA), 1litre PBS              
Dissolve 10g of BSA in 1l of PBS. 
10X PBS; 80g NaCl, 11.5g Na2HPO4, 2g KCl, 2g KH2PO4                  
Dissolve the salts in 800ml dH2O adjust the pH of the solution to 7.4. Add 200ml dH2O to 
make up 1l. 
Blocking buffer (1XPBS/5% normal goat serum/ 0.3% Triton X-100); 2.5ml of 10X 
PBS, 1.25ml normal goat serum, 21.25ml dH2O. Mix the solutions well and add 75μl of 
Triton X-100 while stirring to make-up 25ml of the blocking buffer. 
Antibody dilution buffer (1X PBS/1%BSA/0.3% Triton X-100); 4ml of 10X PBS, 36ml 
dH2O, 0.4g BSA. Mix the solutions with BSA and add 120μl of Triton X-100 while 
stirring, to make up 40ml of the antibody dilution buffer 
10x TBE; 0.9 M Tris, 0.89 M boric acid and 25 mM EDTA, pH 8.3. This stock solution 
was diluted 1/10 for the electrophoresis of agarose gels.  
10x TE; 1M Tris; Tris (hydroxymethyl) aminomethane - 60.57 g in 0.5L milliQ water (pH 
to 8.0 using HCI) 0.5M EDTA; Diaminoethane tetraacetic acid - 18.6 g in 100ml milliQ 
water (pH to 8.0 using NaOH - EDTA will not be soluble until pH reaches 8.0)    
Component for 500ml TE buffer; 1M Tris pH 8* 5ml, 0.5M EDTA pH 8 1ml, dH2O 
496ml. TE buffer was used to solubilise DNA, while protecting it from degradation. 
6 Glycerol BPB Gel-loading Buffer: 30 % glycerol, 0.3 % Bromophenol blue and 0.3 % 
Xylene cyanol. 
10x MOPS: 200 mM 3-[N-mophonolino] propane sulphuric acid (MOPS), 50 mM sodium 
acetate, 10 mM EDTA. 
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A2 
Table A1: List of reagents and suppliers 
CHEMICAL SUPPLIER 
Absolute ethanol 
Merck KGaA, Darmstadt, 
Germany 
Bovine serum albumin V Roche, Mannheim, Germany 
DAPI (4’, 6’-diamidino-2-phenylindole) Sigma, Munich, Germany 
Diethylpyrocarbonate Sigma, Munich, Germany 
EDTA (Ethylene diamine tetra acetic acid) Sigma, Munich, Germany 
Glacial acetic acid 
Merck KGaA, Darmstadt, 
Germany 
Hydrochloric acid 
Merck KGaA, Darmstadt, 
Germany 
Methanol Sigma, Munich, Germany 
MOPS (4-Morpholine propanesulphonic acid) Sigma, Munich, Germany 
Paraformaldehyde Sigma, Munich, Germany 
Sodium hydroxide 
Merck KGaA, Darmstadt, 
Germany 
Tris (Tris[hydroxymethyl] aminoethane) 
Merck KGaA, Darmstadt, 
Germany 
Triton X-100 (iso-octylphenoxypoly-
ethoxyethanol) Sigma, Munich, Germany 
Trypsin Invitrogen, Paisley, UK 
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APPENDIX B 
B1 Procedure for total RNA extraction 
The growth medium was removed from the cells (5x106 cells were used per extraction). 
Cells were rinsed once with PBS to remove residual medium. After discarding PBS, cells 
were detached from the culture dish by trypsinization. Cells were transfered into a 
microcentrifuge tube and pelleted by centrifugation for 5 min at 250 x g. The supernatant 
was discarded and the cells were resuspended in 600 μl of Lysis Buffer supplemented with 
β-mercaptoethanol. The mixture was vortexed for 10 sec to mix thoroughly. Due to the fact 
that incomplete homogenisation will result in a significant reduction of RNA yields, the 
mixture was homogenised with a disposable homogeniser-QIAshredder (QIAGEN®, USA) 
for 5 mins at 14000g (Hermle Z229, Zeiss, West Germany). After homogenisation, 360 μl 
of ethanol (96-100%) was added and the lysate mixed by pipetting. Up to 700 μl of lysate 
was added to the GeneJET RNA Purification Column inserted in a collection tube. The 
column was centrifuged (Hermle Z229, Zeiss, West Germany) for 1 min at 12000 x g. The 
flow-through was discarded and the purification column placed back into the collection 
tube. This step was repeated until all of the lysate has been transferred into the column and 
centrifuged. The collection tube containing the flow-through solution was then discarded. 
The GeneJET RNA Purification Column was then placed into a new 2 ml collection tube. 
700 μl of Wash Buffer 1 (supplemented with ethanol) was added to the GeneJET RNA 
Purification Column and centrifuged (Hermle Z229, Zeiss, West Germany) for 1 min at 
12000 x g. The flow-through was discarded and the purification column placed back into 
the collection tube. Wash Buffer 2 (600 μl) (supplemented with ethanol) was added to the 
GeneJET RNA Purification Column and centrifuged (Hermle Z229, Zeiss, West Germany) 
for 1 min at 12000 x g. The flow-through was discarded and the purification column placed 
back into the collection tube. Wash Buffer 2 (supplemented with ethanol) (250 μl) was 
added to the GeneJET RNA Purification Column and centrifuged (Hermle Z229, Zeiss, 
West Germany) for 2 min at 12000 x g. Residual solution was removed in the purification 
column by emptying the collection tube and re-spinning the column for 1 min at maximum 
speed. The collection tube containing the flow-through solution was discarded and the 
GeneJET RNA Purification Column was transferred to a sterile 1.5 ml RNase-free 
microcentrifuge tube. Nuclease-free water (100 μl), was added to the center of the 
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GeneJET RNA Purification Column membrane and centrifuged (Hermle Z229, Zeiss, West 
Germany) for 1 min at 12000 x g to elute RNA. 
B2 Procedure for RNA Gel Electrophoresis 
A 10X FA gel buffer to pour the gel and to make enough FA gel running buffer to fill the 
electrophoresis tank was prepared. An appropriate amount of agarose, 10X FA gel buffer, 
and RNase-free water was prepared in a flask in the ratio; 1 g agarose, 10 ml 10X FA gel 
buffer and RNase-free water to 100 ml. The mixture was heated in a microwave, swirled 
occasionally until the agarose was dissolved. Care was taken not to let the agarose solution 
boil over as it becomes super-heated. The agarose was cooled to 65-70oC in a water bath 
and swirled to prevent uneven cooling. After cooling, 1.8 ml of 37% [12.3 M] 
formaldehyde and 1 μl of a 10 mg/ml ethidium bromide stock solution were added. The 
agarose solution was then poured onto a gel tray in a fume hood to a thickness of 3-5 mm 
and the comb inserted immediately before pouring. The gel was allowed to set for 30 
minutes. It was ensured that there was enough space between the bottom of the comb and 
the gel tray (0.5-1.0 mm) to allow proper well formation and avoid sample leakage. 
Leaving the comb in the gel, the gel was placed in the electrophoresis tank. The tank was 
filled with 1X FA gel running buffer up to 1mm of liquid above the surface of the gel. 
Prior to running the gel, the comb was carefully removed and the gel was allowed to 
equilibrate in the 1X FA gel running buffer for 30 minutes. 5X RNA loading buffer was 
prepared and mixed with RNA samples in a ratio of 1: 4, incubated for 3-5 minutes at 65oC 
to denature RNA and chilled on ice. Denatured samples were added to the wells already 
submerged in the electrophoresis buffer. The electrodes of the electrophoresis apparatus 
were connected so that the RNA migrated towards the anode (positive lead, red). The gel 
was run in a fume hood because of the formaldehyde fumes. The gel was run at 5-7V/cm 
until the bromophenol blue dye has migrated approximately 2/3 of the way through the gel. 
Ethidium bromide in the gel allows visualisation of the RNA with the UV light. Ethidium 
bromide-RNA complexes display increased fluorescence compared to the un-complexed 
dye in solution. 
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B3 Procedure for Genomic DNA (gDNA) Removal 
Genomic DNA contamination was removed from total RNA according to the 
manufacturer’s instructions, using the DNase I, RNase-free kit (Thermo Scientific, 
Pittsburgh PA. USA). 1 μg RNA was added to an RNase-free tube together with 10X 
reaction buffer containing MgCl2 (1 μl), DNase I, RNase-free (1unit) and nuclease free 
water is added to 10 μl. The mixture was incubated at 37oC for 30 min. The DNAase I 
treated RNA was again cleaned with the GeneJET RNA Purification kit (Thermo 
Scientific, Pittsburgh PA. USA), re-quantified and stored at -80oC until used. 
B4 Optimization for Immunofluorescence 
A guide for cell staining was provided with the datasheet accompanying the primary and 
secondary antibodies used in this study, but to ensure specific antibody binding and 
optimal visualization of the target proteins, the following parameters required initial 
optimization; primary and secondary antibody dilutions, the blocking solution and duration 
and the duration of incubation with primary and secondary antibodies. The recommended 
dilution for polyclonal rabbit antihuman BAX (DAKO) was 1:1500 but a serial dilution of 
1:500, 1:1000, 1:1500 and 1:2000 were tested and a final dilution of 1:1000 was 
considered optimal. The recommended dilution for monoclonal mouse antihuman Bcl2 
(DAKO) was 1:50-1:100. Four serial dilutions at 1:50, 1:100, 1:200 and 1:500 were 
optimised and the 1:100 dilution considered optimal. The recommended dilution for 
polyclonal rabbit anti-human VEGF165b (ABCAM) was 5 μg/ml, but a concentration of 10 
μg/ml was found to be optimal.  Incubating cells with 10 % normal goat serum for 60 min 
was found to be more effective than 1% BSA in PBST for 30 min (according to the 
ABCAM double immunofluorescence – simultaneous protocol) at blocking unspecific 
binding of the antibodies. Incubating the cells with the primary antibodies overnight at 4°C 
gave better results compared to incubating the cells with the primary antibodies for 2 hours 
at room temperature. 
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APPENDIX C 
Appendix C1: Primer properties and products on target templates for all genes 
Table C1: BAX primer properties and products on target templates 
  Forward primer Reverse primer     
Sequence 
(5'->3') 
CCTTTTCTACTTTGCC
AGCAAAC 
GAGGCCGTCCC
AACCAC 
    
Length 23 17     
Tm 58.95 60.01     
GC% 43.48 70.59     
Self 
complemen
tarity 
8 4     
Self 3' 
complemen
tarity 
6 0     
Products 
on target 
templates 
    >NM_138763.
3 Homo 
sapiens BCL2-
associated X 
protein (BAX), 
transcript 
variant delta, 
mRNA 
>NM_138761.
3 Homo 
sapiens BCL2-
associated X 
protein (BAX), 
transcript 
variant alpha, 
mRNA 
Product 
Length 
    148 148 
Forward primer Template   258  .......  280 405  ........427 
Reverse primer Template   405  ......  389 552 ...... 536 
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 Table C2: BCL-2 primer properties and products on target templates 
  Forward primer Reverse primer     
Sequence 
(5'->3') 
ATGTGTGTGGAGAGC
GTCAACC 
GCATCCCAGCCTC
CGTTATC 
    
Length 22 20     
Tm 59.6 60.6     
GC% 50 60     
Self 
complemen
tarity 
2 3     
Self 3' 
complemen
tarity 
0 2     
Products 
on target 
templates 
    >NM_000633.2 
Homo sapiens B-
cell 
CLL/lymphoma 2 
(BCL2), 
transcript variant 
alpha, mRNA 
>NM_000657.2
 Homo sapiens 
B-cell 
CLL/lymphoma 
2 (BCL2), 
transcript 
variant beta, 
mRNA 
Product 
Length 
    122 122 
Forward primer Template   962……...981 962…....981 
Reverse primer Template   1083…...1064 1083… 1064 
 
Table C3: VEGF165A primer properties and products on target templates 
  Forward primer Reverse primer   
Sequence 
(5'->3') 
CAAGATCCGCAG
ACGTGTAA 
GCTTGTCACATCT
GCAAGTA 
  
Length 20 20   
Tm 58.01 56.07   
GC% 50 45   
Self 
complement
arity 
4 8   
Self 3' 
complement
arity 
1 4   
Products on 
target 
templates 
    >NM_001025368.2 Homo sapiens 
vascular endothelial growth factor A 
(VEGFA), transcript variant 4, 
mRNA 
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Product 
Length 
    100 
Forward primer Template   1504...............................1523 
Reverse primer Template   1603……………….......1584 
 
 
Table C4: VEGF165B primer properties and products on target templates 
  Forward primer Reverse primer   
Sequence 
(5'->3') 
CGCAGACGTGTAA
ATGTTCCTG 
TTCCTGGTGAGAG
ATCTGCAAG 
  
Length 22 22   
Tm 60.16 59.76   
GC% 50 50   
Self 
complemen
tarity 
4 6   
Self 3' 
complemen
tarity 
2 2   
Products on 
target 
templates 
    >NM_001033756.2 Homo 
sapiens vascular endothelial 
growth factor A (VEGFA), 
transcript variant 7, mRNA 
Product 
Length 
    97 
Forward primer Template   1511…………….. .......1532 
Reverse primer Template   1607……………..........1586 
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Appendix C2: Amplification Plots of primer pairs for all genes 
 
Figure C1: Amplification Plots of BAX primer pairs 
 
 
 
Figure C2: Amplification Plots of BCL-2 primer pairs 
 
Slope -3.38 
Y-
Intercept 26.29 
R2 0.99 
% 
Efficiency 97.27 
Standard 
Error 
(SE) 0.008 
Slope -3.55 
Y-
Intercept 29.8 
R2 0.99 
% 
Efficiency 91.19 
Standard 
Error 
(SE) 0.016 
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 Figure C3: Amplification Plots of VEGF165A primer pairs 
 
 
Figure C4: Amplification Plots of VEGF165B primer pairs 
 
 
 
 
 
Slope -3.28 
Y-
Intercept 23.29 
R2 0.99 
% 
Efficiency 101.7 
Standard 
Error 
(SE) 0.009 
Slope -3.53 
Y-
Intercept 26 
R2 0.99 
% 
Efficiency 92.1 
Standard 
Error 
(SE) 0.011 
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 Figure C5: Amplification Plots of TBP primer pairs 
 
 
 
Figure C6: Amplification Plots of TFRC primer pairs 
 
 
 
 
Slope -3.39 
Y-
Intercept 21.33 
R2 0.99 
% 
Efficiency 97.16 
Standard 
Error 
(SE) 0.01 
Slope -3.31 
Y-
Intercept 25.37 
R2 0.99 
% 
Efficiency 100.5 
Standard 
Error 
(SE) 0.014 
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 Figure C7: Amplification Plots of RPLP0 primer pairs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Slope -3.53 
Y-
Intercept 25.95 
R2 0.99 
% 
Efficiency 91.95 
Standard 
Error 
(SE) 0.016 
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Appendix C3: Melt curves generated for PCR products for all primer pairs to confirm the 
absence of primer dimers and nonspecific amplification. 
 
 
Figure C8: Melt curves generated for BAX PCR product to confirm the absence of primer dimers 
and nonspecific amplification. Melting Temperature of BAX PCR product=84.50C 
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Figure C9: Melt curves generated for BCL-2 PCR product to confirm the absence of primer dimers 
and nonspecific amplification. Melting Temperature of BCL-2 PCR product=83.50C 
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Figure C10: Melt curves generated for VEGF165A PCR product to confirm the absence of primer 
dimers and nonspecific amplification. Melting Temperature of VEGF165A PCR product=79.50C 
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Figure C11: Melt curves generated for VEGF165B PCR product to confirm the absence of primer 
dimers and nonspecific amplification. Melting Temperature of VEGF165B PCR product=77.670C 
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Figure C12: Melt curves generated for TBP PCR product to confirm the absence of primer dimers 
and nonspecific amplification. Melting Temperature of TBP PCR product=77.810C 
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Figure C13: Melt curves generated for TFRC PCR product to confirm the absence of primer 
dimers and nonspecific amplification. Melting Temperature of TFRC PCR product=77.10C 
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Figure C14: Melt curves generated for RPLP0 PCR product to confirm the absence of primer 
dimers and nonspecific amplification. Melting Temperature of RPLP0 PCR product=83.40C 
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 Appendix C4 
 
 
Figure C15: Agarose gel electrophoresis of PCR products confirming the absence of 
nonspecific amplification. The range of the DNA Ladder (O'GeneRuler Low Range -
Thermo Scientific, Pittsburgh PA, USA) is 25bp to 700bp. BAX PCR product size (148bp), 
BCL-2 PCR product size (122bp), VEGF165A PCR product size (100bp), VEGF165B PCR 
product size (97bp), TBP PCR product size (86bp), TFRC PCR product size (133bp), 
RPLP0 PCR product size (178bp). 
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APPENDIX D1 
Oneway Analysis of effects of TDF on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.400157 
Adj Rsquare 0.349034 
Root Mean Square Error 10.27655 
Mean of Response 101.2925 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 12399.399 826.627 7.8273 <.0001* 
Error 176 18586.932 105.608   
C. Total 191 30986.332    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal treated 24hrs 12 117.818 12.0711 3.4846 110.15 125.49 
Normal treated 48hrs 12 116.427 15.0109 4.3333 106.89 125.96 
Normal treated 72hrs 12 110.505 10.5715 3.0517 103.79 117.22 
Normal treated 96hrs 12 100.927 10.9538 3.1621 93.97 107.89 
Cancer control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer treated 24hrs 12 104.682 23.4962 6.7828 89.75 119.61 
Cancer treated 48hrs 12 94.824 14.8406 4.2841 85.39 104.25 
Cancer treated 72hrs 12 85.245 10.4093 3.0049 78.63 91.86 
Cancer treated 96hrs 12 90.251 14.3622 4.1460 81.13 99.38 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 24hrs A         117.81796 
Normal treated 48hrs A         116.42730 
Normal treated 72hrs A B       110.50502 
Cancer treated 24hrs A B C     104.68199 
Normal treated 96hrs   B C     100.92713 
Normal control 24hrs   B C     100.00000 
Normal control 48hrs   B C     100.00000 
Normal control 72hrs   B C     100.00000 
Normal control 96hrs   B C     100.00000 
Cancer control 24hrs   B C     100.00000 
Cancer control 48hrs   B C     100.00000 
Cancer control 72hrs   B C     100.00000 
Cancer control 96hrs   B C     100.00000 
Cancer treated 48hrs     C D   94.82405 
Cancer treated 96hrs     C D   90.25056 
Cancer treated 72hrs       D   85.24546 
Levels not connected by same letter are significantly different. 
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APPENDIX D2 
Oneway Analysis of effects of TDF on % Viability of Breast cells by Time 
Summary of Fit    
Rsquare 0.386011 
Adj Rsquare 0.333683 
Root Mean Square Error 11.31143 
Mean of Response 99.53261 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 14157.526 943.835 7.3767 <.0001* 
Error 176 22518.928 127.948   
C. Total 191 36676.453    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal treated 24hrs 12 76.470 17.2227 4.9718 65.53 87.41 
Normal treated 48hrs 12 113.955 12.6810 3.6607 105.90 122.01 
Normal treated 72hrs 12 110.192 11.0624 3.1934 103.16 117.22 
Normal treated 96hrs 12 111.891 10.1976 2.9438 105.41 118.37 
Cancer control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer treated 24hrs 12 98.432 23.5714 6.8045 83.46 113.41 
Cancer treated 48hrs 12 87.056 18.0025 5.1969 75.62 98.49 
Cancer treated 72hrs 12 95.741 19.8731 5.7369 83.11 108.37 
Cancer treated 96hrs 12 98.784 9.4199 2.7193 92.80 104.77 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 48hrs A         113.95521 
Normal treated 96hrs A         111.89087 
Normal treated 72hrs A B       110.19218 
Normal control 24hrs A B C     100.00000 
Normal control 48hrs A B C     100.00000 
Normal control 72hrs A B C     100.00000 
Normal control 96hrs A B C     100.00000 
Cancer control 24hrs A B C     100.00000 
Cancer control 48hrs A B C     100.00000 
Cancer control 72hrs A B C     100.00000 
Cancer control 96hrs A B C     100.00000 
Cancer treated 96hrs A B C     98.78367 
Cancer treated 24hrs A B C     98.43235 
Cancer treated 72hrs   B C     95.74097 
Cancer treated 48hrs     C D   87.05630 
Normal treated 24hrs       D   76.47019 
Levels not connected by same letter are significantly different. 
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APPENDIX D3 
Oneway Analysis of effects of FTC on % Viability of Cervical cells by Time 
Summary of Fit   
Rsquare 0.229495 
Adj Rsquare 0.163827 
Root Mean Square Error 12.00947 
Mean of Response 101.7945 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 7560.620 504.041 3.4948 <.0001* 
Error 176 25384.013 144.227   
C. Total 191 32944.633    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal treated 24hrs 12 110.055 15.2043 4.3891 100.39 119.72 
Normal treated 48hrs 12 108.949 15.9227 4.5965 98.83 119.07 
Normal treated 72hrs 12 112.925 15.8747 4.5826 102.84 123.01 
Normal treated 96hrs 12 85.292 14.5986 4.2142 76.02 94.57 
Cancer control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer treated 24hrs 12 103.477 18.3350 5.2929 91.83 115.13 
Cancer treated 48hrs 12 95.236 22.1724 6.4006 81.15 109.32 
Cancer treated 72hrs 12 105.845 9.4188 2.7190 99.86 111.83 
Cancer treated 96hrs 12 106.932 21.0074 6.0643 93.58 120.28 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 72hrs A        112.92539 
Normal treated 24hrs A B      110.05504 
Normal treated 48hrs A B      108.94937 
Cancer treated 96hrs A B      106.93161 
Cancer treated 72hrs A B      105.84543 
Cancer treated 24hrs A B      103.47662 
Normal control 24hrs A B C    100.00000 
Normal control 48hrs A B C    100.00000 
Normal control 72hrs A B C    100.00000 
Normal control 96hrs A B C    100.00000 
Cancer control 24hrs A B C    100.00000 
Cancer control 48hrs A B C    100.00000 
Cancer control 72hrs A B C    100.00000 
Cancer control 96hrs A B C    100.00000 
Cancer treated 48hrs   B C    95.23612 
Normal treated 96hrs     C    85.29229 
Levels not connected by same letter are significantly different. 
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APPENDIX D4 
Oneway Analysis of effects of FTC on % Viability of Breast cells by Time 
Summary of Fit   
Rsquare 0.157168 
Adj Rsquare 0.085335 
Root Mean Square Error 12.05697 
Mean of Response 98.62692 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 4771.018 318.068 2.1880 0.0083* 
Error 176 25585.218 145.371   
C. Total 191 30356.236    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Normal treated 24hrs 12 109.333 12.8693 3.7150 101.16 117.51 
Normal treated 48hrs 12 95.577 19.2952 5.5700 83.32 107.84 
Normal treated 72hrs 12 93.355 15.1454 4.3721 83.73 102.98 
Normal treated 96hrs 12 96.473 13.5340 3.9069 87.87 105.07 
Cancer control 24hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 48hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 72hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer control 96hrs 12 100.000 0.0000 0.0000 100.00 100.00 
Cancer treated 24hrs 12 100.008 24.2170 6.9909 84.62 115.39 
Cancer treated 48hrs 12 83.908 20.3348 5.8701 70.99 96.83 
Cancer treated 72hrs 12 98.053 17.5382 5.0628 86.91 109.20 
Cancer treated 96hrs 12 101.323 8.2402 2.3787 96.09 106.56 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 24hrs A       109.33316 
Cancer treated 96hrs A       101.32328 
Cancer treated 24hrs A B     100.00809 
Normal control 24hrs A B     100.00000 
Normal control 48hrs A B     100.00000 
Normal control 72hrs A B     100.00000 
Normal control 96hrs A B     100.00000 
Cancer control 24hrs A B     100.00000 
Cancer control 48hrs A B     100.00000 
Cancer control 72hrs A B     100.00000 
Cancer control 96hrs A B     100.00000 
Cancer treated 72hrs A B     98.05292 
Normal treated 96hrs A B C    96.47257 
Normal treated 48hrs A B C    95.57695 
Normal treated 72hrs A B C    93.35545 
Cancer treated 48hrs    C    83.90825 
Levels not connected by same letter are significantly different. 
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APPENDIX D5 
Oneway Analysis of effects of EFV on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.196665 
Adj Rsquare 0.128199 
Root Mean Square Error 15.3541 
Mean of Response 100.0608 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 10157.614 677.174 2.8724 0.0005* 
Error 176 41491.741 235.749   
C. Total 191 51649.355    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.28 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.34 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.49 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.78 99.61 
Normal treated 24hrs 12 105.911 20.4551 5.9049 92.91 118.91 
Normal treated 48hrs 12 88.266 16.7104 4.8239 77.65 98.88 
Normal treated 72hrs 12 99.019 12.2719 3.5426 91.22 106.82 
Normal treated 96hrs 12 99.964 10.1948 2.9430 93.49 106.44 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.41 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.36 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.11 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.62 116.30 
Cancer treated 24hrs 12 104.742 14.6382 4.2257 95.44 114.04 
Cancer treated 48hrs 12 117.604 12.2421 3.5340 109.83 125.38 
Cancer treated 72hrs 12 89.259 14.2236 4.1060 80.22 98.30 
Cancer treated 96hrs 12 88.259 12.2522 3.5369 80.47 96.04 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 48hrs A       117.60408 
Normal treated 24hrs A B     105.91089 
Normal control 48hrs A B     104.91403 
Cancer treated 24hrs A B     104.74211 
Normal control 24hrs A B     104.61958 
Cancer control 24hrs A B     102.84158 
Cancer control 72hrs A B     101.87779 
Cancer control 96hrs A B     101.46113 
Normal treated 96hrs A B     99.96434 
Cancer control 48hrs A B     99.08842 
Normal treated 72hrs A B     99.01855 
Normal control 72hrs A B     97.94781 
Normal control 96hrs A  B     95.19797 
Cancer treated 72hrs   B     89.25888 
Normal treated 48hrs   B     88.26624 
Cancer treated 96hrs   B     88.25888 
Levels not connected by same letter are significantly different. 
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APPENDIX D6 
Oneway Analysis of effects of EFV on % Viability of Breast cells by Time 
Summary of Fit   
Rsquare 0.75515 
Adj Rsquare 0.734282 
Root Mean Square Error 13.36748 
Mean of Response 90.00757 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 96994.18 6466.28 36.1872 <.0001* 
Error 176 31449.36 178.69   
C. Total 191 128443.54    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.00 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.06 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.42 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.46 106.00 
Normal treated 24hrs 12 24.714 8.9620 2.5871 19.02 30.41 
Normal treated 48hrs 12 62.743 12.1717 3.5137 55.01 70.48 
Normal treated 72hrs 12 65.743 18.9262 5.4635 53.72 77.77 
Normal treated 96hrs 12 66.743 11.8115 3.4097 59.24 74.25 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.55 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.35 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.75 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.88 104.84 
Cancer treated 24hrs 12 105.537 15.9173 4.5949 95.42 115.65 
Cancer treated 48hrs 12 94.874 12.5722 3.6293 86.89 102.86 
Cancer treated 72hrs 12 110.440 18.4099 5.3145 98.74 122.14 
Cancer treated 96hrs 12 112.356 18.3246 5.2899 100.71 124.00 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 96hrs A        112.35627 
Cancer treated 72hrs A        110.43960 
Cancer treated 24hrs A        105.53700 
Cancer control 24hrs A        103.25258 
Normal control 24hrs A        100.96127 
Cancer control 48hrs A        100.01121 
Cancer control 96hrs A        99.86396 
Normal control 96hrs A        99.22855 
Normal control 48hrs A        98.39523 
Cancer control 72hrs A        97.94729 
Normal control 72hrs A        97.31189 
Cancer treated 48hrs A        94.87380 
Normal treated 96hrs   B      66.74290 
Normal treated 72hrs   B      65.74289 
Normal treated 48hrs   B      62.74289 
Normal treated 24hrs     C    24.71374 
Levels not connected by same letter are significantly different. 
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APPENDIX D7 
Oneway Analysis of effects of ATP on % Viability of Cervical cells by Time 
Summary of Fit   
Rsquare 0.247947 
Adj Rsquare 0.183852 
Root Mean Square Error 16.28944 
Mean of Response 102.4568 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 15396.981 1026.47 3.8684 <.0001* 
Error 176 46700.870 265.35   
C. Total 191 62097.851    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.28 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.34 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.49 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.78 99.61 
Normal treated 24hrs 12 91.607 19.0147 5.4891 79.53 103.69 
Normal treated 48hrs 12 90.582 17.3888 5.0197 79.53 101.63 
Normal treated 72hrs 12 94.726 11.2261 3.2407 87.59 101.86 
Normal treated 96hrs 12 91.815 8.6674 2.5021 86.31 97.32 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.41 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.36 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.11 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.62 116.30 
Cancer treated 24hrs 12 110.655 13.9327 4.0220 101.80 119.51 
Cancer treated 48hrs 12 118.129 14.6240 4.2216 108.84 127.42 
Cancer treated 72hrs 12 120.341 22.0432 6.3633 106.34 134.35 
Cancer treated 96hrs 12 113.507 19.5793 5.6521 101.07 125.95 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 72hrs A        120.34065 
Cancer treated 48hrs A B      118.12880 
Cancer treated 96hrs A B C    113.50732 
Cancer treated 24hrs A B C    110.65505 
Normal control 48hrs A B C    104.91403 
Normal control 24hrs A B C    104.61958 
Cancer control 24hrs A B C    102.84158 
Cancer control 72hrs A B C    101.87779 
Cancer control 96hrs A B C    101.46113 
Cancer control 48hrs A B C    99.08842 
Normal control 72hrs A B C    97.94781 
Normal control 96hrs   B C    95.19797 
Normal treated 72hrs     C    94.72556 
Normal treated 96hrs     C    91.81477 
Normal treated 24hrs     C    91.60749 
Normal treated 48hrs     C    90.58152 
Levels not connected by same letter are significantly different. 
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APPENDIX D8 
Oneway Analysis of effects of ATP on % Viability of Breast cells by Time 
Summary of Fit   
Rsquare 0.200193 
Adj Rsquare 0.132027 
Root Mean Square Error 14.32635 
Mean of Response 99.60847 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 9041.622 602.775 2.9369 0.0004* 
Error 176 36122.987 205.244   
C. Total 191 45164.609    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.00 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.06 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.42 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.46 106.00 
Normal treated 24hrs 12 80.202 21.4543 6.1933 66.57 93.83 
Normal treated 48hrs 12 99.450 17.6067 5.0826 88.26 110.64 
Normal treated 72hrs 12 98.616 13.7489 3.9690 89.88 107.35 
Normal treated 96hrs 12 99.700 21.5245 6.2136 86.02 113.38 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.55 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.35 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.75 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.88 104.84 
Cancer treated 24hrs 12 109.558 15.2805 4.4111 99.85 119.27 
Cancer treated 48hrs 12 101.093 17.5171 5.0568 89.96 112.22 
Cancer treated 72hrs 12 114.314 14.9684 4.3210 104.80 123.82 
Cancer treated 96hrs 12 93.830 7.0836 2.0449 89.33 98.33 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 72hrs A        114.31409 
Cancer treated 24hrs A B      109.55800 
Cancer control 24hrs A B      103.25258 
Cancer treated 48hrs A B      101.09348 
Normal control 24hrs A B      100.96127 
Cancer control 48hrs A B C    100.01121 
Cancer control 96hrs A B C    99.86396 
Normal treated 96hrs A B C    99.69982 
Normal treated 48hrs A B C    99.44982 
Normal control 96hrs A B C    99.22855 
Normal treated 72hrs A B C    98.61649 
Normal control 48hrs A B C    98.39523 
Cancer control 72hrs A B C    97.94729 
Normal control 72hrs A B C    97.31189 
Cancer treated 96hrs   B C    93.83001 
Normal treated 24hrs     C    80.20178 
Levels not connected by same letter are significantly different. 
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APPENDIX D9 
Oneway Analysis of effects of LPV on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.246833 
Adj Rsquare 0.182643 
Root Mean Square Error 15.80714 
Mean of Response 98.97962 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 14412.244 960.816 3.8453 <.0001* 
Error 176 43976.369 249.866   
C. Total 191 58388.613    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.28 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.34 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.49 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.78 99.61 
Normal treated 24hrs 12 83.305 16.5049 4.7646 72.82 93.79 
Normal treated 48hrs 12 86.671 15.5202 4.4803 76.81 96.53 
Normal treated 72hrs 12 94.027 13.1159 3.7862 85.69 102.36 
Normal treated 96hrs 12 96.724 19.5782 5.6517 84.28 109.16 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.41 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.36 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.11 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.62 116.30 
Cancer treated 24hrs 12 115.366 15.2685 4.4076 105.66 125.07 
Cancer treated 48hrs 12 116.027 17.5876 5.0771 104.85 127.20 
Cancer treated 72hrs 12 92.136 13.2591 3.8276 83.71 100.56 
Cancer treated 96hrs 12 91.470 10.3803 2.9965 84.87 98.07 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 48hrs A       116.02716 
Cancer treated 24hrs A       115.36553 
Normal control 48hrs A B     104.91403 
Normal control 24hrs A B     104.61958 
Cancer control 24hrs A B     102.84158 
Cancer control 72hrs A B     101.87779 
Cancer control 96hrs A B     101.46113 
Cancer control 48hrs A B     99.08842 
Normal control 72hrs A B     97.94781 
Normal treated 96hrs A B     96.72358 
Normal control 96hrs A B     95.19797 
Normal treated 72hrs A B     94.02653 
Cancer treated 72hrs   B     92.13641 
Cancer treated 96hrs   B     91.46974 
Normal treated 48hrs   B     86.67140 
Normal treated 24hrs   B     83.30528 
Levels not connected by same letter are significantly different. 
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APPENDIX D10 
Oneway Analysis of effects of LPV on % Viability of Breast cells by Time 
Summary of Fit   
Rsquare 0.463325 
Adj Rsquare 0.417585 
Root Mean Square Error 13.27362 
Mean of Response 101.7714 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 26771.029 1784.74 10.1297 <.0001* 
Error 176 31009.243 176.19   
C. Total 191 57780.272    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.00 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.06 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.42 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.46 106.00 
Normal treated 24hrs 12 63.991 10.1815 2.9391 57.52 70.46 
Normal treated 48hrs 12 111.708 11.9766 3.4574 104.10 119.32 
Normal treated 72hrs 12 114.542 17.5199 5.0576 103.41 125.67 
Normal treated 96hrs 12 113.208 15.0140 4.3342 103.67 122.75 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.55 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.35 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.75 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.88 104.84 
Cancer treated 24hrs 12 106.649 13.7934 3.9818 97.88 115.41 
Cancer treated 48hrs 12 94.477 18.0611 5.2138 83.00 105.95 
Cancer treated 72hrs 12 112.481 15.8847 4.5855 102.39 122.57 
Cancer treated 96hrs 12 114.314 14.9684 4.3210 104.80 123.82 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 72hrs A        114.54158 
Cancer treated 96hrs A        114.31409 
Normal treated 96hrs A B      113.20826 
Cancer treated 72hrs A B      112.48076 
Normal treated 48hrs A B      111.70824 
Cancer treated 24hrs A B      106.64879 
Cancer control 24hrs A B      103.25258 
Normal control 24hrs A B      100.96127 
Cancer control 48hrs A B      100.01121 
Cancer control 96hrs A B      99.86396 
Normal control 96hrs A B      99.22855 
Normal control 48hrs A B      98.39523 
Cancer control 72hrs A B      97.94729 
Normal control 72hrs A B      97.31189 
Cancer treated 48hrs   B      94.47673 
Normal treated 24hrs     C    63.99143 
Levels not connected by same letter are significantly different. 
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APPENDIX D11 
Oneway Analysis of effects of RTV on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.085086 
Adj Rsquare 0.00711 
Root Mean Square Error 15.71516 
Mean of Response 99.74839 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 4042.297 269.486 1.0912 0.3676 
Error 176 43466.066 246.966   
C. Total 191 47508.363    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.280 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.341 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.487 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.783 99.61 
Normal treated 24hrs 12 92.413 11.9950 3.4627 84.792 100.03 
Normal treated 48hrs 12 95.155 19.8640 5.7343 82.534 107.78 
Normal treated 72hrs 12 98.074 13.0692 3.7728 89.770 106.38 
Normal treated 96hrs 12 89.363 7.8654 2.2705 84.365 94.36 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.407 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.362 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.109 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.621 116.30 
Cancer treated 24hrs 12 101.336 15.2671 4.4072 91.636 111.04 
Cancer treated 48hrs 12 105.268 14.6369 4.2253 95.968 114.57 
Cancer treated 72hrs 12 104.333 22.3094 6.4402 90.158 118.51 
Cancer treated 96hrs 12 102.083 11.4924 3.3176 94.781 109.38 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 48hrs A      105.26825 
Normal control 48hrs A      104.91403 
Normal control 24hrs A      104.61958 
Cancer treated 72hrs A      104.33294 
Cancer control 24hrs A      102.84158 
Cancer treated 96hrs A      102.08294 
Cancer control 72hrs A      101.87779 
Cancer control 96hrs A      101.46113 
Cancer treated 24hrs A      101.33642 
Cancer control 48hrs A      99.08842 
Normal treated 72hrs A      98.07411 
Normal control 72hrs A      97.94781 
Normal control 96hrs A      95.19797 
Normal treated 48hrs A      95.15534 
Normal treated 24hrs A      92.41339 
Normal treated 96hrs A      89.36255 
Levels not connected by same letter are significantly different. 
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APPENDIX D12 
Oneway Analysis of effects of RTV on % Viability of Breast cells by Time 
Summary of Fit   
Rsquare 0.31555 
Adj Rsquare 0.257216 
Root Mean Square Error 13.32825 
Mean of Response 102.4972 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 14414.019 960.935 5.4094 <.0001* 
Error 176 31265.041 177.642   
C. Total 191 45679.060    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.00 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.06 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.42 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.46 106.00 
Normal treated 24hrs 12 79.907 12.3541 3.5663 72.06 87.76 
Normal treated 48hrs 12 113.163 12.4211 3.5857 105.27 121.06 
Normal treated 72hrs 12 117.163 15.3658 4.4357 107.40 126.93 
Normal treated 96hrs 12 115.663 17.3576 5.0107 104.63 126.69 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.55 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.35 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.75 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.88 104.84 
Cancer treated 24hrs 12 112.159 17.7029 5.1104 100.91 123.41 
Cancer treated 48hrs 12 101.031 20.6438 5.9593 87.91 114.15 
Cancer treated 72hrs 12 101.115 13.3510 3.8541 92.63 109.60 
Cancer treated 96hrs 12 102.782 5.7841 1.6697 99.11 106.46 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 72hrs A        117.16314 
Normal treated 96hrs A B      115.66314 
Normal treated 48hrs A B      113.16314 
Cancer treated 24hrs A B      112.15945 
Cancer control 24hrs A B      103.25258 
Cancer treated 96hrs A B      102.78180 
Cancer treated 72hrs A B      101.11513 
Cancer treated 48hrs A B      101.03066 
Normal control 24hrs A B      100.96127 
Cancer control 48hrs A B      100.01121 
Cancer control 96hrs A B      99.86396 
Normal control 96hrs A B      99.22855 
Normal control 48hrs A B C    98.39523 
Cancer control 72hrs   B C    97.94729 
Normal control 72hrs   B C    97.31189 
Normal treated 24hrs     C    79.90671 
Levels not connected by same letter are significantly different. 
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APPENDIX D13 
Oneway Analysis of effects of LPV/r on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.118332 
Adj Rsquare 0.04319 
Root Mean Square Error 18.20467 
Mean of Response 100.0854 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 7828.479 521.899 1.5748 0.0848 
Error 176 58328.165 331.410   
C. Total 191 66156.643    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.280 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.341 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.487 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.783 99.61 
Normal treated 24hrs 12 89.863 13.1722 3.8025 81.494 98.23 
Normal treated 48hrs 12 90.555 17.0542 4.9231 79.719 101.39 
Normal treated 72hrs 12 98.096 22.0108 6.3540 84.111 112.08 
Normal treated 96hrs 12 89.020 13.1967 3.8096 80.635 97.40 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.407 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.362 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.109 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.621 116.30 
Cancer treated 24hrs 12 112.535 20.8060 6.0062 99.316 125.75 
Cancer treated 48hrs 12 109.047 18.8896 5.4529 97.045 121.05 
Cancer treated 72hrs 12 102.776 25.1405 7.2574 86.803 118.75 
Cancer treated 96hrs 12 101.526 25.5853 7.3858 85.270 117.78 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 24hrs A      112.53509 
Cancer treated 48hrs A      109.04665 
Normal control 48hrs A      104.91403 
Normal control 24hrs A      104.61958 
Cancer control 24hrs A      102.84158 
Cancer treated 72hrs A      102.77611 
Cancer control 72hrs A      101.87779 
Cancer treated 96hrs A      101.52611 
Cancer control 96hrs A      101.46113 
Cancer control 48hrs A      99.08842 
Normal treated 72hrs A      98.09628 
Normal control 72hrs A      97.94781 
Normal control 96hrs A      95.19797 
Normal treated 48hrs A      90.55475 
Normal treated 24hrs A      89.86316 
Normal treated 96hrs A      89.01976 
Levels not connected by same letter are significantly different. 
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APPENDIX D14 
Oneway Analysis of effects of LPV/r on % Viability of Breast cells by Time 
Summary of Fit    
Rsquare 0.048589 
Adj Rsquare  -0.0325 
Root Mean Square Error 14.97004 
Mean of Response 99.13889 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 2014.308 134.287 0.5992 0.8730 
Error 176 39441.993 224.102   
C. Total 191 41456.301    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.002 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.063 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.418 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.457 106.00 
Normal treated 24hrs 12 92.949 27.3322 7.8901 75.583 110.32 
Normal treated 48hrs 12 99.228 13.0793 3.7757 90.917 107.54 
Normal treated 72hrs 12 98.311 14.0731 4.0625 89.369 107.25 
Normal treated 96hrs 12 98.965 15.8492 4.5753 88.895 109.03 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.547 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.352 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.751 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.884 104.84 
Cancer treated 24hrs 12 103.564 16.4679 4.7539 93.101 114.03 
Cancer treated 48hrs 12 91.417 16.4340 4.7441 80.976 101.86 
Cancer treated 72hrs 12 101.575 17.0906 4.9336 90.716 112.43 
Cancer treated 96hrs 12 103.242 18.3903 5.3088 91.557 114.93 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 24hrs A      103.56390 
Cancer control 24hrs A      103.25258 
Cancer treated 96hrs A      103.24172 
Cancer treated 72hrs A      101.57506 
Normal control 24hrs A      100.96127 
Cancer control 48hrs A      100.01121 
Cancer control 96hrs A      99.86396 
Normal control 96hrs A      99.22855 
Normal treated 48hrs A      99.22756 
Normal treated 96hrs A      98.96482 
Normal control 48hrs A      98.39523 
Normal treated 72hrs A      98.31089 
Cancer control 72hrs A      97.94729 
Normal control 72hrs A      97.31189 
Normal treated 24hrs A      92.94904 
Cancer treated 48hrs A      91.41729 
Levels not connected by same letter are significantly different. 
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APPENDIX D15 
Oneway Analysis of effects of TDF/FTC/LPV/r on % Viability of Cervical cells by Time 
Summary of Fit    
Rsquare 0.19781 
Adj Rsquare 0.129442 
Root Mean Square Error 15.32801 
Mean of Response 99.20963 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 10196.613 679.774 2.8933 0.0004* 
Error 176 41350.823 234.948   
C. Total 191 51547.436    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 104.620 8.4035 2.4259 99.28 109.96 
Normal control 48hrs 12 104.914 11.9183 3.4405 97.34 112.49 
Normal control 72hrs 12 97.948 10.1678 2.9352 91.49 104.41 
Normal control 96hrs 12 95.198 6.9494 2.0061 90.78 99.61 
Normal treated 24hrs 12 83.183 12.2129 3.5255 75.42 90.94 
Normal treated 48hrs 12 86.893 18.3546 5.2985 75.23 98.56 
Normal treated 72hrs 12 92.028 9.4739 2.7349 86.01 98.05 
Normal treated 96hrs 12 96.122 14.5087 4.1883 86.90 105.34 
Cancer control 24hrs 12 102.842 13.2754 3.8323 94.41 111.28 
Cancer control 48hrs 12 99.088 20.0293 5.7820 86.36 111.81 
Cancer control 72hrs 12 101.878 24.8176 7.1642 86.11 117.65 
Cancer control 96hrs 12 101.461 23.3571 6.7426 86.62 116.30 
Cancer treated 24hrs 12 105.201 10.6723 3.0808 98.42 111.98 
Cancer treated 48hrs 12 114.515 13.5614 3.9148 105.90 123.13 
Cancer treated 72hrs 12 101.190 17.7801 5.1327 89.89 112.49 
Cancer treated 96hrs 12 100.273 15.9906 4.6161 90.11 110.43 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Cancer treated 48hrs A        114.51456 
Cancer treated 24hrs A B      105.20077 
Normal control 48hrs A B     104.91403 
Normal control 24hrs A B     104.61958 
Cancer control 24hrs A B     102.84158 
Cancer control 72hrs A B C    101.87779 
Cancer control 96hrs A B C    101.46113 
Cancer treated 72hrs A B C    101.19009 
Cancer treated 96hrs A B C    100.27342 
Cancer control 48hrs A B C    99.08842 
Normal control 72hrs A B C    97.94781 
Normal treated 96hrs A B C    96.12198 
Normal control 96hrs A B C    95.19797 
Normal treated 72hrs   B C    92.02849 
Normal treated 48hrs   B C    86.89318 
Normal treated 24hrs     C    83.18326 
Levels not connected by same letter are significantly different. 
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APPENDIX D16 
Oneway Analysis of effects of TDF/FTC/LPV/r on % Viability of Breast cells by Time 
Summary of Fit    
Rsquare 0.273928 
Adj Rsquare 0.212047 
Root Mean Square Error 12.70453 
Mean of Response 102.8484 
Observations (or Sum Wgts) 192 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Time 15 10717.335 714.489 4.4267 <.0001* 
Error 176 28407.312 161.405   
C. Total 191 39124.648    
Means and Std Deviations 
Level Number Mean Std Dev Std Err Mean Lower 95% Upper 95% 
Normal control 24hrs 12 100.961 6.2315 1.7989 97.00 104.92 
Normal control 48hrs 12 98.395 8.3918 2.4225 93.06 103.73 
Normal control 72hrs 12 97.312 9.2757 2.6777 91.42 103.21 
Normal control 96hrs 12 99.229 10.6578 3.0767 92.46 106.00 
Normal treated 24hrs 12 90.612 16.7531 4.8362 79.97 101.26 
Normal treated 48hrs 12 113.225 11.6850 3.3732 105.80 120.65 
Normal treated 72hrs 12 116.225 14.9957 4.3289 106.70 125.75 
Normal treated 96hrs 12 114.808 11.0426 3.1877 107.79 121.82 
Cancer control 24hrs 12 103.253 13.7016 3.9553 94.55 111.96 
Cancer control 48hrs 12 100.011 15.2025 4.3886 90.35 109.67 
Cancer control 72hrs 12 97.947 16.0481 4.6327 87.75 108.14 
Cancer control 96hrs 12 99.864 7.8385 2.2628 94.88 104.84 
Cancer treated 24hrs 12 99.797 13.5684 3.9169 91.18 108.42 
Cancer treated 48hrs 12 93.647 12.5528 3.6237 85.67 101.62 
Cancer treated 72hrs 12 108.562 16.0556 4.6349 98.36 118.76 
Cancer treated 96hrs 12 111.728 13.1261 3.7892 103.39 120.07 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.47644 0.05 
Connecting Letters Report 
Level             Mean 
Normal treated 72hrs A        116.22456 
Normal treated 96hrs A B      114.80768 
Normal treated 48hrs A B      113.22456 
Cancer treated 96hrs A B      111.72844 
Cancer treated 72hrs A B C    108.56177 
Cancer control 24hrs A B C    103.25258 
Normal control 24hrs A B C    100.96127 
Cancer control 48hrs A B C    100.01121 
Cancer control 96hrs A B C    99.86396 
Cancer treated 24hrs A B C    99.79685 
Normal control 96hrs A B C    99.22855 
Normal control 48hrs A B C    98.39523 
Cancer control 72hrs   B C    97.94729 
Normal control 72hrs   B C    97.31189 
Cancer treated 48hrs     C    93.64720 
Normal treated 24hrs     C    90.61158 
Levels not connected by same letter are significantly different. 
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APPENDIX E1 
Oneway Analysis of Fluorescence Intensity of effects of ARVs on Cervical cells 
Oneway Analysis of Fluorescence Intensity of TDF on Cervical cells 
Summary of Fit 
    
Rsquare 0.998224 
Adj Rsquare 0.997887 
Root Mean Square Error 9.196458 
Mean of Response 400.421 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4753633.2 250191 2958.223 <.0001* 
Error 100 8457.5 85   
C. Total 119 4762090.7    
Means for Oneway Anova 
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 576.077 9.9957 4.0807 565.59 586.57 
Normal treated Bax Nucleus 6 572.468 6.5711 2.6826 565.57 579.36 
Normal control Bax Cytoplasm 6 307.727 3.4534 1.4098 304.10 311.35 
Normal treated Bax Cytoplasm 6 306.628 6.0649 2.4760 300.26 312.99 
Normal Control VEGF165b Nucleus 6 373.772 8.9153 3.6397 364.42 383.13 
Normal treated VEGF 165b Nucleus 6 376.739 12.5491 5.1232 363.57 389.91 
Normal Control VEGF 165b Cytoplasm 6 822.998 20.2078 8.2498 801.79 844.20 
Normal treated VEGF 165b Cytoplasm 6 819.989 9.5117 3.8831 810.01 829.97 
Cancer Control Bax Nucleus 6 276.353 4.7441 1.9368 271.37 281.33 
Cancer treated Bax Nucleus 6 273.537 6.8808 2.8091 266.32 280.76 
Cancer Control Bax Cytoplasm 6 192.531 5.1956 2.1211 187.08 197.98 
Cancer treated Bax Cytoplasm 6 194.570 5.4018 2.2053 188.90 200.24 
Cancer control Bcl2 Nucleus 6 314.768 6.6436 2.7122 307.80 321.74 
Cancer Treated Bcl2 Nucleus 6 315.693 4.9127 2.0056 310.54 320.85 
Cancer control Bcl2 Cytoplasm 6 189.813 5.0311 2.0539 184.53 195.09 
Cancer Treated Bcl2 Cytoplasm 6 190.597 4.8863 1.9948 185.47 195.72 
Cancer Control VEGF 165b Nucleus 6 305.645 4.9207 2.0089 300.48 310.81 
Cancer treated VEGF 165b Nucleus 6 306.305 9.5898 3.9150 296.24 316.37 
Cancer Control VEGF 165b Cytoplasm 6 644.643 18.1028 7.3905 625.65 663.64 
Cancer treated VEGF 165b Cytoplasm 6 647.568 8.7479 3.5713 638.39 656.75 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
 
Level               Mean 
Normal Control VEGF 165b Cytoplasm A             822.99761 
Normal treated VEGF 165b Cytoplasm A             819.98866 
Cancer treated VEGF 165b Cytoplasm   B           647.56755 
Cancer Control VEGF 165b Cytoplasm   B           644.64310 
Normal control Bax Nucleus     C         576.07677 
Normal treated Bax Nucleus     C         572.46816 
Normal treated VEGF 165b Nucleus       D       376.73941 
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Level               Mean 
Normal Control VEGF165b Nucleus       D       373.77185 
Cancer Treated Bcl2 Nucleus         E     315.69289 
Cancer control Bcl2 Nucleus         E     314.76758 
Normal control Bax Cytoplasm         E     307.72696 
Normal treated Bax Cytoplasm         E     306.62818 
Cancer treated VEGF 165b Nucleus         E     306.30500 
Cancer Control VEGF 165b Nucleus         E     305.64500 
Cancer Control Bax Nucleus           F   276.35280 
Cancer treated Bax Nucleus           F   273.53700 
Cancer treated Bax Cytoplasm             G 194.57001 
Cancer Control Bax Cytoplasm             G 192.53124 
Cancer Treated Bcl2 Cytoplasm             G 190.59672 
Cancer control Bcl2 Cytoplasm             G 189.81300 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of FTC on Cervical cells 
Summary of Fit 
    
Rsquare 0.997771 
Adj Rsquare 0.997348 
Root Mean Square Error 10.31391 
Mean of Response 400.5181 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4762765.7 250672 2356.452 <.0001* 
Error 100 10637.7 106   
C. Total 119 4773403.3    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 576.077 9.9957 4.0807 565.59 586.57 
Normal treated Bax Nucleus 6 578.506 6.3650 2.5985 571.83 585.19 
Normal control Bax Cytoplasm 6 307.727 3.4534 1.4098 304.10 311.35 
Normal treated Bax Cytoplasm 6 306.852 5.3769 2.1951 301.21 312.50 
Normal Control VEGF165b Nucleus 6 373.772 8.9153 3.6397 364.42 383.13 
Normal treated VEGF 165b Nucleus 6 378.112 11.1957 4.5706 366.36 389.86 
Normal Control VEGF 165b Cytoplasm 6 822.998 20.2078 8.2498 801.79 844.20 
Normal treated VEGF 165b Cytoplasm 6 821.337 18.9896 7.7525 801.41 841.27 
Cancer Control Bax Nucleus 6 276.353 4.7441 1.9368 271.37 281.33 
Cancer treated Bax Nucleus 6 274.176 11.3968 4.6527 262.22 286.14 
Cancer Control Bax Cytoplasm 6 192.531 5.1956 2.1211 187.08 197.98 
Cancer treated Bax Cytoplasm 6 190.582 1.8121 0.7398 188.68 192.48 
Cancer control Bcl2 Nucleus 6 314.768 6.6436 2.7122 307.80 321.74 
Cancer Treated Bcl2 Nucleus 6 315.711 5.4703 2.2333 309.97 321.45 
Cancer control Bcl2 Cytoplasm 6 189.813 5.0311 2.0539 184.53 195.09 
Cancer Treated Bcl2 Cytoplasm 6 190.824 5.4796 2.2370 185.07 196.57 
Cancer Control VEGF 165b Nucleus 6 305.645 4.9207 2.0089 300.48 310.81 
Cancer treated VEGF 165b Nucleus 6 307.923 3.3419 1.3643 304.42 311.43 
Cancer Control VEGF 165b Cytoplasm 6 644.643 18.1028 7.3905 625.65 663.64 
Cancer treated VEGF 165b Cytoplasm 6 642.011 17.2429 7.0394 623.92 660.11 
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Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
 
Level               Mean 
Normal Control VEGF 165b Cytoplasm A             822.99761 
Normal treated VEGF 165b Cytoplasm A             821.33750 
Cancer Control VEGF 165b Cytoplasm   B           644.64310 
Cancer treated VEGF 165b Cytoplasm   B           642.01050 
Normal treated Bax Nucleus     C         578.50632 
Normal control Bax Nucleus     C         576.07677 
Normal treated VEGF 165b Nucleus       D       378.11178 
Normal Control VEGF165b Nucleus       D       373.77185 
Cancer Treated Bcl2 Nucleus         E     315.71124 
Cancer control Bcl2 Nucleus         E     314.76758 
Cancer treated VEGF 165b Nucleus         E     307.92333 
Normal control Bax Cytoplasm         E     307.72696 
Normal treated Bax Cytoplasm         E     306.85245 
Cancer Control VEGF 165b Nucleus         E     305.64500 
Cancer Control Bax Nucleus           F   276.35280 
Cancer treated Bax Nucleus           F   274.17620 
Cancer Control Bax Cytoplasm             G 192.53124 
Cancer Treated Bcl2 Cytoplasm             G 190.82426 
Cancer treated Bax Cytoplasm             G 190.58184 
Cancer control Bcl2 Cytoplasm             G 189.81300 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of EFV on Cervical cells 
Summary of Fit 
    
Rsquare 0.997764 
Adj Rsquare 0.99734 
Root Mean Square Error 10.34972 
Mean of Response 400.5535 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4780635.4 251612 2348.955 <.0001* 
Error 100 10711.7 107   
C. Total 119 4791347.1    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 577.811 14.0923 5.7532 563.02 592.60 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 309.040 5.4424 2.2219 303.33 314.75 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 375.038 13.4286 5.4822 360.95 389.13 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 825.421 14.4638 5.9048 810.24 840.60 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 276.970 5.6517 2.3073 271.04 282.90 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 194.673 5.9368 2.4237 188.44 200.90 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 312.976 9.1597 3.7394 303.36 322.59 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 189.700 5.0531 2.0629 184.40 195.00 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 307.788 6.5457 2.6723 300.92 314.66 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 637.934 17.1409 6.9977 619.95 655.92 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
 
Level               Mean 
Normal treated VEGF 165b Cytoplasm A             825.42136 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Cancer treated VEGF 165b Cytoplasm   B           637.93385 
Normal treated Bax Nucleus     C         577.81098 
Normal control Bax Nucleus     C         573.10382 
Normal Control VEGF165b Nucleus       D       377.58481 
Normal treated VEGF 165b Nucleus       D       375.03771 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     312.97569 
Normal treated Bax Cytoplasm         E     309.03955 
Cancer treated VEGF 165b Nucleus         E     307.78833 
Normal control Bax Cytoplasm         E     305.71493 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Cancer treated Bax Nucleus           F   276.97040 
Cancer Control Bax Nucleus           F   272.73013 
Cancer treated Bax Cytoplasm             G 194.67279 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer Treated Bcl2 Cytoplasm             G 189.70005 
Cancer control Bcl2 Cytoplasm             G 189.51469 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of ATP on Cervical cells 
Summary of Fit 
    
Rsquare 0.997624 
Adj Rsquare 0.997172 
Root Mean Square Error 10.67895 
Mean of Response 400.0672 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
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Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4787710.0 251985 2209.616 <.0001* 
Error 100 11404.0 114   
C. Total 119 4799114.0    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 571.923 14.7126 6.0064 556.48 587.36 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 305.231 7.1985 2.9388 297.68 312.78 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 376.044 6.5215 2.6624 369.20 382.89 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 825.194 15.0897 6.1604 809.36 841.03 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 274.538 7.8387 3.2001 266.31 282.76 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 192.700 7.1707 2.9274 185.17 200.22 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 314.763 8.0695 3.2944 306.29 323.23 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 190.269 6.9923 2.8546 182.93 197.61 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 305.833 6.8830 2.8100 298.61 313.06 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 641.130 21.3712 8.7248 618.70 663.56 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
Level               Mean 
Normal treated VEGF 165b Cytoplasm A             825.19418 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Cancer treated VEGF 165b Cytoplasm   B           641.12980 
Normal control Bax Nucleus     C         573.10382 
Normal treated Bax Nucleus     C         571.92322 
Normal Control VEGF165b Nucleus       D       377.58481 
Normal treated VEGF 165b Nucleus       D       376.04370 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     314.76261 
Cancer treated VEGF 165b Nucleus         E     305.83333 
Normal control Bax Cytoplasm         E     305.71493 
Normal treated Bax Cytoplasm         E     305.23051 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Cancer treated Bax Nucleus           F   274.53840 
Cancer Control Bax Nucleus           F   272.73013 
Cancer treated Bax Cytoplasm             G 192.69959 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer Treated Bcl2 Cytoplasm             G 190.26891 
Cancer control Bcl2 Cytoplasm             G 189.51469 
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Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of LPV on Cervical cells 
Summary of Fit 
    
Rsquare 0.998161 
Adj Rsquare 0.997811 
Root Mean Square Error 9.381051 
Mean of Response 399.7788 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4776215.7 251380 2856.455 <.0001* 
Error 100 8800.4 88   
C. Total 119 4785016.2    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 570.441 8.9215 3.6422 561.08 579.80 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 303.657 4.5796 1.8696 298.85 308.46 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 374.171 3.8839 1.5856 370.09 378.25 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 817.907 19.4362 7.9348 797.51 838.30 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 271.164 6.7775 2.7669 264.05 278.28 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 194.087 3.9941 1.6306 189.90 198.28 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 315.138 9.0493 3.6944 305.64 324.64 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 191.215 5.6173 2.2932 185.32 197.11 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 304.325 6.0617 2.4747 297.96 310.69 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 649.749 6.5782 2.6855 642.85 656.65 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
Level               Mean 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Normal treated VEGF 165b Cytoplasm A             817.90736 
Cancer treated VEGF 165b Cytoplasm   B           649.74922 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Normal control Bax Nucleus     C         573.10382 
Normal treated Bax Nucleus     C         570.44136 
Normal Control VEGF165b Nucleus       D       377.58481 
Normal treated VEGF 165b Nucleus       D       374.17077 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     315.13838 
Normal control Bax Cytoplasm         E     305.71493 
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Level               Mean 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Cancer treated VEGF 165b Nucleus         E     304.32500 
Normal treated Bax Cytoplasm         E     303.65701 
Cancer Control Bax Nucleus           F   272.73013 
Cancer treated Bax Nucleus           F   271.16447 
Cancer treated Bax Cytoplasm             G 194.08721 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer Treated Bcl2 Cytoplasm             G 191.21516 
Cancer control Bcl2 Cytoplasm             G 189.51469 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of RTV on Cervical cells 
Summary of Fit 
    
Rsquare 0.997696 
Adj Rsquare 0.997259 
Root Mean Square Error 10.51859 
Mean of Response 400.4318 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4792022.0 252212 2279.554 <.0001* 
Error 100 11064.1 111   
C. Total 119 4803086.1    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 574.577 14.2574 5.8206 559.61 589.54 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 307.887 5.2155 2.1292 302.41 313.36 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 376.292 6.6290 2.7063 369.34 383.25 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 818.542 19.0366 7.7717 798.56 838.52 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 276.841 7.5305 3.0743 268.94 284.74 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 191.437 6.0060 2.4519 185.13 197.74 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 313.282 8.3450 3.4068 304.52 322.04 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 188.846 2.7162 1.1089 186.00 191.70 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 305.732 6.7635 2.7612 298.63 312.83 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 651.480 18.6855 7.6283 631.87 671.09 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
Level               Mean 
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Level               Mean 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Normal treated VEGF 165b Cytoplasm A             818.54182 
Cancer treated VEGF 165b Cytoplasm   B           651.48025 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Normal treated Bax Nucleus     C         574.57690 
Normal control Bax Nucleus     C         573.10382 
Normal Control VEGF165b Nucleus       D       377.58481 
Normal treated VEGF 165b Nucleus       D       376.29183 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     313.28180 
Normal treated Bax Cytoplasm         E     307.88696 
Cancer treated VEGF 165b Nucleus         E     305.73167 
Normal control Bax Cytoplasm         E     305.71493 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Cancer treated Bax Nucleus           F   276.84120 
Cancer Control Bax Nucleus           F   272.73013 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer treated Bax Cytoplasm             G 191.43692 
Cancer control Bcl2 Cytoplasm             G 189.51469 
Cancer Treated Bcl2 Cytoplasm             G 188.84616 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of LPV/R on Cervical cells 
Summary of Fit 
    
Rsquare 0.997672 
Adj Rsquare 0.99723 
Root Mean Square Error 10.55208 
Mean of Response 399.321 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4772426.9 251180 2255.848 <.0001* 
Error 100 11134.6 111   
C. Total 119 4783561.5    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 571.528 13.8961 5.6731 556.94 586.11 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 304.245 8.9752 3.6641 294.83 313.66 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 372.959 9.2655 3.7826 363.24 382.68 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 820.022 19.9263 8.1349 799.11 840.93 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 272.496 4.9677 2.0280 267.28 277.71 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 191.500 2.5169 1.0275 188.86 194.14 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 314.221 11.5475 4.7142 302.10 326.34 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 189.224 3.4496 1.4083 185.60 192.84 
270 
 
 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 305.390 11.2981 4.6124 293.53 317.25 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 641.116 12.4557 5.0850 628.04 654.19 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
Level               Mean 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Normal treated VEGF 165b Cytoplasm A             820.02183 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Cancer treated VEGF 165b Cytoplasm   B           641.11615 
Normal control Bax Nucleus     C         573.10382 
Normal treated Bax Nucleus     C         571.52750 
Normal Control VEGF165b Nucleus       D       377.58481 
Normal treated VEGF 165b Nucleus       D       372.95937 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     314.22125 
Normal control Bax Cytoplasm         E     305.71493 
Cancer treated VEGF 165b Nucleus         E     305.39000 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Normal treated Bax Cytoplasm         E     304.24452 
Cancer Control Bax Nucleus           F   272.73013 
Cancer treated Bax Nucleus           F   272.49607 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer treated Bax Cytoplasm             G 191.50019 
Cancer control Bcl2 Cytoplasm             G 189.51469 
Cancer Treated Bcl2 Cytoplasm             G 189.22392 
 
Levels not connected by same letter are significantly different. 
 
 
 
 
 
 
Oneway Analysis of Fluorescence Intensity of TDF/FTC/LPV/R on Cervical cells 
Summary of Fit 
    
Rsquare 0.99754 
Adj Rsquare 0.997072 
Root Mean Square Error 10.85025 
Mean of Response 400.124 
Observations (or Sum Wgts) 120 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 19 4773452.6 251234 2134.025 <.0001* 
Error 100 11772.8 118   
C. Total 119 4785225.4    
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Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 573.104 13.0980 5.3472 559.36 586.85 
Normal treated Bax Nucleus 6 572.333 17.6780 7.2170 553.78 590.89 
Normal control Bax Cytoplasm 6 305.715 4.5406 1.8537 300.95 310.48 
Normal treated Bax Cytoplasm 6 306.051 7.5508 3.0826 298.13 313.97 
Normal Control VEGF165b Nucleus 6 377.585 10.5504 4.3072 366.51 388.66 
Normal treated VEGF 165b Nucleus 6 378.353 9.7607 3.9848 368.11 388.60 
Normal Control VEGF 165b Cytoplasm 6 824.282 19.7112 8.0471 803.60 844.97 
Normal treated VEGF 165b Cytoplasm 6 818.950 21.3011 8.6961 796.60 841.30 
Cancer Control Bax Nucleus 6 272.730 7.8329 3.1978 264.51 280.95 
Cancer treated Bax Nucleus 6 275.329 4.2477 1.7341 270.87 279.79 
Cancer Control Bax Cytoplasm 6 192.489 3.0724 1.2543 189.26 195.71 
Cancer treated Bax Cytoplasm 6 190.330 5.1141 2.0878 184.96 195.70 
Cancer control Bcl2 Nucleus 6 315.272 8.7886 3.5879 306.05 324.50 
Cancer Treated Bcl2 Nucleus 6 315.121 9.6775 3.9508 304.96 325.28 
Cancer control Bcl2 Cytoplasm 6 189.515 5.5464 2.2643 183.69 195.34 
Cancer Treated Bcl2 Cytoplasm 6 188.514 2.2562 0.9211 186.15 190.88 
Cancer Control VEGF 165b Nucleus 6 304.397 5.2417 2.1399 298.90 309.90 
Cancer treated VEGF 165b Nucleus 6 308.467 2.8416 1.1601 305.48 311.45 
Cancer Control VEGF 165b Cytoplasm 6 648.631 10.6315 4.3403 637.47 659.79 
Cancer treated VEGF 165b Cytoplasm 6 645.313 16.5438 6.7540 627.95 662.67 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.64086 0.05 
Connecting Letters Report 
Level               Mean 
Normal Control VEGF 165b Cytoplasm A             824.28228 
Normal treated VEGF 165b Cytoplasm A             818.94977 
Cancer Control VEGF 165b Cytoplasm   B           648.63135 
Cancer treated VEGF 165b Cytoplasm   B           645.31270 
Normal control Bax Nucleus     C         573.10382 
Normal treated Bax Nucleus     C         572.33310 
Normal treated VEGF 165b Nucleus       D       378.35287 
Normal Control VEGF165b Nucleus       D       377.58481 
Cancer control Bcl2 Nucleus         E     315.27240 
Cancer Treated Bcl2 Nucleus         E     315.12072 
Cancer treated VEGF 165b Nucleus         E     308.46667 
Normal treated Bax Cytoplasm         E     306.05051 
Normal control Bax Cytoplasm         E     305.71493 
Cancer Control VEGF 165b Nucleus         E     304.39667 
Cancer treated Bax Nucleus           F   275.32900 
Cancer Control Bax Nucleus           F   272.73013 
Cancer Control Bax Cytoplasm             G 192.48892 
Cancer treated Bax Cytoplasm             G 190.33006 
Cancer control Bcl2 Cytoplasm             G 189.51469 
Cancer Treated Bcl2 Cytoplasm             G 188.51435 
 
Levels not connected by same letter are significantly different. 
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APPENDIX E2 
Oneway Analysis of Fluorescence Intensity of effects of ARVs on Breast cells 
Oneway Analysis of Fluorescence Intensity of TDF on Breast cells 
Summary of Fit 
    
Rsquare 0.998159 
Adj Rsquare 0.997808 
Root Mean Square Error 13.47935 
Mean of Response 429.829 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 10838584 516123 2840.633 <.0001* 
Error 110 19986 182   
C. Total 131 10858570    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 95% 
Normal control Bax Nucleus 6 245.46 9.0193 3.6821 236.0 254.9 
Normal treated Bax Nucleus 6 244.36 7.2360 2.9541 236.8 252.0 
Normal control Bax Cytoplasm 6 560.54 24.0055 9.8002 535.3 585.7 
Normal treated Bax Cytoplasm 6 563.56 15.4398 6.3033 547.4 579.8 
Normal control Bcl2 Nucleus 6 152.66 4.8650 1.9861 147.6 157.8 
Normal treated Bcl2 Nucleus 6 151.52 2.6058 1.0638 148.8 154.3 
Normal Control VEGF165b Nucleus 6 356.76 10.1859 4.1584 346.1 367.5 
Normal treated VEGF 165b Nucleus 6 353.39 10.7901 4.4050 342.1 364.7 
Normal Control VEGF 165b Cytoplasm 6 935.70 22.5602 9.2102 912.0 959.4 
Normal treated VEGF 165b Cytoplasm 6 933.66 21.8533 8.9216 910.7 956.6 
Cancer Control Bax Nucleus 6 344.20 6.5877 2.6894 337.3 351.1 
Cancer treated Bax Nucleus 6 343.30 9.0488 3.6941 333.8 352.8 
Cancer Control Bax Cytoplasm 6 192.04 2.8324 1.1563 189.1 195.0 
Cancer treated Bax Cytoplasm 6 192.82 3.8414 1.5682 188.8 196.8 
Cancer control Bcl2 Nucleus 6 314.65 7.8314 3.1972 306.4 322.9 
Cancer Treated Bcl2 Nucleus 6 310.37 10.8950 4.4479 298.9 321.8 
Cancer control Bcl2 Cytoplasm 6 197.05 2.4784 1.0118 194.4 199.6 
Cancer Treated Bcl2 Cytoplasm 6 194.99 4.6866 1.9133 190.1 199.9 
Cancer Control VEGF 165b Nucleus 6 387.06 10.9729 4.4797 375.5 398.6 
Cancer treated VEGF 165b Nucleus 6 389.63 14.8254 6.0525 374.1 405.2 
Cancer Control VEGF 165b Cytoplasm 6 1048.77 24.1119 9.8436 1023.5 1074.1 
Cancer treated VEGF 165b Cytoplasm 6 1043.76 23.1072 9.4335 1019.5 1068.0 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                     Mean 
Cancer Control VEGF 165b Cytoplasm A                   1048.7683 
Cancer treated VEGF 165b Cytoplasm A                   1043.7617 
Normal Control VEGF 165b Cytoplasm   B                 935.7000 
Normal treated VEGF 165b Cytoplasm   B                 933.6600 
Normal treated Bax Cytoplasm     C               563.5617 
Normal control Bax Cytoplasm     C               560.5400 
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Level                     Mean 
Cancer treated VEGF 165b Nucleus       D             389.6300 
Cancer Control VEGF 165b Nucleus       D             387.0617 
Normal Control VEGF165b Nucleus         E           356.7617 
Normal treated VEGF 165b Nucleus         E           353.3883 
Cancer Control Bax Nucleus         E           344.1988 
Cancer treated Bax Nucleus         E F         343.2955 
Cancer control Bcl2 Nucleus           F G       314.6500 
Cancer Treated Bcl2 Nucleus             G       310.3700 
Normal control Bax Nucleus               H     245.4617 
Normal treated Bax Nucleus               H     244.3617 
Cancer control Bcl2 Cytoplasm                 I   197.0467 
Cancer Treated Bcl2 Cytoplasm                 I   194.9850 
Cancer treated Bax Cytoplasm                 I   192.8150 
Cancer Control Bax Cytoplasm                 I   192.0367 
Normal control Bcl2 Nucleus                   J 152.6600 
Normal treated Bcl2 Nucleus                   J 151.5233 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of FTC on Breast cells 
Summary of Fit 
    
Rsquare 0.998535 
Adj Rsquare 0.998255 
Root Mean Square Error 12.05997 
Mean of Response 430.2606 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 10903653 519222 3569.936 <.0001* 
Error 110 15999 145   
C. Total 131 10919652    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 245.46 9.0193 3.6821 236.0 254.9 
Normal treated Bax Nucleus 6 240.92 8.4179 3.4366 232.1 249.8 
Normal control Bax Cytoplasm 6 560.54 24.0055 9.8002 535.3 585.7 
Normal treated Bax Cytoplasm 6 557.13 16.8189 6.8663 539.5 574.8 
Normal control Bcl2 Nucleus 6 152.66 4.8650 1.9861 147.6 157.8 
Normal treated Bcl2 Nucleus 6 150.56 1.6449 0.6715 148.8 152.3 
Normal Control VEGF165b Nucleus 6 356.76 10.1859 4.1584 346.1 367.5 
Normal treated VEGF 165b Nucleus 6 355.33 13.4362 5.4853 341.2 369.4 
Normal Control VEGF 165b Cytoplasm 6 935.70 22.5602 9.2102 912.0 959.4 
Normal treated VEGF 165b Cytoplasm 6 940.31 13.4421 5.4877 926.2 954.4 
Cancer Control Bax Nucleus 6 344.20 6.5877 2.6894 337.3 351.1 
Cancer treated Bax Nucleus 6 346.00 4.9552 2.0230 340.8 351.2 
Cancer Control Bax Cytoplasm 6 192.04 2.8324 1.1563 189.1 195.0 
Cancer treated Bax Cytoplasm 6 192.58 3.5000 1.4289 188.9 196.3 
Cancer control Bcl2 Nucleus 6 314.65 7.8314 3.1972 306.4 322.9 
Cancer Treated Bcl2 Nucleus 6 312.89 3.2828 1.3402 309.4 316.3 
Cancer control Bcl2 Cytoplasm 6 197.05 2.4784 1.0118 194.4 199.6 
Cancer Treated Bcl2 Cytoplasm 6 196.04 2.7705 1.1310 193.1 198.9 
Cancer Control VEGF 165b Nucleus 6 387.06 10.9729 4.4797 375.5 398.6 
Cancer treated VEGF 165b Nucleus 6 390.65 10.7043 4.3700 379.4 401.9 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Cancer Control VEGF 165b Cytoplasm 6 1048.77 24.1119 9.8436 1023.5 1074.1 
Cancer treated VEGF 165b Cytoplasm 6 1048.44 14.0559 5.7383 1033.7 1063.2 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer Control VEGF 165b Cytoplasm A                 1048.7683 
Cancer treated VEGF 165b Cytoplasm A                 1048.4433 
Normal treated VEGF 165b Cytoplasm   B               940.3100 
Normal Control VEGF 165b Cytoplasm   B               935.7000 
Normal control Bax Cytoplasm     C             560.5400 
Normal treated Bax Cytoplasm     C             557.1267 
Cancer treated VEGF 165b Nucleus       D           390.6517 
Cancer Control VEGF 165b Nucleus       D           387.0617 
Normal Control VEGF165b Nucleus         E         356.7617 
Normal treated VEGF 165b Nucleus         E         355.3267 
Cancer treated Bax Nucleus         E         346.0035 
Cancer Control Bax Nucleus         E         344.1988 
Cancer control Bcl2 Nucleus           F       314.6500 
Cancer Treated Bcl2 Nucleus           F       312.8850 
Normal control Bax Nucleus             G     245.4617 
Normal treated Bax Nucleus             G     240.9217 
Cancer control Bcl2 Cytoplasm               H   197.0467 
Cancer Treated Bcl2 Cytoplasm               H   196.0383 
Cancer treated Bax Cytoplasm               H   192.5783 
Cancer Control Bax Cytoplasm               H   192.0367 
Normal control Bcl2 Nucleus                 I 152.6600 
Normal treated Bcl2 Nucleus                 I 150.5617 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of EFV on Breast cells 
Summary of Fit 
    
Rsquare 0.998818 
Adj Rsquare 0.998593 
Root Mean Square Error 10.9133 
Mean of Response 430.8519 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 11073126 527292 4427.297 <.0001* 
Error 110 13101 119   
C. Total 131 11086228    
 
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.3113 235.0 252.0 
Normal treated Bax Nucleus 6 243.34 5.4806 2.2374 237.6 249.1 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 95% 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.7314 539.6 584.5 
Normal treated Bax Cytoplasm 6 559.69 11.8261 4.8280 547.3 572.1 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.6293 146.4 154.8 
Normal treated Bcl2 Nucleus 6 150.72 1.7893 0.7305 148.8 152.6 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.0972 342.5 368.7 
Normal treated VEGF 165b Nucleus 6 355.81 6.5286 2.6653 349.0 362.7 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.0669 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 945.61 18.8638 7.7011 925.8 965.4 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.4344 329.3 352.1 
Cancer treated Bax Nucleus 6 341.96 1.1745 0.4795 340.7 343.2 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.9718 190.6 195.6 
Cancer treated Bax Cytoplasm 6 193.32 4.4619 1.8216 188.6 198.0 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.1214 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 311.52 3.5745 1.4593 307.8 315.3 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.7140 191.0 205.0 
Cancer Treated Bcl2 Cytoplasm 6 195.56 1.5925 0.6501 193.9 197.2 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.2679 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 386.19 11.6610 4.7606 374.0 398.4 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.6996 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1050.43 22.7030 9.2685 1026.6 1074.3 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Cancer treated VEGF 165b Cytoplasm A                 1050.4283 
Normal treated VEGF 165b Cytoplasm   B               945.6133 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal control Bax Cytoplasm     C             562.0883 
Normal treated Bax Cytoplasm     C             559.6867 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Cancer treated VEGF 165b Nucleus       D           386.1883 
Normal treated VEGF 165b Nucleus         E         355.8117 
Normal Control VEGF165b Nucleus         E         355.6250 
Cancer treated Bax Nucleus         E         341.9588 
Cancer Control Bax Nucleus         E         340.7252 
Cancer control Bcl2 Nucleus           F       311.5967 
Cancer Treated Bcl2 Nucleus           F       311.5150 
Normal control Bax Nucleus             G     243.4750 
Normal treated Bax Nucleus             G     243.3350 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   195.5567 
Cancer treated Bax Cytoplasm               H   193.3233 
Cancer Control Bax Cytoplasm               H   193.1117 
Normal treated Bcl2 Nucleus                 I 150.7200 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
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Oneway Analysis of Fluorescence Intensity of ATP on Breast cells 
Summary of Fit 
    
Rsquare 0.998786 
Adj Rsquare 0.998554 
Root Mean Square Error 11.04102 
Mean of Response 430.9074 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 11033511 525405 4309.987 <.0001* 
Error 110 13409 122   
C. Total 131 11046921    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.3113 235.0 252.0 
Normal treated Bax Nucleus 6 242.60 5.5505 2.2660 236.8 248.4 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.7314 539.6 584.5 
Normal treated Bax Cytoplasm 6 558.33 10.0050 4.0845 547.8 568.8 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.6293 146.4 154.8 
Normal treated Bcl2 Nucleus 6 151.60 2.1091 0.8610 149.4 153.8 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.0972 342.5 368.7 
Normal treated VEGF 165b Nucleus 6 354.31 4.3220 1.7644 349.8 358.8 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.0669 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 938.37 23.1829 9.4644 914.0 962.7 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.4344 329.3 352.1 
Cancer treated Bax Nucleus 6 342.98 6.2511 2.5520 336.4 349.5 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.9718 190.6 195.6 
Cancer treated Bax Cytoplasm 6 190.60 5.4838 2.2387 184.8 196.4 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.1214 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 316.43 5.5660 2.2723 310.6 322.3 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.7140 191.0 205.0 
Cancer Treated Bcl2 Cytoplasm 6 195.16 6.7883 2.7713 188.0 202.3 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.2679 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 393.30 7.1313 2.9113 385.8 400.8 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.6996 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1051.69 20.8017 8.4923 1029.9 1073.5 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Cancer treated VEGF 165b Cytoplasm A                 1051.6867 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal treated VEGF 165b Cytoplasm   B               938.3717 
Normal control Bax Cytoplasm     C             562.0883 
Normal treated Bax Cytoplasm     C             558.3300 
Cancer treated VEGF 165b Nucleus       D           393.2950 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Normal Control VEGF165b Nucleus         E         355.6250 
Normal treated VEGF 165b Nucleus         E         354.3083 
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Level                   Mean 
Cancer treated Bax Nucleus         E         342.9817 
Cancer Control Bax Nucleus         E         340.7252 
Cancer Treated Bcl2 Nucleus           F       316.4250 
Cancer control Bcl2 Nucleus           F       311.5967 
Normal control Bax Nucleus             G     243.4750 
Normal treated Bax Nucleus             G     242.6033 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   195.1617 
Cancer Control Bax Cytoplasm               H   193.1117 
Cancer treated Bax Cytoplasm               H   190.5967 
Normal treated Bcl2 Nucleus                 I 151.5983 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis Fluorescence Intensity of LPV on Breast cells 
Summary of Fit 
    
Rsquare 0.998896 
Adj Rsquare 0.998685 
Root Mean Square Error 10.50484 
Mean of Response 430.2275 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 10983781 523037 4739.733 <.0001* 
Error 110 12139 110   
C. Total 131 10995919    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.3113 235.0 252.0 
Normal treated Bax Nucleus 6 242.33 4.0191 1.6408 238.1 246.5 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.7314 539.6 584.5 
Normal treated Bax Cytoplasm 6 563.02 10.2409 4.1808 552.3 573.8 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.6293 146.4 154.8 
Normal treated Bcl2 Nucleus 6 151.46 2.7117 1.1070 148.6 154.3 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.0972 342.5 368.7 
Normal treated VEGF 165b Nucleus 6 354.18 4.7369 1.9338 349.2 359.1 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.0669 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 932.08 20.7826 8.4845 910.3 953.9 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.4344 329.3 352.1 
Cancer treated Bax Nucleus 6 345.78 7.9642 3.2514 337.4 354.1 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.9718 190.6 195.6 
Cancer treated Bax Cytoplasm 6 190.68 3.9724 1.6217 186.5 194.8 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.1214 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 313.10 5.7813 2.3602 307.0 319.2 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.7140 191.0 205.0 
Cancer Treated Bcl2 Cytoplasm 6 194.74 3.9739 1.6223 190.6 198.9 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.2679 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 384.99 7.2961 2.9786 377.3 392.6 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.6996 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1048.06 17.3985 7.1029 1029.8 1066.3 
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Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Cancer treated VEGF 165b Cytoplasm A                 1048.0550 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal treated VEGF 165b Cytoplasm   B               932.0817 
Normal treated Bax Cytoplasm     C             563.0167 
Normal control Bax Cytoplasm     C             562.0883 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Cancer treated VEGF 165b Nucleus       D           384.9900 
Normal Control VEGF165b Nucleus         E         355.6250 
Normal treated VEGF 165b Nucleus         E         354.1750 
Cancer treated Bax Nucleus         E         345.7832 
Cancer Control Bax Nucleus         E         340.7252 
Cancer Treated Bcl2 Nucleus           F       313.0983 
Cancer control Bcl2 Nucleus           F       311.5967 
Normal control Bax Nucleus             G     243.4750 
Normal treated Bax Nucleus             G     242.3250 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   194.7350 
Cancer Control Bax Cytoplasm               H   193.1117 
Cancer treated Bax Cytoplasm               H   190.6783 
Normal treated Bcl2 Nucleus                 I 151.4617 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of RTV on Breast cells 
Summary of Fit 
    
Rsquare 0.998902 
Adj Rsquare 0.998693 
Root Mean Square Error 10.5307 
Mean of Response 431.1424 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 11099147 528531 4766.023 <.0001* 
Error 110 12199 111   
C. Total 131 11111346    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.3113 235.0 252.0 
Normal treated Bax Nucleus 6 242.56 4.9044 2.0022 237.4 247.7 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.7314 539.6 584.5 
Normal treated Bax Cytoplasm 6 566.13 6.8715 2.8053 558.9 573.3 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.6293 146.4 154.8 
Normal treated Bcl2 Nucleus 6 150.74 4.2281 1.7261 146.3 155.2 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.0972 342.5 368.7 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal treated VEGF 165b Nucleus 6 355.25 9.4655 3.8643 345.3 365.2 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.0669 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 937.22 20.6352 8.4243 915.6 958.9 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.4344 329.3 352.1 
Cancer treated Bax Nucleus 6 341.18 9.8620 4.0261 330.8 351.5 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.9718 190.6 195.6 
Cancer treated Bax Cytoplasm 6 191.99 5.0352 2.0556 186.7 197.3 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.1214 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 310.64 6.2444 2.5493 304.1 317.2 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.7140 191.0 205.0 
Cancer Treated Bcl2 Cytoplasm 6 194.94 3.8133 1.5568 190.9 198.9 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.2679 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 391.45 7.2022 2.9403 383.9 399.0 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.6996 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1058.45 15.7002 6.4096 1042.0 1074.9 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer treated VEGF 165b Cytoplasm A                 1058.4533 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal treated VEGF 165b Cytoplasm   B               937.2150 
Normal treated Bax Cytoplasm     C             566.1300 
Normal control Bax Cytoplasm     C             562.0883 
Cancer treated VEGF 165b Nucleus       D           391.4450 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Normal Control VEGF165b Nucleus         E         355.6250 
Normal treated VEGF 165b Nucleus         E         355.2483 
Cancer treated Bax Nucleus         E         341.1767 
Cancer Control Bax Nucleus         E         340.7252 
Cancer control Bcl2 Nucleus           F       311.5967 
Cancer Treated Bcl2 Nucleus           F       310.6400 
Normal control Bax Nucleus             G     243.4750 
Normal treated Bax Nucleus             G     242.5617 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   194.9350 
Cancer Control Bax Cytoplasm               H   193.1117 
Cancer treated Bax Cytoplasm               H   191.9850 
Normal treated Bcl2 Nucleus                 I 150.7367 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
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Oneway Analysis of Fluorescence Intensity of LPVr on Breast cells 
Summary of Fit 
   
Rsquare 0.998719 
Adj Rsquare 0.998475 
Root Mean Square Error 11.32883 
Mean of Response 430.792 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 11009422 524258 4084.841 <.0001* 
Error 110 14118 128   
C. Total 131 11023540    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.311 235.0 252.0 
Normal treated Bax Nucleus 6 244.02 1.8067 0.738 242.1 245.9 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.731 539.6 584.5 
Normal treated Bax Cytoplasm 6 566.04 7.8452 3.203 557.8 574.3 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.629 146.4 154.8 
Normal treated Bcl2 Nucleus 6 151.36 2.3337 0.953 148.9 153.8 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.097 342.5 368.7 
Normal treated VEGF 165b Nucleus 6 356.24 7.8274 3.196 348.0 364.5 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.067 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 936.90 25.3196 10.337 910.3 963.5 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.434 329.3 352.1 
Cancer treated Bax Nucleus 6 341.73 6.3479 2.592 335.1 348.4 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.972 190.6 195.6 
Cancer treated Bax Cytoplasm 6 191.80 6.1463 2.509 185.3 198.3 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.121 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 313.67 7.4277 3.032 305.9 321.5 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.714 191.0 205.0 
Cancer Treated Bcl2 Cytoplasm 6 195.10 4.6020 1.879 190.3 199.9 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.268 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 388.00 5.4058 2.207 382.3 393.7 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.700 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1047.97 22.5088 9.189 1024.3 1071.6 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
 
Connecting Letters Report 
 
Level 
                  Mean 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Cancer treated VEGF 165b Cytoplasm A                 1047.9700 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal treated VEGF 165b Cytoplasm   B               936.9017 
Normal treated Bax Cytoplasm     C             566.0383 
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Connecting Letters Report 
 
Level 
                  Mean 
Normal control Bax Cytoplasm     C             562.0883 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Cancer treated VEGF 165b Nucleus       D           387.9967 
Normal treated VEGF 165b Nucleus         E         356.2433 
Normal Control VEGF165b Nucleus         E         355.6250 
Cancer treated Bax Nucleus         E         341.7302 
Cancer Control Bax Nucleus         E         340.7252 
Cancer Treated Bcl2 Nucleus           F       313.6650 
Cancer control Bcl2 Nucleus           F       311.5967 
Normal treated Bax Nucleus             G     244.0150 
Normal control Bax Nucleus             G     243.4750 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   195.1033 
Cancer Control Bax Cytoplasm               H   193.1117 
Cancer treated Bax Cytoplasm               H   191.8000 
Normal treated Bcl2 Nucleus                 I 151.3550 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of Fluorescence Intensity of TDF/FTC/LPV/r on Breast cells 
Summary of Fit 
    
Rsquare 0.998687 
Adj Rsquare 0.998436 
Root Mean Square Error 11.49501 
Mean of Response 431.1353 
Observations (or Sum Wgts) 132 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Gene 21 11053622 526363 3983.513 <.0001* 
Error 110 14535 132   
C. Total 131 11068157    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Normal control Bax Nucleus 6 243.48 8.1109 3.311 235.0 252.0 
Normal treated Bax Nucleus 6 245.75 3.9169 1.599 241.6 249.9 
Normal control Bax Cytoplasm 6 562.09 21.3875 8.731 539.6 584.5 
Normal treated Bax Cytoplasm 6 567.27 14.2712 5.826 552.3 582.2 
Normal control Bcl2 Nucleus 6 150.57 3.9908 1.629 146.4 154.8 
Normal treated Bcl2 Nucleus 6 151.87 3.5829 1.463 148.1 155.6 
Normal Control VEGF165b Nucleus 6 355.63 12.4854 5.097 342.5 368.7 
Normal treated VEGF 165b Nucleus 6 355.94 8.2213 3.356 347.3 364.6 
Normal Control VEGF 165b Cytoplasm 6 945.16 12.4112 5.067 932.1 958.2 
Normal treated VEGF 165b Cytoplasm 6 938.57 21.5284 8.789 916.0 961.2 
Cancer Control Bax Nucleus 6 340.73 10.8621 4.434 329.3 352.1 
Cancer treated Bax Nucleus 6 340.18 8.9627 3.659 330.8 349.6 
Cancer Control Bax Cytoplasm 6 193.11 2.3805 0.972 190.6 195.6 
Cancer treated Bax Cytoplasm 6 190.17 3.9897 1.629 186.0 194.4 
Cancer control Bcl2 Nucleus 6 311.60 10.0953 4.121 301.0 322.2 
Cancer Treated Bcl2 Nucleus 6 310.95 4.7263 1.930 306.0 315.9 
Cancer control Bcl2 Cytoplasm 6 197.98 6.6480 2.714 191.0 205.0 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 
95% 
Upper 
95% 
Cancer Treated Bcl2 Cytoplasm 6 195.95 3.8492 1.571 191.9 200.0 
Cancer Control VEGF 165b Nucleus 6 389.71 10.4542 4.268 378.7 400.7 
Cancer treated VEGF 165b Nucleus 6 391.54 5.6698 2.315 385.6 397.5 
Cancer Control VEGF 165b Cytoplasm 6 1054.57 11.5117 4.700 1042.5 1066.7 
Cancer treated VEGF 165b Cytoplasm 6 1052.19 24.8573 10.148 1026.1 1078.3 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.68436 0.05 
Connecting Letters Report 
 
Level                   Mean 
Cancer Control VEGF 165b Cytoplasm A                 1054.5700 
Cancer treated VEGF 165b Cytoplasm A                 1052.1850 
Normal Control VEGF 165b Cytoplasm   B               945.1600 
Normal treated VEGF 165b Cytoplasm   B               938.5667 
Normal treated Bax Cytoplasm     C             567.2717 
Normal control Bax Cytoplasm     C             562.0883 
Cancer treated VEGF 165b Nucleus       D           391.5433 
Cancer Control VEGF 165b Nucleus       D           389.7133 
Normal treated VEGF 165b Nucleus         E         355.9350 
Normal Control VEGF165b Nucleus         E         355.6250 
Cancer Control Bax Nucleus         E         340.7252 
Cancer treated Bax Nucleus         E         340.1757 
Cancer control Bcl2 Nucleus           F       311.5967 
Cancer Treated Bcl2 Nucleus           F       310.9500 
Normal treated Bax Nucleus             G     245.7450 
Normal control Bax Nucleus             G     243.4750 
Cancer control Bcl2 Cytoplasm               H   197.9750 
Cancer Treated Bcl2 Cytoplasm               H   195.9533 
Cancer Control Bax Cytoplasm               H   193.1117 
Cancer treated Bax Cytoplasm               H   190.1733 
Normal treated Bcl2 Nucleus                 I 151.8733 
Normal control Bcl2 Nucleus                 I 150.5650 
 
Levels not connected by same letter are significantly different. 
 
APPENDIX F 
Oneway Analysis of Nuclear Axis lengths (μm) By Treatment Groups 
Oneway Analysis of Normal Cervix Nuc. Long Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.029034 
Adj Rsquare  -0.14574 
Root Mean Square Error 0.479142 
Mean of Response 22.64983 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 0.343248 0.038139 0.1661 0.9966 
Error 50 11.478850 0.229577   
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Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
C. Total 59 11.822098    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 22.7367 0.682574 0.27866 22.020 23.453 
0.01%Methanol 6 22.5417 0.246367 0.10058 22.283 22.800 
0.3 μg/ml TDF 6 22.5617 0.267014 0.10901 22.281 22.842 
1.8μg/ml FTC 6 22.6917 0.316128 0.12906 22.360 23.023 
4.07μg/ml EFV 6 22.7317 0.259647 0.10600 22.459 23.004 
ATRIPLA 6 22.5633 0.337441 0.13776 22.209 22.917 
9.8μg/ml LPV 6 22.7467 0.607607 0.24805 22.109 23.384 
0.6 μg/ml RTV 6 22.5917 0.644590 0.26315 21.915 23.268 
KALETRA(LPV/r) 6 22.6883 0.688169 0.28094 21.966 23.411 
TDF/FTC/LPVr 6 22.6450 0.397982 0.16248 22.227 23.063 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
9.8μg/ml LPV A       
Untreated Control A       
4.07μg/ml EFV A       
1.8μg/ml FTC A       
KALETRA(LPV/r) A       
TDF/FTC/LPVr A       
0.6 μg/ml RTV A       
ATRIPLA A       
0.3 μg/ml TDF A       
0.01%Methanol A       
Levels not connected by same letter are significantly different. 
 
 
 
Oneway Analysis of Normal Cervix Nuc. Short Axis μm By GROUPS 
Summary of Fit 
   
Rsquare 0.022329 
Adj Rsquare  -0.15365 
Root Mean Square Error 0.408818 
Mean of Response 15.237 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 0.1908600 0.021207 0.1269 0.9988 
Error 50 8.3566000 0.167132   
C. Total 59 8.5474600    
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Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 15.2800 0.423367 0.17284 14.836 15.724 
0.01%Methanol 6 15.1833 0.413747 0.16891 14.749 15.618 
0.3 μg/ml TDF 6 15.2667 0.579126 0.23643 14.659 15.874 
1.8μg/ml FTC 6 15.1900 0.505767 0.20648 14.659 15.721 
4.07μg/ml EFV 6 15.2483 0.511094 0.20865 14.712 15.785 
ATRIPLA 6 15.1617 0.194362 0.07935 14.958 15.366 
9.8μg/ml LPV 6 15.1933 0.191172 0.07805 14.993 15.394 
0.6 μg/ml RTV 6 15.3217 0.387320 0.15812 14.915 15.728 
KALETRA(LPV/r) 6 15.2000 0.318559 0.13005 14.866 15.534 
TDF/FTC/LPVr 6 15.3250 0.377717 0.15420 14.929 15.721 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
TDF/FTC/LPVr A       
0.6 μg/ml RTV A       
Untreated Control A       
0.3 μg/ml TDF A       
4.07μg/ml EFV A       
KALETRA(LPV/r) A       
9.8μg/ml LPV A       
1.8μg/ml FTC A       
0.01%Methanol A       
ATRIPLA A       
 
Levels not connected by same letter are significantly different. 
 
 
 
Oneway Analysis of Cancer Cervix Nuc. Long Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.138576 
Adj Rsquare  -0.01648 
Root Mean Square Error 0.409774 
Mean of Response 14.9365 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 1.3506150 0.150068 0.8937 0.5377 
Error 50 8.3957500 0.167915   
C. Total 59 9.7463650    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 15.0017 0.389996 0.15922 14.592 15.411 
0.01%Methanol 6 14.9833 0.500466 0.20431 14.458 15.509 
0.3 μg/ml TDF 6 15.0367 0.446169 0.18215 14.568 15.505 
1.8μg/ml FTC 6 14.8250 0.518295 0.21159 14.281 15.369 
4.07μg/ml EFV 6 14.9750 0.337268 0.13769 14.621 15.329 
ATRIPLA 6 14.9300 0.342053 0.13964 14.571 15.289 
9.8μg/ml LPV 6 14.5450 0.645376 0.26347 13.868 15.222 
0.6 μg/ml RTV 6 14.9283 0.300361 0.12262 14.613 15.244 
KALETRA(LPV/r) 6 15.0167 0.111654 0.04558 14.899 15.134 
TDF/FTC/LPVr 6 15.1233 0.242789 0.09912 14.869 15.378 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
TDF/FTC/LPVr A       
0.3 μg/ml TDF A       
KALETRA(LPV/r) A       
Untreated Control A       
0.01%Methanol A       
4.07μg/ml EFV A       
ATRIPLA A       
0.6 μg/ml RTV A       
1.8μg/ml FTC A       
9.8μg/ml LPV A       
 
Levels not connected by same letter are significantly different. 
 
 
 
 
Oneway Analysis of Cancer Cervix Nuc. Short Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.153208 
Adj Rsquare 0.000786 
Root Mean Square Error 0.245944 
Mean of Response 9.646167 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 0.5472017 0.060800 1.0052 0.4485 
Error 50 3.0244167 0.060488   
C. Total 59 3.5716183    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 9.78167 0.320775 0.13096 9.4450 10.118 
0.01%Methanol 6 9.63000 0.117983 0.04817 9.5062 9.754 
0.3 μg/ml TDF 6 9.76833 0.199641 0.08150 9.5588 9.978 
1.8μg/ml FTC 6 9.75500 0.158461 0.06469 9.5887 9.921 
4.07μg/ml EFV 6 9.58833 0.313332 0.12792 9.2595 9.917 
ATRIPLA 6 9.66667 0.341389 0.13937 9.3084 10.025 
9.8μg/ml LPV 6 9.66333 0.261891 0.10692 9.3885 9.938 
0.6 μg/ml RTV 6 9.47667 0.286333 0.11690 9.1762 9.777 
KALETRA(LPV/r) 6 9.55833 0.217937 0.08897 9.3296 9.787 
TDF/FTC/LPVr 6 9.57333 0.101522 0.04145 9.4668 9.680 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
Untreated Control A       
0.3 μg/ml TDF A       
1.8μg/ml FTC A       
ATRIPLA A       
9.8μg/ml LPV A       
0.01%Methanol A       
4.07μg/ml EFV A       
TDF/FTC/LPVr A       
KALETRA(LPV/r) A       
0.6 μg/ml RTV A       
 
Levels not connected by same letter are significantly different. 
 
 
 
 
Oneway Analysis of Normal Breast Nuc. Long Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.13224 
Adj Rsquare  -0.02396 
Root Mean Square Error 0.418844 
Mean of Response 15.23528 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 1.336713 0.148524 0.8466 0.5776 
Error 50 8.771515 0.175430   
C. Total 59 10.108228    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 15.3189 0.498624 0.20356 14.796 15.842 
0.01%Methanol 6 15.3385 0.454163 0.18541 14.862 15.815 
0.3 μg/ml TDF 6 15.1226 0.528383 0.21571 14.568 15.677 
1.8μg/ml FTC 6 15.2740 0.344052 0.14046 14.913 15.635 
4.07μg/ml EFV 6 15.2280 0.348213 0.14216 14.863 15.593 
ATRIPLA 6 14.8366 0.656238 0.26791 14.148 15.525 
9.8μg/ml LPV 6 15.2254 0.307662 0.12560 14.902 15.548 
0.6 μg/ml RTV 6 15.3166 0.113286 0.04625 15.198 15.435 
KALETRA(LPV/r) 6 15.3284 0.356844 0.14568 14.954 15.703 
TDF/FTC/LPVr 6 15.3639 0.339301 0.13852 15.008 15.720 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
TDF/FTC/LPVr A       
0.01%Methanol A       
KALETRA(LPV/r) A       
Untreated Control A       
0.6 μg/ml RTV A       
1.8μg/ml FTC A       
4.07μg/ml EFV A       
9.8μg/ml LPV A       
0.3 μg/ml TDF A       
ATRIPLA A       
Levels not connected by same letter are significantly different. 
 
 
 
 
 
Oneway Analysis of Normal Breast Nuc. Short Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.038834 
Adj Rsquare  -0.13418 
Root Mean Square Error 0.28052 
Mean of Response 10.89584 
Observations (or Sum Wgts) 60 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 0.1589695 0.017663 0.2245 0.9895 
Error 50 3.9345653 0.078691   
C. Total 59 4.0935349    
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Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 10.8340 0.258414 0.10550 10.563 11.105 
0.01%Methanol 6 10.9445 0.305808 0.12485 10.624 11.265 
0.3 μg/ml TDF 6 10.9200 0.363743 0.14850 10.538 11.302 
1.8μg/ml FTC 6 10.9598 0.324512 0.13248 10.619 11.300 
4.07μg/ml EFV 6 10.8707 0.389236 0.15890 10.462 11.279 
ATRIPLA 6 10.8998 0.189029 0.07717 10.701 11.098 
9.8μg/ml LPV 6 10.8455 0.112577 0.04596 10.727 10.964 
0.6 μg/ml RTV 6 10.9070 0.192144 0.07844 10.705 11.109 
KALETRA(LPV/r) 6 10.8104 0.268565 0.10964 10.529 11.092 
TDF/FTC/LPVr 6 10.9667 0.282918 0.11550 10.670 11.264 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
TDF/FTC/LPVr A       
1.8μg/ml FTC A       
0.01%Methanol A       
0.3 μg/ml TDF A       
0.6 μg/ml RTV A       
ATRIPLA A       
4.07μg/ml EFV A       
9.8μg/ml LPV A       
Untreated Control A       
KALETRA(LPV/r) A       
 
Levels not connected by same letter are significantly different. 
 
 
 
Oneway Analysis of Cancer Breast Nuc. Long Axis μm 2 By GROUPS 
Summary of Fit 
    
Rsquare 0.143803 
Adj Rsquare  -0.01031 
Root Mean Square Error 0.454352 
Mean of Response 16.41 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 1.733600 0.192622 0.9331 0.5052 
Error 50 10.321800 0.206436   
C. Total 59 12.055400    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 16.2567 0.466762 0.19055 15.767 16.747 
0.01%Methanol 6 16.5100 0.446497 0.18228 16.041 16.979 
0.3 μg/ml TDF 6 16.4367 0.469283 0.19158 15.944 16.929 
1.8μg/ml FTC 6 16.7750 0.371308 0.15159 16.385 17.165 
4.07μg/ml EFV 6 16.2633 0.308199 0.12582 15.940 16.587 
ATRIPLA 6 16.1350 0.806666 0.32932 15.288 16.982 
9.8μg/ml LPV 6 16.3933 0.226774 0.09258 16.155 16.631 
0.6 μg/ml RTV 6 16.5417 0.241447 0.09857 16.288 16.795 
KALETRA(LPV/r) 6 16.4500 0.515946 0.21063 15.909 16.991 
TDF/FTC/LPVr 6 16.3383 0.409166 0.16704 15.909 16.768 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
1.8μg/ml FTC A       
0.6 μg/ml RTV A       
0.01%Methanol A       
KALETRA(LPV/r) A       
0.3 μg/ml TDF A       
9.8μg/ml LPV A       
TDF/FTC/LPVr A       
4.07μg/ml EFV A       
Untreated Control A       
ATRIPLA A       
 
Levels not connected by same letter are significantly different. 
 
 
 
 
Oneway Analysis of Cancer Breast Nuc. Short Axis μm By GROUPS 
Summary of Fit 
    
Rsquare 0.184926 
Adj Rsquare 0.038213 
Root Mean Square Error 0.282699 
Mean of Response 10.809 
Observations (or Sum Wgts) 60 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 9 0.9066067 0.100734 1.2605 0.2816 
Error 50 3.9959333 0.079919   
C. Total 59 4.9025400    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Untreated Control 6 10.8200 0.339588 0.13864 10.464 11.176 
0.01%Methanol 6 10.7233 0.325924 0.13306 10.381 11.065 
0.3 μg/ml TDF 6 10.7833 0.408542 0.16679 10.355 11.212 
1.8μg/ml FTC 6 10.7183 0.183893 0.07507 10.525 10.911 
4.07μg/ml EFV 6 10.6650 0.201569 0.08229 10.453 10.877 
ATRIPLA 6 10.8650 0.237550 0.09698 10.616 11.114 
9.8μg/ml LPV 6 10.7867 0.194285 0.07932 10.583 10.991 
0.6 μg/ml RTV 6 10.8533 0.172704 0.07051 10.672 11.035 
KALETRA(LPV/r) 6 11.1317 0.340495 0.13901 10.774 11.489 
TDF/FTC/LPVr 6 10.7433 0.310398 0.12672 10.418 11.069 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
3.31028 0.05 
Connecting Letters Report 
Level              
KALETRA(LPV/r) A       
ATRIPLA A       
0.6 μg/ml RTV A       
Untreated Control A       
9.8μg/ml LPV A       
0.3 μg/ml TDF A       
TDF/FTC/LPVr A       
0.01%Methanol A       
1.8μg/ml FTC A       
4.07μg/ml EFV A       
 
Levels not connected by same letter are significantly different. 
 
 
APPENDIX G1 
Oneway Analysis of % Apoptotic cells (Acridine Orange) By Groups 
 
Oneway Analysis of % Apoptotic HCS-2 cells By Groups 
Summary of Fit 
   
Rsquare 0.965275 
Adj Rsquare 0.960066 
Root Mean Square Error 0.889757 
Mean of Response 5.458333 
Observations (or Sum Wgts) 24 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Groups 3 440.12500 146.708 185.3158 <.0001* 
Error 20 15.83333 0.792   
C. Total 23 455.95833    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
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Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Control 6 1.3333 0.81650 0.33333 0.476 2.190 
0.01%Methanol 6 1.5000 0.54772 0.22361 0.925 2.075 
CPT 6 11.5000 1.04881 0.42817 10.399 12.601 
LPV/r 6 7.5000 1.04881 0.42817 6.399 8.601 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.79894 0.05 
Connecting Letters Report 
 
Level             Mean 
CPT A        11.500000 
LPV/r   B      7.500000 
0.01%Methanol     C    1.500000 
Control     C    1.333333 
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of %Apoptotic NCE16IIA cells By Groups 
Summary of Fit 
    
Rsquare 0.918907 
Adj Rsquare 0.906743 
Root Mean Square Error 2.361144 
Mean of Response 9.291667 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Groups 3 1263.4583 421.153 75.5431 <.0001* 
Error 20 111.5000 5.575   
C. Total 23 1374.9583    
 
 
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Control 6 2.1667 0.75277 0.3073 1.377 2.957 
0.01%Methanol 6 2.0000 0.63246 0.2582 1.336 2.664 
CPT 6 15.3333 3.93277 1.6055 11.206 19.461 
LPV/r 6 17.6667 2.42212 0.9888 15.125 20.209 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.79894 0.05 
Connecting Letters Report 
 
Level              
LPV/r A        
CPT A        
Control   B      
0.01%Methanol   B      
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Levels not connected by same letter are significantly different. 
 
Oneway Analysis of %apoptotic MCF-7 cells By Groups 
Summary of Fit 
    
Rsquare 0.9124 
Adj Rsquare 0.89926 
Root Mean Square Error 2.411777 
Mean of Response 10.5 
Observations (or Sum Wgts) 24 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Groups 3 1211.6667 403.889 69.4365 <.0001* 
Error 20 116.3333 5.817   
C. Total 23 1328.0000    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Control 6 3.6667 0.81650 0.3333 2.810 4.524 
0.01%Methanol 6 3.1667 1.16905 0.4773 1.940 4.394 
CPT 6 16.8333 3.48807 1.4240 13.173 20.494 
LPV/r 6 18.3333 3.01109 1.2293 15.173 21.493 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.79894 0.05 
Connecting Letters Report 
Level              
LPV/r A        
CPT A        
Control   B      
0.01%Methanol   B      
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of %Apoptotic MCF-10A cells By Groups 
Summary of Fit 
    
Rsquare 0.966355 
Adj Rsquare 0.961308 
Root Mean Square Error 0.866025 
Mean of Response 5.416667 
Observations (or Sum Wgts) 24 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Groups 3 430.83333 143.611 191.4815 <.0001* 
Error 20 15.00000 0.750   
C. Total 23 445.83333    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
Control 6 1.1667 0.75277 0.30732 0.3767 1.957 
0.01%Methanol 6 1.3333 0.81650 0.33333 0.4765 2.190 
CPT 6 8.5000 0.54772 0.22361 7.9252 9.075 
LPV/r 6 10.6667 1.21106 0.49441 9.3957 11.938 
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Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.79894 0.05 
Connecting Letters Report 
 
Level              
LPV/r A         
CPT   B       
0.01%Methanol     C     
Control     C     
Levels not connected by same letter are significantly different. 
 
APPENDIX G2 
Oneway Analysis of ELISA ABSORBANCE By GROUPS 
Oneway Analysis of HCS-2 ABSORBANCE By GROUPS 
Summary of Fit 
    
Rsquare 0.998659 
Adj Rsquare 0.998391 
Root Mean Square Error 0.144882 
Mean of Response 2.756757 
Observations (or Sum Wgts) 25 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 4 312.71758 78.1794 3724.449 <.0001* 
Error 20 0.41982 0.0210   
C. Total 24 313.13739    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
UNTREATED 5 0.10084 0.006382 0.00285 0.0929 0.1088 
0.01%Methanol 5 0.10611 0.010164 0.00455 0.0935 0.1187 
CPT 5 2.36066 0.125129 0.05596 2.2053 2.5160 
LPV/r 5 1.60518 0.298238 0.13338 1.2349 1.9755 
Positive Control 5 9.61100 0.014387 0.00643 9.5931 9.6289 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.99238 0.05 
Connecting Letters Report 
Level              
Positive Control A          
CPT   B        
LPV/r     C      
0.01%Methanol       D    
UNTREATED       D    
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of NCE16IIA Absorbance By GROUPS 
Summary of Fit 
    
Rsquare 0.996879 
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Adj Rsquare 0.996255 
Root Mean Square Error 0.216366 
Mean of Response 3.500777 
Observations (or Sum Wgts) 25 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 4 299.06240 74.7656 1597.073 <.0001* 
Error 20 0.93628 0.0468   
C. Total 24 299.99868    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
UNTREATED 5 0.15126 0.009573 0.00428 0.1394 0.1631 
0.01%Methanol 5 0.16977 0.016262 0.00727 0.1496 0.1900 
CPT 5 3.77706 0.200206 0.08953 3.5285 4.0256 
LPV/r 5 3.79480 0.439801 0.19669 3.2487 4.3409 
Positive Control 5 9.61100 0.014387 0.00643 9.5931 9.6289 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.99238 0.05 
Connecting Letters Report 
Level              
Positive Control A         
LPV/r   B       
CPT   B       
0.01%Methanol     C     
UNTREATED     C     
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of MCF-7 Absorbance By GROUPS 
Summary of Fit 
    
Rsquare 0.999511 
Adj Rsquare 0.999413 
Root Mean Square Error 0.085364 
Mean of Response 2.806257 
Observations (or Sum Wgts) 25 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 4 298.01156 74.5029 10224.16 <.0001* 
Error 20 0.14574 0.0073   
C. Total 24 298.15730    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
UNTREATED 5 0.43109 0.027282 0.01220 0.3972 0.4650 
0.01%Methanol 5 0.46880 0.026930 0.01204 0.4354 0.5022 
CPT 5 1.71456 0.128368 0.05741 1.5552 1.8739 
LPV/r 5 1.80584 0.135203 0.06046 1.6380 1.9737 
Positive Control 5 9.61100 0.014387 0.00643 9.5931 9.6289 
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Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.99238 0.05 
Connecting Letters Report 
Level              
Positive Control A         
LPV/r   B       
CPT   B       
0.01%Methanol     C     
UNTREATED     C     
 
Levels not connected by same letter are significantly different. 
 
Oneway Analysis of MCF-10A Absorbance By GROUPS 
Summary of Fit 
    
Rsquare 0.998013 
Adj Rsquare 0.997615 
Root Mean Square Error 0.180819 
Mean of Response 2.42632 
Observations (or Sum Wgts) 25 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
GROUPS 4 328.40751 82.1019 2511.102 <.0001* 
Error 20 0.65391 0.0327   
C. Total 24 329.06142    
Means and Std Deviations 
Level Number Mean Std Dev Std Err 
Mean 
Lower 95% Upper 95% 
UNTREATED 5 0.10200 0.016432 0.00735 0.0816 0.1224 
0.01%Methanol 5 0.11000 0.021213 0.00949 0.0837 0.1363 
CPT 5 0.98400 0.131643 0.05887 0.8205 1.1475 
LPV/r 5 1.32460 0.381078 0.17042 0.8514 1.7978 
Positive Control 5 9.61100 0.014387 0.00643 9.5931 9.6289 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
Confidence Quantile 
q* Alpha 
2.99238 0.05 
Connecting Letters Report 
Level              
Positive Control A         
LPV/r   B       
CPT   B       
0.01%Methanol     C     
UNTREATED     C     
Levels not connected by same letter are significantly different. 
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